Double-stranded oligonucleotide, conjugate thereof, and use thereof
By introducing large space volume modification and double substituent modification into double-stranded oligonucleotides and combining target ligands, the problems of unstable double-stranded oligonucleotide activity and low silencing efficiency in the prior art are solved. , achieving efficient target gene expression regulation and disease treatment.
Patent Information
- Application Number
- PCT/CN2024/093907
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
In pharmaceutical applications, existing double-stranded oligonucleotides have problems with instability in activity and low silencing efficiency of target genes, especially the differences in activity and loss of activity caused by different modification combinations.
A double-stranded oligonucleotide is designed that contains 17 to 35 nucleotides of sense and antisense strands, modified by large spatial volume and bisubstituent modification, site-specific modification to improve tolerance and pharmacy activity and binding to targeted ligands to improve delivery efficiency.
The pharmacological activity maintenance of double-stranded oligonucleotides and the regulatory efficiency of target gene expression have been improved, the stability and targeting in target cells have been improved, and it is suitable for the treatment and prevention of diseases related to target gene expression.
Smart Images

Figure PCTCN2024093907-FTAPPB-I100001 
Figure PCTCN2024093907-FTAPPB-I100002 
Figure PCTCN2024093907-FTAPPB-I100003
Abstract
Description
Double-stranded oligonucleotides and their conjugates and uses
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Chinese patent application No. 202310574400.2 filed with the State Intellectual Property Office of China on May 19, 2023, entitled “Double-stranded oligonucleotides, their conjugates and uses”, the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present disclosure relates to the field of oligonucleotides, and in particular to methods for preparing and using modified double-stranded oligonucleotides, oligonucleotide conjugates or compositions. Background Art
[0004] Double-stranded oligonucleotides (dsRNA) are well known in the art for their ability to direct gene-specific post-transcriptional silencing and have been used as effective pharmaceutical active ingredients.
[0005] As is well known, drug development based on RNA interference (RNAi) requires double-stranded oligonucleotide molecules with good gene silencing properties or inhibitory activity, and they usually need to be modified. For example, using siRNA duplexes containing alternative modifications, it is common to use different combinations of 2'-OMe, 2'-F and phosphorothioate modifications to stabilize siRNA in serum; however, different modifications usually result in differences in the activity of double-stranded oligonucleotides or even loss of activity. For example, Tai, W. ("Chemical modulation of siRNA lipophilicity for efficient delivery." J Control Release 307:98-107.) proposed that one or more MOE modifications weakened siRNA activity.
[0006] In the drug development of double-stranded oligonucleotides, the development of double-stranded oligonucleotide modification strategies with good pharmaceutical activity has always been a direction of exploration in this field.
[0007] Summary of the Invention
[0008] The present disclosure aims to solve one of the technical problems in the related art at least to a certain extent.
[0009] To this end, in one aspect, the present disclosure provides a double-stranded oligonucleotide (dsRNA) for inhibiting target gene expression, wherein the double-stranded oligonucleotide comprises a sense strand and an antisense strand, each strand having 17 to 35 nucleotides, wherein each nucleotide is a modified or unmodified nucleotide; the sense strand and the antisense strand are at least partially reverse-complementary to form a double-stranded region, and the double-stranded region comprises nucleotides modified with large steric bulk and / or nucleotides modified with disubstituents; wherein the composition of the double-stranded region is as shown in the following formula (I):
[0010] SS:5'-(N)a'-(X)p'-(N)b'-(X)q'-(N)c'-(X)r'-(N)d'-3'
[0011] AS:3'-(N)a-(X)p-(N)b-(X)q-(N)c-5'(I),
[0012] Among them, SS represents the sense strand and AS represents the antisense strand.
[0013] In formula (I), each X independently represents a nucleotide in which the 2'-hydroxyl group in the ribose is replaced by a large steric bulk group or a nucleotide in which the 2'-position is substituted by a disubstituted group (i.e., both the 2'-hydroxyl group and hydrogen are replaced), and the 2'-hydroxyl group is selected from a group having a steric bulk greater than that of the 2'-methoxy group; each substituent in the disubstituted group is independently selected from a C1-C6 alkyl group or a halogen.
[0014] In some embodiments, when X represents a nucleotide in which the 2'-hydroxyl group of the ribose is replaced by a bulky group, it is independently selected from the following 2'-modified nucleotides: 2'-(O) m1 (CH2) n (O) m2 R1, wherein m1 or m2 are each independently 0 or 1, and n is selected from an integer from 0 to 6; R1 is selected from a substituted or unsubstituted C1-C6 alkyl group, or -Si(R2)3; wherein R2 is each independently selected from: a substituted or unsubstituted C 1- C6 alkyl, substituted or unsubstituted C1-C6 alkoxy; wherein the substitution includes one or more substituents selected from the following substituents: halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, amino, cycloalkyl having no more than 6 carbon atoms, aryl having no more than 12 carbon atoms, or heteroaryl having no more than 12 carbon atoms.
[0015] In some embodiments, m1=0, n=0, m2=1, and R1=Si(R2)3.
[0016] In some embodiments, m1=1, m2=0, and n is a positive integer.
[0017] In some embodiments, each of the Xs is independently selected from the following modified nucleotides: 2'-O(CH2) n OR1 or 2'-R3-2'-R4. Wherein, n is 1 or 2, and substituents R1 and R2 are as defined above. Wherein, R3 and R4 are each independently selected from C1-C6 alkyl or halogen. Optionally, the halogen is fluorine. Optionally, the C1-C6 alkyl is selected from methyl or ethyl.
[0018] In formula (I), each N independently represents an unmodified nucleotide, or a nucleotide in which the 2' position of the ribose is modified and is not X (i.e., not the aforementioned 2' modification in X); optionally, the modified nucleotide is selected from the group consisting of 2'-O-alkyl, 2'-alkyl, 2'-substituted alkyl, 2'-halo, 2'-deoxy (i.e., 2'-H modification), or a nucleotide-like group, wherein the alkyl group has 1-6 carbon atoms; the nucleotide-like group is selected from ENA, BNA, LNA, GNA, or UNA; optionally, the total number of carbon atoms in the 2'-substituted alkyl group is 1-6. In the present disclosure, the alkyl group includes branched or linear alkyl groups.
[0019] Preferably, each N is independently selected from a 2'-OMe modified, a 2'-F modified or a 2'-deoxy modified nucleotide.
[0020] In Formula I, a, a', p, p', b, b', q, q', c, c', r', and d' in the general formula of the double-stranded region structure each independently represent the number of nucleotides, wherein:
[0021] a' is selected from integers 3-8; p' is selected from integers 0-3; b' is selected from integers 4-13; q' is selected from integers 0-4; c' is selected from integers 3-9; r' is selected from integers 0-3; d' is selected from integers 0-9; a is selected from integers 4-7; p is selected from integers 0-1; b is selected from integers 4-8; q is selected from integers 0-4; c is selected from integers 6-10; and p', q', r', p, q are not all 0 at the same time, and optionally 0≤q'+r'≤4.
[0022] In some embodiments of the present disclosure, in a double-stranded oligonucleotide molecule containing a double-stranded region represented by the above formula (I) of the present disclosure, in the direction from the 5' end to the 3' end, the sense strand and / or the antisense strand has at least one modified nucleotide X, i.e., a nucleotide with a large steric bulk or a nucleotide modified with a disubstituent, at a specific position of the nucleotide sequence.
[0023] In some embodiments of the present disclosure, from the 5' end to the 3' end, the nucleotide modified with large steric volume and / or double substituent modification is located at a specific position in the antisense strand in the double-stranded region shown in Formula I, and the specific position is at least one of positions 10 and 15.
[0024] In some embodiments of the present disclosure, the specific position further includes at least one of positions 8-10.
[0025] In some embodiments of the present disclosure, the large steric volume modified and / or disubstituent modified nucleotide is located in a specific position of the sense strand in the double-stranded region shown in Formula I, and the specific position is the para position (i.e., the relative position) relative to at least one of positions 2, 8, 12 or 15 (in the direction from the 5' end to the 3' end) of the antisense strand.
[0026] In some embodiments of the present disclosure, the modified nucleotide X on the sense strand is located at a position relative to any one of positions 2, 8, and 15 of the complementary antisense strand.
[0027] In some embodiments of the present disclosure, optionally, starting from the 5'-end, X is located at position 15 of the antisense strand, and: there is at least one fluorinated modification at position 9 or position 12 of the antisense strand, and / or the position of the sense strand opposite to position 10 of the antisense strand is fluorinated.
[0028] In some embodiments of the present disclosure, at least one fluoro-modified nucleotide is present in (N)a.
[0029] In some embodiments of the present disclosure, there are at least two fluorinated modified nucleotides in (N)c.
[0030] In some embodiments of the present disclosure, when q'+c'+r'+d'=9, 0≤q'+r'≤4.
[0031] In some embodiments of the present disclosure, the first four nucleotides of (N)b' on the sense strand, in the direction from the 5' end to the 3' end, contain at least two fluorinated modified nucleotides.
[0032] In some embodiments of the present disclosure, each X is independently selected from the following modified nucleotides: 2'-O-methoxyethyl (MOE), 2'-O-TBDMS, 2'-O-TOM, and 2'-O-CH2-O-R5; wherein R5 is a substituted or unsubstituted C1-C3 alkyl group; optionally, the substituents are each independently selected from one or more of the following substituents: halogen, C1-C3 alkyl, C1-C3 alkoxy, and amino; optionally, the halogen is fluorine. wherein MOE is methoxyethyl, TBDMS is tert-butyldimethylchlorosilyl, and TOM is triisopropylmethoxysilyl.
[0033] In some embodiments of the present disclosure, the nucleotides with a disubstituted 2' position are selected from [2'-halogen-2'-halogen], [2'-halogen-2'-alkyl], or [2'-alkyl-2'-alkyl] modified nucleotides; illustratively, selected from [2'-F-2'-F] difluoro-substituted nucleotides. The alkyl group is a C1-C3 alkyl group.
[0034] In some embodiments of the present disclosure, the antisense strand further contains one or two phosphorothioate linkage modifications.
[0035] In some embodiments of the present disclosure, the double-stranded oligonucleotide consists of a double-stranded region and an overhang region, that is, the double-stranded oligonucleotide may further comprise one or more overhang regions at the 3'-end or 5'-end or both ends of one chain, and the overhang region may be 1-6 nucleotides in length.
[0036] In some embodiments of the present disclosure, a double-stranded oligonucleotide molecule containing an overhang region may be represented by the following formula (II):
[0037] SS:5'-(T)t1-(N)a'-(X)p'-(N)b'-(X)q'-(N)c'-(X)r'-(N)d'-(T)t2-3'
[0038] AS:3'-(T)t1-(N)a-(X)p-(N)b-(X)q-(N)c-(T)t2-5'(II),
[0039] Wherein, SS represents the sense strand, AS represents the antisense strand; T represents the overhang nucleotide; t1 and t2 are independently selected from integers ranging from 0 to 6 and cannot be 0 at the same time; the remaining substituents are defined as above in Formula I. The overhang nucleotides T each independently represent a modified or unmodified nucleotide, wherein the modified nucleotide is selected from the group consisting of 2'-O-alkyl (2'-alkoxy), 2'-alkyl, 2'-substituted alkyl, 2'-halo, 2'-deoxy, abasic nucleotides, or inverted nucleotides; optionally, the alkyl group has 1-6 carbon atoms, preferably 1-3 carbon atoms. The substituents are selected from one or more of the following substituents: C1-C6 alkyl, C1-C6 alkoxy, halogen, and amino.
[0040] In some embodiments of the present disclosure, the antisense strand of the double-stranded oligonucleotide has a nucleotide overhang at the 3' end and a flat 5' end; and the overhang includes 1-3 nucleotides. In this case, the double-stranded oligonucleotide molecule can be represented by the following formula (IIa):
[0041] SS:5'-(N)a'-(X)p'-(N)b'-(X)q'-(N)c'-(X)r'-(N)d'-3'
[0042] AS:3'-(T)t1-(N)a-(X)p-(N)b-(X)q-(N)c-5'(IIa),
[0043] Wherein, t1 is selected from an integer of 1-3, and the definitions of the remaining substituents are the same as those of Formula II above.
[0044] In some embodiments of the present disclosure, the overhang region (T) t1 has phosphorothioate groups between the nucleotides. In one embodiment, the double-stranded oligonucleotide of the present disclosure may also have two blunt ends at both ends of its duplex.
[0045] In some embodiments of the present disclosure, the double-stranded oligonucleotides of the present disclosure have a double-stranded region of 19-21 nucleotides (nt) in length.
[0046] In some embodiments of the present disclosure, each strand of the double-stranded oligonucleotide comprises 17-35 nucleotides.
[0047] In some embodiments of the present disclosure, each strand of the double-stranded oligonucleotide comprises 17-25 nucleotides.
[0048] In some embodiments of the present disclosure, each strand of the double-stranded oligonucleotide comprises 17-21 nucleotides.
[0049] In some embodiments of the present disclosure, each strand of the double-stranded oligonucleotide comprises 19-23 nucleotides.
[0050] In some embodiments of the present disclosure, each strand of the double-stranded oligonucleotide comprises 19-21 nucleotides.
[0051] In some embodiments of the present disclosure, the modified nucleotide X in Formula I and Formula II is represented by the following formula (A), or is a tautomer of formula (A):
[0052] Wherein, B is selected from nucleotide bases, including: uracil or its derivatives, thymine or its derivatives, cytosine or its derivatives, 5-methylcytosine or its derivatives, adenine or its derivatives, guanine or its derivatives.
[0053] In some embodiments of the present disclosure, when the modified nucleotide X is a nucleotide modified with a 2' bulky group, W1 and W2 are independently selected from H, -O-MOE, -O-TBDMS, -O-TOM, -O-CH2-OR groups, wherein R is a substituted or unsubstituted C1-C3 alkyl group; and, one of W1 and W2 is H and W1 and W2 are different.
[0054] In some embodiments of the present disclosure, when the modified nucleotide X is a 2' disubstituted group-modified nucleotide, W1 and W2 are both halogens, or one of W1 and W2 is a halogen and the other is a C1-C6 alkyl.
[0055] In some embodiments of the present disclosure, the halogen is fluorine (F).
[0056] In some embodiments of the present disclosure, W1 and W2 are both F.
[0057] In some embodiments of the present disclosure, one of W1 and W2 is F and the other is C1-C3 alkyl.
[0058] In some embodiments of the present disclosure, the overhang (T) t1 of the AS strand comprises at least one 2'-F-2'-Me substituted nucleotide.
[0059] In some embodiments of the present disclosure, the double-stranded oligonucleotide further comprises at least one ligand.
[0060] In some embodiments of the present disclosure, the ligand includes a liver-targeting ligand and a non-liver-targeting ligand.
[0061] In some embodiments of the present disclosure, the ligand is a liver-targeted ASGPR ligand comprising GalNAc or a derivative thereof attached via a branched linker.
[0062] In another aspect, the present disclosure further provides a double-stranded oligonucleotide comprising a sense strand and an antisense strand, each strand having 17 to 35 nucleotides, wherein each nucleotide is a modified or unmodified nucleotide, and the sense strand and the antisense strand are at least partially reverse-complementary to form a double-stranded region; characterized in that the double-stranded oligonucleotide comprises at least one nucleotide modified with a 2'-disubstituent, and each substituent in the 2'-disubstituent is independently selected from methyl or fluorine;
[0063] Wherein, when the double-stranded region of the double-stranded oligonucleotide contains a 2'-disubstituted modified nucleotide, the 2'-disubstituted modified nucleotide is selected from a 2'-diF substituted nucleotide; or, when a position outside the double-stranded region of the double-stranded oligonucleotide contains a 2'-disubstituted modified nucleotide, the 2'-disubstituted modified nucleotide is selected from a 2'-F-2'-Me substituted nucleotide.
[0064] In some embodiments of the present disclosure, the double-stranded oligonucleotide has one or more of the following characteristics:
[0065] (1) When the double-stranded oligonucleotide comprises a 2'-bis-F substituted nucleotide, the 2'-bis-F substituted nucleotide is located at least one of positions 7, 8, 9, or 10 from the 5' end of the sense strand;
[0066] (2) when the double-stranded oligonucleotide comprises a 2'-bis-F substituted nucleotide, the 2'-bis-F substituted nucleotide is located at least one of positions 2, 4, 6, 8, 9, 10, 12, 14, or 16 from the 5' end of the antisense strand;
[0067] (3) When the double-stranded oligonucleotide contains a 2'-F-2'-Me substituted nucleotide, the 2'-F-2'-Me substituted nucleotide is located outside the double-stranded region of the oligonucleotide.
[0068] (4) When the double-stranded oligonucleotide contains a 2'-F-2'-Me substituted nucleotide, the 2'-F-2'-Me substituted nucleotide is located at the overhang at the 3' end of the antisense strand.
[0069] In some embodiments of the present disclosure, in feature (1), when the double-stranded oligonucleotide comprises 2'-bis-F substituted nucleotides, the 2'-bis-F substituted nucleotides are located at least 2 or at least 3 of positions 7, 8, 9 or 10 starting from the 5' end of the sense strand.
[0070] In some embodiments of the present disclosure, in feature (2), when the double-stranded oligonucleotide comprises 2'-bis-F substituted nucleotides, the 2'-bis-F substituted nucleotides are located at least 2 of positions 2, 4, 6, 8, 9, 10, 12, 14 or 16 from the 5' end of the antisense strand.
[0071] In another aspect, the present disclosure also provides an oligonucleotide conjugate, which contains the double-stranded oligonucleotide provided by the present disclosure and a conjugated group conjugated to the double-stranded oligonucleotide; the conjugated group comprises a linker and a pharmaceutically acceptable targeting group and / or a delivery auxiliary group, and the targeting group is selected from a ligand capable of binding to a cell surface receptor, and the delivery auxiliary group is selected from a group capable of increasing the biocompatibility of the oligonucleotide conjugate in the target organ or tissue for delivery.
[0072] In another aspect, the present disclosure also provides a pharmaceutical composition comprising the double-stranded oligonucleotide or its conjugate provided by the present disclosure and a pharmaceutically acceptable carrier.
[0073] In another aspect, the present disclosure also provides use of the double-stranded oligonucleotide, pharmaceutical composition and / or oligonucleotide conjugate described in the present disclosure in the preparation of a medicament for treating and / or preventing diseases or symptoms associated with the level of mRNA expressed by a target gene.
[0074] In another aspect, the present disclosure also provides a method for treating and / or preventing diseases or symptoms associated with the level of mRNA expressed by a target gene, comprising administering the double-stranded oligonucleotide, pharmaceutical composition and / or oligonucleotide conjugate of the present disclosure to a subject in need thereof.
[0075] In another aspect, the present disclosure further provides a method of delivering a double-stranded oligonucleotide of the present disclosure to a specific target in a subject, including by subcutaneous or intravenous administration.
[0076] In another aspect, the present disclosure also provides a method for regulating the expression level of a target gene in a cell, comprising contacting an effective amount of the double-stranded oligonucleotide, pharmaceutical composition and / or oligonucleotide conjugate of the present disclosure with the cell.
[0077] In addition, the present disclosure also provides a kit comprising the double-stranded oligonucleotide, pharmaceutical composition and / or oligonucleotide conjugate of the present disclosure.
[0078] Additional aspects and advantages of the present disclosure will be given in part in the description that follows and, in part, will be obvious from the description that follows, or will be learned through practice of the present disclosure. Beneficial effects
[0079] The double-stranded oligonucleotides and / or oligonucleotide conjugates disclosed herein have good tolerance for specific modifications at single or multiple sites on the sense strand and / or antisense strand, can well maintain the pharmaceutical activity of the oligonucleotides, and have high target gene expression regulation activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0080] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the following is a brief introduction to the drawings required for use in the embodiments. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other relevant drawings can be obtained based on these drawings without creative work.
[0081] FIG1 shows the relative expression levels of the target gene CC3 mRNA after HepG2 cells were transfected with TBDMS-modified siRNAs at different sites on the positive strand in Example 2 of the present disclosure;
[0082] FIG2 shows the relative expression levels of the target gene CC3 mRNA after HepG2 cells were transfected with siRNA modified with TBDMS at different sites of the antisense strand in Example 2 of the present disclosure;
[0083] FIG3 shows the expression level of serum CC3 protein in mice after administration of siRNA conjugates in Example 3 of the present disclosure;
[0084] FIG4 shows the relative expression level of the target gene ANGPTL3 mRNA after mouse primary hepatocytes freely take up TBDMS-modified siRNA at different sites of the positive chain in Example 4 of the present disclosure;
[0085] FIG5 shows the relative expression level of the target gene ANGPTL3 mRNA after mouse primary hepatocytes freely take up siRNA modified with TBDMS at different sites of the antisense chain in Example 4 of the present disclosure;
[0086] FIG6 shows the expression level of ANGPTL3 mRNA in mice after administration of the siRNA conjugate in Example 5 of the present disclosure;
[0087] FIG7 shows the relative expression level of the target gene FXI mRNA after mouse primary hepatocytes freely take up TBDMS-modified siRNAs at different sites of the positive chain in Example 6 of the present disclosure;
[0088] FIG8 shows the relative expression level of the target gene FXI mRNA after mouse primary hepatocytes freely take up siRNA modified with TBDMS at different sites of the antisense chain in Example 6 of the present disclosure;
[0089] FIG9 shows the expression level of CC3 mRNA in mice after administration of the siRNA conjugate in Example 7 of the present disclosure;
[0090] FIG10 shows the relative expression levels of target gene CC3 mRNA after HepG2 cells were transfected with siRNA modified with MOE at different sites of the sense chain in Example 8 of the present disclosure;
[0091] FIG11 shows the relative expression level of target gene CC3 mRNA after HepG2 cells were transfected with siRNA modified with MOE at different sites of the antisense strand in Example 8 of the present disclosure;
[0092] FIG12 shows the relative expression level of target gene CC3 mRNA after HepG2 cells were transfected with positive chain multi-site MOE-modified siRNA in Example 9 of the present disclosure;
[0093] FIG13 shows the relative expression level of target gene CC3 mRNA after HepG2 cells were transfected with antisense strand multi-site MOE-modified siRNA in Example 9 of the present disclosure;
[0094] FIG14 shows the relative expression level of target gene CC3 mRNA after HepG2 cells were transfected with sense and antisense strands of multi-site MOE-modified siRNA in Example 9 of the present disclosure;
[0095] FIG15 shows the expression level of CC3 mRNA in mice after administration of siRNA conjugates (RZ502031, RZ502033, RZ502034, RZ502035, RZ502039) in Example 10 of the present disclosure;
[0096] FIG16 shows the expression level of CC3 mRNA in mice after administration of siRNA conjugates (RZ502031, RZ502036, RZ502049, RZ502087) in Example 10 of the present disclosure;
[0097] FIG17 shows the expression level of SOD1 mRNA in mice after administration of the siRNA conjugates in Example 11 of the present disclosure;
[0098] Figures 18a-d show the relative expression levels of the target gene CC3 mRNA after HepG2 cells were transfected with siRNA conjugates (RZ002003, RZ002006, RZ002011 and RZ002031 converted into different modification schemes) in Example 12 of the present disclosure.
[0099] FIG19 shows the relative expression level of the target gene CC3 mRNA after Huh7 cells were transfected with siRNA conjugates (RZ003017 and RZ003020 converted into different modification schemes) in Example 13 of the present disclosure.
[0100] FIG20 shows the AGT protein expression level in the serum of hREN×hAGT hypertensive mice after administration of siRNA conjugates (RZ003021, RZ003065, RZ003066) in Example 14 of the present disclosure.
[0101] FIG21 shows the relative expression levels of target gene mRNA in the HDI mouse model of LPA target after administration of siRNA conjugates (RZ001032, RZ001034, RZ001037, RZ001039) in Example 15 of the present disclosure.
[0102] FIG22 shows the LPA protein expression level in hApo(a) transgenic mice after administration of siRNA conjugates (RZ001032, RZ001034) in Example 16 of the present disclosure.
[0103] FIG23 shows the relative expression level of SOD1 mRNA in mice after administration of siRNA conjugates modified with NM062 and NM063 at different sites of the antisense chain in Example 17 of the present disclosure.
[0104] FIG24 shows the relative expression level of the target gene SOD1 mRNA after the mouse primary hepatocytes freely take up the antisense chains NM096, NM097, NM098 and NM099 modified siRNA conjugates in Example 18 of the present disclosure.
[0105] FIG25 shows the relative expression level of the target gene SOD1 mRNA after the mouse primary hepatocytes freely took up the sense chain 2'-position double F-modified siRNA conjugate (RZ599051) in Example 19 of the present disclosure.
[0106] FIG26 shows the relative expression level of the target gene SOD1 mRNA after the mouse primary hepatocytes freely took up the sense chain 2'-position double F-modified siRNA conjugates (RZ599055, RZ599056) in Example 20 of the present disclosure.
[0107] FIG27 shows the relative expression level of the target gene ANGPTL3 mRNA after the mouse primary hepatocytes freely took up the 2′-position double F-modified siRNA conjugate of the positive chain in Example 21 of the present disclosure.
[0108] FIG28 shows the relative expression level of the target gene CFB mRNA after the mouse primary hepatocytes freely took up the 2′-position double F-modified siRNA conjugate of the sense chain in Example 22 of the present disclosure.
[0109] FIG29 shows the relative expression level of the target gene CFB mRNA in mice after administration of the sense strand 2'-position double F-modified siRNA conjugate in Example 23 of the present disclosure.
[0110] FIG30 shows the relative expression level of the target gene ANGPTL3 mRNA after the antisense chain 2'-position double F-modified siRNA conjugate was freely taken up by primary mouse hepatocytes in Example 24 of the present disclosure.
[0111] FIG31 shows the relative expression level of the target gene CFB mRNA after the antisense chain 2′-position double F-modified siRNA conjugates (RZM11504, RZM11505) were freely taken up by primary mouse hepatocytes in Example 25 of the present disclosure.
[0112] FIG32 shows the relative expression level of the target gene CFB mRNA after the antisense chain 2'-position double F-modified siRNA conjugate (RZM11507) was freely taken up by primary mouse hepatocytes in Example 26 of the present disclosure.
[0113] FIG33 shows the relative expression level of the target gene CFB mRNA in mice after administration of the antisense chain 2'-position double F-modified siRNA conjugate in Example 27 of the present disclosure.
[0114] FIG34 shows the relative expression level of the target gene C4B mRNA in mice after administration of the antisense chain 2′-position double F-modified siRNA conjugate in Example 28 of the present disclosure.
[0115] FIG35 shows the relative expression level of the target gene SOD1 mRNA in mice after administration of the antisense strand-containing NM054-modified siRNA conjugate in Example 29 of the present disclosure.
[0116] FIG36 shows the relative expression level of the target gene ANGPTL3 mRNA in mice after administration of the antisense strand-containing NM054-modified siRNA conjugate in Example 30 of the present disclosure.
[0117] FIG37 shows the CC3 protein expression level in the serum of cynomolgus monkeys after administration of siRNA conjugates (RZ002099, RZ002101, RZ002106, RZ002113) in Example 31 of the present disclosure.
[0118] FIG38 shows the AGT protein expression level in the serum of cynomolgus monkeys after administration of the siRNA conjugate (RZ003069) in Example 32 of the present disclosure. DETAILED DESCRIPTION
[0119] The embodiments of the present disclosure are described in detail below. The embodiments described below are exemplary and are only used to explain the present disclosure, and should not be understood as limiting the present disclosure.
[0120] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Therefore, features defined as "first" or "second" may explicitly or implicitly include one or more of the features. Furthermore, in the description of this disclosure, unless otherwise specified, "plurality" means two or more.
[0121] The endpoints of the ranges and any values disclosed herein are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoints of each range, the endpoints of each range and individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered to be specifically disclosed herein.
[0122] In order to make the present disclosure more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which the present disclosure belongs.
[0123] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present disclosure, but not excluding other contents.
[0124] As used herein, the terms "optionally," "optional," or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0125] In this article, the term "complement component 3" (CC3) refers to the intrinsic component involved in the three complement activation pathways and is the complement component with the highest plasma concentration. During complement activation, C3 is cleaved by C3 convertase into the small fragment C3a and the large fragment C3b. C3a is free in the fluid phase and has anaphylatoxin activity; C3b is a key component of the C5 convertase in the three activation pathways and the C3 convertase in the alternative pathway. It can also bind to immune complexes, microorganisms, macromolecular substances, or cell membranes, thereby mediating opsonization and immune adhesion.
[0126] As used herein, the term "angiopoietin-like 3" (ANGPTL3) refers to a member of the angiopoietin-like protein family, which also includes ANGPTL4 and ANGPTL8, involved in regulating lipid metabolism. The protein encoded by the ANGPTL3 gene is produced exclusively in the liver and secreted into the circulation. In the liver, ANGPTL3 is produced exclusively by hepatocytes, and its expression is regulated by the hydroxysterol-activated liver X receptor (LXR).
[0127] As used herein, the term "factor XI" (FXI) refers to factor XI (FXI), a plasma glycoprotein involved in the contact phase of the coagulation process (intrinsic coagulation pathway). FXI is very important for normal hemostasis in vivo.
[0128] As used herein, the term "oligonucleotide" refers to a nucleic acid molecule (RNA or DNA) having a length of, for example, less than 100, 200 or 300 nucleotides.
[0129] As used herein, the term 'LNA' refers to locked nucleic acid, which is a modified RNA nucleotide. The ribose moiety of an LNA nucleotide is modified with an additional bridge (e.g., a methylene bridge or an ethylene bridge) linking the 2' hydroxyl group to the 4' carbon of the same ribose. The term 'ENA' refers to ethylene-bridged nucleic acid and generally refers to constrained or inaccessible RNA. The term 'BNA' refers to bridged nucleic acid, which can contain a 5-membered, 6-membered, or even 7-membered bridge structure with a "fixed" C3'-endo sugar condensation, which is generally incorporated into the 2'-, 4'-position of the ribose to provide a 2', 4'-BNA nucleotide (e.g., LNA or ENA). The term GNA refers to glycerol nucleic acid, and UNA refers to open-ring nucleotide.
[0130] In this article, unless otherwise specified, capital letters C, G, U, A, and T represent the base composition of nucleotides; lowercase letter m indicates that the nucleotide adjacent to the left of letter m is a methoxy-modified nucleotide; lowercase letter f indicates that the nucleotide adjacent to the left of letter f is a fluorine-modified nucleotide; lowercase letter s indicates that the two nucleotides adjacent to the left and right of letter s are connected by phosphorothioate groups.
[0131] As used herein, "fluoro-modified nucleotides" refer to nucleotides in which the 2'-hydroxyl group of the ribose group is replaced by fluorine. Unless otherwise specified, fluoro-modification refers to monofluoro-modification. "Nucleotide-like" or "nucleotide analogs" refer to groups that can replace nucleotides in nucleic acids but differ in structure from adenine, guanine, cytosine, uracil, thymine, or deoxyribonucleotides. Examples include isonucleotides, bridged nucleic acids (BNAs), and acyclic nucleotides. "Methoxy-modified nucleotides" refer to nucleotides in which the 2'-hydroxyl group of the ribose group is replaced by a methoxy group. Herein, 2-methoxy can also be represented by 2'-OMe, and 2-methoxy and 2'-OMe can be used interchangeably. Unless otherwise specified, "modified nucleotides" herein and below refer to nucleotides in which the 2'-hydroxyl group of the ribose group is modified.
[0132] Nucleotide herein refers to an individual nucleotide or a nucleotide residue in an oligonucleotide; nucleotide herein may be singular or plural, and when plural, may refer to a class of nucleotides. Double-stranded oligonucleotide herein may also be represented by dsRNA, siRNA, or double-stranded oligonucleotide, and double-stranded oligonucleotide, double-stranded oligonucleotide, dsRNA, and siRNA may be used interchangeably herein.
[0133] As used herein, "alkyl" refers to straight and branched chains having a specified number of carbon atoms, typically 1 to 20 carbon atoms, for example, C1-C6 alkyl, which includes straight and branched chain alkyl groups having 1 to 6 carbon atoms.
[0134] In this article, the siRNA molecule is composed of two chains, wherein the chain that binds to the target mRNA is called the antisense strand or guide strand, and the other chain is called the sense strand or passenger strand. The term "antisense strand" refers to such a chain of siRNA, and the chain includes a region that is completely or substantially complementary to the target sequence. The term "sense strand" refers to such a chain of siRNA, and the chain includes a region that is basically complementary to the region of the antisense strand as the term defined herein. The term "complementary region" refers to a region on the antisense strand that is completely or substantially complementary to the target mRNA sequence. In the case where the complementary region is not completely complementary to the target sequence, mismatches can be located in the interior or terminal regions of the molecule. As used herein, the term "complementary" refers to the ability of a first polynucleotide to hybridize with a second polynucleotide under certain conditions, such as stringent conditions.
[0135] In the context of this article, the expressions "duplex", "duplex region" and "double-stranded region" are used interchangeably and have the meanings well known to those skilled in the art, that is, in a double-stranded nucleic acid molecule, the sense strand and the antisense strand are paired in a complementary manner to form a double-stranded structure.
[0136] As used herein, the expressions "complementary" and "reverse complementary" are used interchangeably and have the meanings known to those skilled in the art, i.e., in a double-stranded nucleic acid molecule, the bases of one strand are paired with bases on the other strand in a complementary manner.
[0137] As used herein, unless otherwise specified, the term "complementary" includes "substantially reverse complementary," "essentially reverse complementary," and "perfectly reverse complementary." "Substantially reverse complementary" means that there are no more than three base mismatches between the two nucleotide sequences involved; "essentially reverse complementary" means that there is no more than one base mismatch between the two nucleotide sequences involved; and "perfectly reverse complementary" means that there are no base mismatches between the two nucleotide sequences involved.
[0138] As used herein, unless otherwise indicated, "conjugation" refers to the covalent attachment of two or more chemical moieties, each with a specific function, to one another; accordingly, a "conjugate" refers to a compound formed by covalent attachment of these chemical moieties. Furthermore, an "oligonucleotide conjugate" refers to a compound formed by covalent attachment of one or more chemical moieties with a specific function to an oligonucleotide. In the context of the present disclosure, a "conjugate molecule" should be understood as a specific compound that can be conjugated to an oligonucleotide through a reaction to ultimately form the oligonucleotide conjugate of the present disclosure.
[0139] After repeated research and experiments, the inventors found that specific modifications at single or multiple sites on specific sites of the sense strand and / or antisense strand of a double-stranded oligonucleotide can be well tolerated and can well maintain or even further enhance the activity of the double-stranded oligonucleotide molecule.
[0140] In a first aspect, the present disclosure provides double-stranded oligonucleotide molecules with modifications that do not reduce inhibitory activity or even increase inhibitory activity, and reagents thereof, as well as pharmaceutical compositions suitable for therapeutic use.
[0141] In a specific embodiment, the present disclosure provides a double-stranded oligonucleotide (dsRNA) for inhibiting target gene expression, the double-stranded oligonucleotide comprising a sense strand and an antisense strand, each strand having 17 to 35 nucleotides, wherein each nucleotide is a modified or unmodified nucleotide; the sense strand and the antisense strand are at least partially reverse-complemented to form a double-stranded region; in the direction from the 5' end to the 3' end, the nucleotide sequence of the sense strand and / or the antisense strand has a large steric volume modified nucleotide and / or a disubstituted modified nucleotide at a specific position, wherein the large steric volume modified nucleotide refers to a nucleotide in which the 2' hydroxyl group of the ribose of the nucleotide is replaced by a large steric volume group, and the 2' large steric volume group is selected from a group having a steric volume greater than 2'-O-methyl; the disubstituted modified nucleotide refers to a nucleotide in which the hydroxyl and hydrogen at the 2' position of the ribose of the nucleotide are simultaneously replaced. Optionally, each substituent in the disubstituted group is independently selected from a C1-C6 alkyl or a halogen.
[0142] In some embodiments, in the double-stranded oligonucleotide disclosed herein, in the 5' to 3' direction, at least one of the 8th, 9th, 10th, or 15th nucleotides of the antisense strand is a sterically bulky modified nucleotide or a disubstituted modified nucleotide; and / or, the sense strand may or may not contain a modified nucleotide X; when the sense strand contains a modified nucleotide X, at least one nucleotide X is located relative to any position of the 2nd, 8th, or 15th nucleotide of the antisense strand (in the 5' to 3' direction).
[0143] In some embodiments, the antisense strand and the sense strand of the double-stranded oligonucleotide are complementary to each other to form a double-stranded region, and the structure of the double-stranded region is represented by the following formula (I):
[0144] SS:5'-(N)a'-(X)p'-(N)b'-(X)q'-(N)c'-(X)r'-(N)d'-3'
[0145] AS:3'-(N)a-(X)p-(N)b-(X)q-(N)c-5'(I),
[0146] Among them, SS represents the sense strand and AS represents the antisense strand.
[0147] In formula (I), each X independently represents a nucleotide in which the 2'-hydroxyl group in the ribose is replaced by a large steric bulk group or a nucleotide in which the 2'-hydroxyl group and hydrogen are replaced by a disubstituent; the 2'-hydroxyl group is selected from a group having a steric bulk greater than that of the 2'-methoxy group; and each substituent in the disubstituent is independently selected from a C1-C6 alkyl group or a halogen.
[0148] In some embodiments, when X represents a nucleotide in which the 2'-hydroxyl group of the ribose is replaced by a bulky group, it is independently selected from the following 2'-modified nucleotides: 2'-(O) m1 (CH2) n (O) m2 R1, wherein m1 or m2 are each independently 0 or 1, and n is selected from an integer from 0 to 6; R1 is selected from a substituted or unsubstituted C1-C6 alkyl group, or -Si(R2)3; wherein R2 are each independently selected from: a substituted or unsubstituted C 1- C6 alkyl, substituted or unsubstituted C1-C6 alkoxy; wherein the substitution or substituent is selected from one or more of the following: halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, amino, cycloalkyl with no more than 6 carbon atoms, aryl with no more than 12 carbon atoms, or heteroaryl with no more than 12 carbon atoms.
[0149] In some embodiments, each of the Xs is independently selected from the following modified nucleotides: 2'-O(CH2) n OR1 or 2'-R3-2'-R4. Wherein, n is 1 or 2, R1 is selected from a substituted or unsubstituted C1-C6 alkyl group, or -Si(R2)3; wherein R2 is independently selected from a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted C1-C6 alkoxy group; wherein the substituent is selected from a halogen, a C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxyl group, an amino group, a cycloalkyl group having no more than 6 carbon atoms, an aryl group having no more than 12 carbon atoms, or a heteroaryl group having no more than 12 carbon atoms.
[0150] wherein R3 and R4 are each independently selected from a C1-C6 alkyl group or a halogen. Optionally, the halogen is fluorine. Optionally, the C1-C6 alkyl group is selected from a methyl group or an ethyl group.
[0151] In Formula I, each N independently represents an unmodified nucleotide, or a nucleotide that is different from X and has a modified 2' position in the ribose, wherein the modified nucleotide is selected from the group consisting of 2'-O-alkyl, 2'-alkyl, 2'-substituted alkyl, 2'-halo, 2'-deoxy, or a nucleotide-like group; the nucleotide-like group is selected from ENA, BNA, LNA, GNA, or UNA; optionally, the alkyl or alkoxy group has 1-6 carbon atoms.
[0152] In some embodiments, each N is independently selected from a 2'-OMe modified, 2'-F modified, or 2'-H modified nucleotide, wherein 2'-H or 2'-deoxy modified nucleotides have the same meaning, i.e., the 2'-hydroxyl group is replaced by H. In other embodiments, each N is independently selected from a 2'-OMe modified or 2'-F modified nucleotide.
[0153] In some embodiments, the nucleotide X in which the 2'-hydroxyl group is substituted by a large steric bulk group is independently selected from the following modified nucleotides: 2'-O-methoxyethyl (MOE), 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-OR group, R is a substituted or unsubstituted C1-C3 alkyl group; optionally, the substituents are independently selected from one or more of the following substituents: halogen, C1-C3 alkyl, C1-C3 alkoxy, amino.
[0154] In some embodiments, each X is independently selected from the following modified nucleotides: 2'-O-methoxyethyl (MOE), 2'-O-CH2-O-CH2-CH3, 2'-O-CH2-O-CH2-CF3.
[0155] In some embodiments, the nucleotide with a disubstituted 2' position is selected from a nucleotide modified with [2'-halo-2'-halo], [2'-halo-2'-alkyl], or [2'-alkyl-2'-alkyl]; optionally, selected from a nucleotide modified with [2'-F-2'-F] or [2'-fluoro-2'-alkyl]. Optionally, the alkyl group is a C1-C3 alkyl group.
[0156] In Formula I, a, a', p, p', b, b', q, q', c, c', r', and d' each independently represent the number of nucleotides. For example, in (N)a, when a is 3, it represents three consecutive modified nucleotides NNN, wherein each N may be the same or different. wherein: a' is an integer from 3 to 8; p' is an integer from 0 to 3; b' is an integer from 4 to 13; q' is an integer from 0 to 4; c' is an integer from 3 to 9; r' is an integer from 0 to 3; d' is an integer from 0 to 9; a is an integer from 4 to 7; p is an integer from 0 to 1; b is an integer from 4 to 8; q is an integer from 0 to 4; c is an integer from 6 to 10; and p', q', r', p, and q are not all 0 at the same time.
[0157] Optionally, q' and r' are not 0 at the same time.
[0158] Optionally, q'+c'+r'+d'=9, and 0≤q'+r'≤4.
[0159] Optionally, there is at least one fluorinated modified nucleotide in each of (N)a and (N)b, and there are at least two fluorinated modified nucleotides in (N)c.
[0160] In some embodiments, the structure of the nucleotide X described in the present disclosure may be as shown in the following formula (A), or a tautomer of formula (A):
[0161] Wherein, B is selected from nucleotide bases, including: uracil or its derivatives, thymine or its derivatives, cytosine or its derivatives, 5-methylcytosine or its derivatives, adenine or its derivatives, guanine or its derivatives.
[0162] In some embodiments of the present disclosure, when the modified nucleotide X is a nucleotide modified with a 2' bulky group, W1 and W2 are independently selected from H, -O-MOE, -O-TBDMS, -O-TOM, -O-CH2-OR groups, wherein R is a substituted or unsubstituted C1-C3 alkyl group; and, one of W1 and W2 is H and W1 and W2 are different.
[0163] In some embodiments of the present disclosure, when the modified nucleotide X is a 2' disubstituted group-modified nucleotide, W1 and W2 are both halogens, or one of W1 and W2 is a halogen and the other is a C1-C6 alkyl.
[0164] In some embodiments of the present disclosure, the halogen is fluorine (F).
[0165] In some embodiments of the present disclosure, W1 and W2 are both F.
[0166] In some embodiments of the present disclosure, one of W1 and W2 is F and the other is methyl or ethyl.
[0167] The wavy lines represent the bonds between nucleotides.
[0168] In some embodiments, the double-stranded oligonucleotides of the present invention may further comprise one or more overhang regions, the overhang region being 1-6 nucleotides in length, in addition to comprising the above-mentioned double-stranded region. These overhangs may make one chain longer than the other, or the two chains have the same length. The overhang may form a mismatch with the target mRNA, or it may be complementary to the targeted gene sequence, or it may be other sequences, for example, the sense strand and the antisense strand may be connected to form a hairpin by additional bases, or may be connected by other non-base linkers. In one example, the nucleotides in the overhang groups may each independently be modified or unmodified nucleotides.
[0169] In one example, the overhang is present at the 3' end of the sense strand, the antisense strand, or both strands. Optionally, the double-stranded oligonucleotide of the present disclosure contains only one overhang. In another example, the 3'-overhang is present in the antisense strand. In another example, the 3'-overhang is present in the sense strand.
[0170] In some embodiments of the present disclosure, the double-stranded oligonucleotide molecule comprising an overhang region may be represented by the following Formula II:
[0171] SS:5'-(T)t1-(N)a'-(X)p'-(N)b'-(X)q'-(N)c'-(X)r'-(N)d'-(T)t2-3'
[0172] AS:3'-(T)t1-(N)a-(X)p-(N)b-(X)q-(N)c-(T)t2-5'(II),
[0173] Wherein, SS represents the sense strand, AS represents the antisense strand; T represents the overhanging nucleotide; t1 and t2 are independently selected from integers of 0-6 and cannot be 0 at the same time; the definitions of the remaining substituents are the same as those of formula (I).
[0174] Wherein, the protruding end nucleotides T each independently represent a modified or unmodified nucleotide, and the modified nucleotide is selected from the following group: 2'-alkoxy, 2'-alkoxy substituted by C1-C6, 2'-alkyl, 2'-alkyl substituted by C1-C6, 2'-halo, 2'-deoxy, abasic nucleotide, or inverted nucleotide; optionally, the number of carbon atoms of the alkyl and alkoxy groups is 1-6, preferably the number of carbon atoms is 1-3.
[0175] In some embodiments of the present disclosure, the antisense strand of the double-stranded oligonucleotide has a nucleotide overhang at the 3' end; and the overhang includes 1-3 nucleotides. In this case, the double-stranded oligonucleotide molecule can be represented by the following formula (IIa):
[0176] SS:5'-(N)a'-(X)p'-(N)b'-(X)q'-(N)c'-(X)r'-(N)d'-3'
[0177] AS:3'-(T)t1-(N)a-(X)p-(N)b-(X)q-(N)c-5'(IIa),
[0178] wherein t1 is selected from an integer of 1-3, and the remaining substituents are defined as above in formula (II).
[0179] In some examples, the overhang group (T) t1 has a phosphorothioate group between the two nucleotides. In one embodiment, the double-stranded oligonucleotide of the present disclosure may further have two blunt ends at both ends of the duplex.
[0180] In some embodiments, the double-stranded region of the double-stranded oligonucleotide of the present disclosure has a length of 17-30 nucleotide pairs. For example, the double-stranded region has a length of 17-25 nucleotide pairs, 17-21 nucleotide pairs, 17-19 nucleotide pairs, or 19-25 nucleotide pairs, 19-23 nucleotide pairs, 19-21 nucleotide pairs, or 21-25 nucleotide pairs, 21-23 nucleotide pairs.
[0181] In some embodiments, the length of the double-stranded region is selected from 17, 18, 19, 20, 21, 22, and 23 nucleotide pairs.
[0182] In one embodiment, the duplex region is 19 or 21 nucleotide pairs in length.
[0183] In some embodiments, in the double-stranded oligonucleotides of the present disclosure, the antisense strand in the double-stranded region shown in formula (I) is complementary to the sense strand, and the complementary includes: substantially reverse complementary, substantially reverse complementary, or completely reverse complementary. In one embodiment, the antisense strand in the double-stranded region shown in formula (I) is completely reverse complementary to the sense strand. In another embodiment, there is 1-3 base mismatches between the antisense strand and the sense strand in the double-stranded region shown in formula (I), thereby achieving substantially reverse complementary or substantially reverse complementary.
[0184] In some embodiments, each strand of the double-stranded oligonucleotide of formula (II) provided herein can have a length of 17-35 nucleotides. For example, each strand of the double-stranded oligonucleotide can have a length of 17-23 nucleotides, 17-21 nucleotides, 17-19 nucleotides, or 19-25 nucleotides, 19-23 nucleotides, 19-21 nucleotides, or 21-23 nucleotides.
[0185] In some embodiments, in the double-stranded oligonucleotide molecules of the present disclosure, nucleotide X is a nucleotide modified with a bulky group, and: one or more nucleotides X are present and located only in the antisense strand. In some embodiments, from the 5' end to the 3' end, when the antisense strand contains only one X, X can be located at any position between 8 and 10 or at position 15 of the antisense strand. Optionally, X can be located at position 10 or 15 of the antisense strand.
[0186] In some embodiments, in the double-stranded oligonucleotide molecules disclosed herein, the nucleotide X is a nucleotide modified with a large steric bulk group, and: one or more Xs are present and located only in the sense strand. Optionally, the sense strand may contain one or two Xs. Optionally, the X in the sense strand may be located in a position opposite to any position at position 2, 8, or 15 (based on the 5' end) of the antisense strand. Wherein, the position refers to the position (i.e., relative position) of a nucleotide on one strand in the duplex region to the corresponding complementary nucleotide on the other strand.
[0187] In some embodiments, nucleotide X is a nucleotide modified with a large steric bulk group; in a double-stranded oligonucleotide molecule containing the double-stranded region structure described in formula (I) of the present disclosure, when the duplex is 19 nucleotide pairs (or the double-stranded oligonucleotide molecule is 19 / 21 nucleotides), at least one nucleotide X is located between positions 7 and 9 of the sense strand (calculated in the 5'-3' direction), and positions 7 to 9 of the sense strand are in alignment with nucleotides 11 to 13 of the antisense strand (calculated in the 5'-3' direction).
[0188] In some embodiments, the nucleotide X is a nucleotide modified with a large steric bulk group; in a double-stranded oligonucleotide molecule containing the duplex structure described in Formula (I) of the present disclosure, two or more nucleotides X are present and are respectively located in the antisense strand and the sense strand. In some embodiments, when the antisense strand contains only one X, the sense strand may contain one or two Xs. In some embodiments, X can be located at any position between 8 and 10 or 15 (starting from the 5' end) of the antisense strand; at the same time, X in the sense strand can be located in the para position relative to any position between 2, 8, 12 or 15 (starting from the 5' end) of the antisense strand.
[0189] In some embodiments, the nucleotide X is a nucleotide modified with a large steric bulky group; in the double-stranded oligonucleotide molecule, there is at least one X and is located at position 15 of the antisense strand (starting from the 5'-end).
[0190] In some embodiments, the 2'-bulky steric group is 2'-O-methoxyethyl (MOE). In other embodiments, the 2'-bulky steric group is 2'-O-CH2-O-CH2-CH3, or 2'-O-CH2-O-CH2-CF3.
[0191] In some embodiments, in the double-stranded oligonucleotide of formula (II) or the double-stranded oligonucleotide comprising the double-stranded region structure of formula (I), wherein: N is independently selected from 2'-OMe modified, 2'-F modified or 2'-deoxy modified nucleotides; X is independently selected from 2'-O-MOE, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2-CH3, 2'-O-CH2-O-CH2-CF3 modified nucleotides; wherein, a, a', p, The number of nucleotides represented by p', b, b', q, q', c, c', r', and d' are each independently defined as follows: a' is an integer from 3 to 8; p' is an integer from 0 to 3; b' is an integer from 4 to 13; q' is an integer from 0 to 4; c' is an integer from 3 to 9; r' is an integer from 0 to 3; d' is an integer from 0 to 9; a is an integer from 4 to 7; p is an integer from 0 to 1; b is an integer from 4 to 8; q is an integer from 0 to 4; c is an integer from 6 to 10; and p', q', r', p, and q are not all 0 at the same time.
[0192] Optionally, q' and r' are not zero at the same time.
[0193] Optionally, q′+c′+r′+d′=9, and 0≤q′+r′≤4.
[0194] Optionally, at least one fluorinated modified nucleotide is present in both (N)a and (N)b, and at least two fluorinated modified nucleotides are present in (N)c.
[0195] In one embodiment, p'=0, ie, when (X)p' is absent, a'=6. In another embodiment, when the double-stranded oligonucleotide has SS / AS=21 / 23 nt, a'=8.
[0196] In one embodiment, when p'=1, X is located on the sense strand and is located at any position opposite to positions 14-16 of the antisense strand (starting from the 5'-end).
[0197] In one embodiment, there is at least one X in (X)p' and one X is located at the para position to position 15 (from the 5' end) of the antisense strand; optionally, when p'=1, X is located at the para position to position 15 (from the 5' end) of the antisense strand.
[0198] In one embodiment, when (X)q' and (X)r' are both absent (i.e., q' and r' are both 0), the sense strand contains only (X)p', and the sense strand SS of the double-stranded region is: 5'-(N)a'-(X)p'-(N)k'-(N)d'-3'; wherein k'=7-22.
[0199] In one embodiment, the first four nucleotides of (N)b' on the sense strand (starting from the 5'-end) are located at the para position relative to positions 10-13 (starting from the 5'-end) of the antisense strand, and the first four nucleotides contain at least two fluorinated modified nucleotides.
[0200] In one embodiment, q' is preferably 0-2; more preferably 0-1.
[0201] In one embodiment, when both r' and q' are not 0, d' is not 0. For example, when r'=1 and q'=1, b' and c' can be 5, and d' is 1 (in this case, one X is at position 12 and the other X is at position 18 on the sense strand, starting from the 5'-end).
[0202] In one embodiment, q' and r' are not both 0. Further, when q' and r' are not both 0, at least one X on the sense strand is located para to the seed region (positions 1-8, starting from the 5' end) of the antisense strand. In another embodiment, at least one X on the sense strand is located para to positions 2-8 (starting from the 5' end) of the seed region of the antisense strand.
[0203] In one embodiment, d'=1-9.
[0204] In one embodiment, q'+c'+r'+d'=9, and 0≤q'+r'≤4.
[0205] In one embodiment, when (X)p is absent, a=5-7, for example, when the dsRNA is SS / AS=21 / 23 nt, a=7.
[0206] In one embodiment: there is at least one fluorinated modified nucleotide in (N)a; preferably located at position 16 of the antisense strand (starting from the 5'-end).
[0207] In one embodiment, when p≠0 (ie, p=1), X is located at position 15 of the antisense strand (starting from the 5'-end).
[0208] In one embodiment, when (X)q is absent, b is 8 (ie, b = 8 when q = 0).
[0209] In one embodiment, when (X)q is absent, b+c=14.
[0210] In a preferred embodiment, there is at least one fluorinated modified nucleotide in (N)b, preferably located at position 14 (from the 5' end) of the antisense strand.
[0211] In one embodiment, c is 10 when (X)q is absent.
[0212] In a preferred embodiment, there are at least two fluorinated modified nucleotides in (N)c; more preferably, there are at least two fluorinated modified nucleotides and they are located at positions 2 and 6 (starting from the 5'-end) of the antisense strand, respectively.
[0213] In some embodiments, in the double-stranded oligonucleotide of formula (II) disclosed herein or the double-stranded oligonucleotide comprising the double-stranded region of formula (I), the sequences of the antisense strand and the sense strand are sufficiently complementary to each other to form a double-stranded region of 17 to 23 base pairs; wherein each N is independently a 2'-OMe-modified, 2'-F-modified, or 2'-deoxy-modified nucleotide; each X is independently selected from a 2'-O-MOE, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2-CH3, or 2'-O-CH2-O-CH2-CF3-modified nucleotide; and each of a', p, p', b, b', q, q', c, c', r', and d' independently represents the number of nucleotides, further defined as follows:
[0214] a' is an integer from 3 to 8; p' is an integer from 0 to 2; b' is an integer from 4 to 12; q' is an integer from 0 to 2; c' is an integer from 3 to 8; r' is an integer from 0 to 2; d' is an integer from 1 to 9; a is an integer from 4 to 7; p is 0 or 1; b is an integer from 4 to 8; q is an integer from 0 to 2; c is an integer from 6 to 10; and:
[0215] 1) There is at least one fluorinated modified nucleotide in each of (N)a and (N)b, and there are at least two fluorinated modified nucleotides in (N)c; q'+c'+r'+d'=9, and 0≤q'+r'≤4;
[0216] 2) The first four nucleotides of (N)b' (starting from the 5'-end) contain at least two fluorinated modified nucleotides.
[0217] In some embodiments, in the double-stranded oligonucleotide of formula (II) disclosed herein or the double-stranded oligonucleotide comprising the double-stranded region of formula (I), the sequences of the antisense strand and the sense strand are sufficiently complementary to each other to form a duplex region of 19 to 21 base pairs; wherein each N is independently selected from a 2'-OMe-modified, 2'-F-modified or 2'-deoxy-modified nucleotide; each X is independently selected from 2'-O-MOE, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2 -CH3, 2'-O-CH2-O-CH2-CF3 modified nucleotides; a', p, p', b, b', q, q', c, c', r', d' each independently represent the number of nucleotides: a' is an integer of 3-8; p' is 0 or 1; b' is an integer of 4-13; q' is 0 or 1; c' is an integer of 3-9; r' is 0 or 1; d' is an integer of 1-8; a is an integer of 4-7; p is 1; b is an integer of 4-8; q is 0 or 1; c is an integer of 6-10; and:
[0218] 1) There is at least one fluorinated modified nucleotide in (N)a, and position 16 of the antisense strand (starting from the 5'-end) is a fluorinated modified nucleotide;
[0219] 2) (N) b contains at least one fluorinated modified nucleotide, and position 14 of the antisense strand (starting from the 5'-end) is a fluorinated modified nucleotide;
[0220] 3) There are at least two fluorinated modified nucleotides in (N)c, and positions 2 and 6 (starting from the 5'-end) of the antisense strand are both fluorinated modified nucleotides;
[0221] 4) q'+c'+r'+d'=9, 0≤q'+r'≤2; optionally, q' and r' are not 0 at the same time;
[0222] 5) There is at least one X on the sense strand located opposite to the antisense strand seed region (positions 1-8, starting from the 5' end);
[0223] 6) (N) The first four nucleotides of b' (based on the 5'-3' direction) are located in the opposite position (at the opposite site) to positions 10-13 (starting from the 5' end) of the antisense strand, and the first four nucleotides contain at least two fluorinated modified nucleotides, and optionally contain one or at least one non-fluorinated modified nucleotide. The non-fluorinated modified nucleotides can be selected from one or more of the following: 2' bulky modified nucleotides X, 2'-deoxy modified nucleotides, and 2'-methoxy modified nucleotides.
[0224] Optionally, the non-fluorinated modified nucleotide is a 2' bulky modified nucleotide X, and X is located in the first 3 nucleotides of (N)b'; further optionally, X is located in the first 2 nucleotides of (N)b'.
[0225] In one embodiment, the first four nucleotides of (N)b' (starting from the 5'-end) contain two or three fluoro-modified nucleotides and one 2' bulky modified nucleotide X or a disubstituted modified nucleotide as described in the present disclosure.
[0226] In another embodiment, the first three nucleotides of (N)b' (starting from the 5'-end) contain two fluoro-modified nucleotides and one disubstituted modified nucleotide or 2'-deoxy modified nucleotide.
[0227] In one embodiment, the double-stranded oligonucleotide represented by formula (I) has a duplex region of 19 nucleotide pairs, wherein the first four nucleotides of the (N)b' region on the sense strand (starting from the 5'-end) are located at positions 7-10; in this case, the non-fluorinated modified nucleotide may be located at any one of positions 7, 8, 9 or 10. Exemplarily, the disubstituted modified nucleotide X or the 2'-deoxy modified nucleotide (DNA) is located at any one of positions 7, 8, and 9 of the sense strand. Alternatively, the disubstituted modified nucleotide X is located at position 8 of the sense strand.
[0228] In one embodiment, when q=0, b+c=14. In another embodiment, when q=0, b=8, c=6; and in another embodiment, when q=0, b=4, c=10.
[0229] In some embodiments, in the double-stranded oligonucleotide molecules of the present disclosure, one or more Xs are present and located only in the antisense strand. In some embodiments, when the antisense strand contains only one X, X is located at any one of positions 8-10 or 15 of the antisense strand, as viewed from the 5' end to the 3' end. Optionally, X is located at position 15 of the antisense strand.
[0230] In some embodiments, in the double-stranded oligonucleotide molecules disclosed herein, one or more Xs are present and are only located in the sense strand. Optionally, the sense strand may contain one or two Xs. For example, X in the sense strand may be located in the opposite position relative to any position in position 2, 8 or 15 (starting from the 5'-end) of the antisense strand. Wherein, the opposite position refers to the position of the nucleotides on one chain in the duplex region and the corresponding complementary nucleotides on the other chain. For example, in the 5'-3' direction, in the 19 / 21 nucleotide pair structure, the SS chain position opposite to the 15-nucleotide nucleotide of the AS chain is the 5th position, and the SS chain position opposite to the 8-nucleotide nucleotide of the AS chain is the 12th position. This is well known in the art.
[0231] In some embodiments, in the double-stranded oligonucleotide molecules of the present disclosure, two or more Xs are present and are located in both the antisense strand and the sense strand. In some embodiments, X can be located at any position between 8 and 10 or 15 (starting from the 5' end) of the antisense strand; and in the sense strand, X can be located in a para position relative to any position between 2, 8, or 15 (starting from the 5' end) of the antisense strand.
[0232] In some embodiments, in the double-stranded oligonucleotide of formula (II) or the double-stranded oligonucleotide comprising the double-stranded region of formula (I) disclosed herein, the sense strand has one or more or all of the following characteristics:
[0233] 1) There is at least one X on the sense strand, and there is one X located at the para position to position 15 (starting from the 5' end) of the antisense strand;
[0234] 2) The sense strand contains at least two fluorinated modified nucleotides among the four nucleotides located at positions 10-13 (starting from the 5' end) of the antisense strand;
[0235] 3) Optionally, there is at least one X on the sense strand located in the para position to the antisense strand seed region (positions 1-8, based on the 5' end);
[0236] And / or, the antisense strand of the double-stranded oligonucleotide has one or more or all of the following characteristics:
[0237] 1) Positions 2, 6, 14, and 16 (based on the 5' end) of the antisense strand are all fluorinated modified nucleotides;
[0238] 2) The nucleotides at other positions of the antisense strand are all non-fluorinated modified nucleotides;
[0239] 3) There is no X or at least one X on the antisense strand; and when X is present on the antisense strand, the X is optionally located at any one of positions 8, 9, 10 or 15 of the antisense strand.
[0240] Optionally, the antisense strand contains one X nucleotide at position 15.
[0241] Optionally, the double-stranded region of the double-stranded oligonucleotide comprises sequences of the antisense strand and the sense strand that are sufficiently complementary to each other to form 19-23 base pairs (e.g., 19, 20, or 21 base pairs).
[0242] In other embodiments, the double-stranded oligonucleotide of formula (II) or the double-stranded oligonucleotide comprising the double-stranded region of formula (I) disclosed herein has at least two, at least three, or all of the following characteristics:
[0243] 1) There is at least one X nucleotide on the sense strand; and at least one X is located opposite to any one of position 15, position 8, or position 2 (starting from the 5'-end) on the antisense strand;
[0244] 2) The sense strand contains at least two fluoro-modified nucleotides among the four nucleotides located at positions 10-13 (starting from the 5' end) relative to the antisense strand;
[0245] 3) positions 2, 6, 14, and 16 (starting from the 5'-end) of the antisense strand are all fluorinated modified nucleotides, and the nucleotides at other positions are all non-fluorinated modified nucleotides;
[0246] 4) at least one of positions 8, 9, 10, and 15 of the antisense strand is an X nucleotide;
[0247] 5) Optionally, there is at least one X on the sense strand located in the para position to the antisense strand seed region (positions 1-8, starting from the 5' end).
[0248] Alternatively, the duplex region comprises sequences of the antisense strand and the sense strand that are sufficiently complementary to each other to form 19-21 base pairs (e.g., 19, 20, or 21 base pairs). Exemplarily, the double-stranded oligonucleotide may comprise a sense strand of 19 to 21 nucleotides in length and an antisense strand of 19 to 23 nucleotides in length.
[0249] In another embodiment, the double-stranded oligonucleotide of formula (II) or the double-stranded oligonucleotide comprising the double-stranded region of formula (I) disclosed herein has all of the following characteristics:
[0250] 1) There are one or two X nucleotides on the sense strand, and: optionally, at least one X is located at the para position to any position 15, 8, or 2 (starting from the 5'-end) of the antisense strand;
[0251] 2) Among the four nucleotides located at positions 10-13 (starting from the 5' end) of the antisense strand on the sense strand, at least two are fluorinated modified nucleotides;
[0252] 3) positions 2, 6, 14, and 16 (starting from the 5'-end) of the antisense strand are all fluorinated modified nucleotides, and the nucleotides at other positions are all non-fluorinated modified nucleotides;
[0253] 4) At least one of positions 8, 9, 10, and 15 of the antisense strand is a nucleotide X.
[0254] Optionally, there is a nucleotide X on the sense strand, and is located opposite to any one of position 15, position 8, or position 2 (based on the 5' end) on the antisense strand.
[0255] Optionally, position 15 of the antisense strand is nucleotide X.
[0256] In another embodiment, the double-stranded oligonucleotide of formula (II) or the double-stranded oligonucleotide comprising the double-stranded region of formula (I) disclosed herein has all of the following characteristics:
[0257] 1) There is an X on the sense strand, and it is located opposite to any one of position 15, position 8, or position 2 (based on the 5' end) of the antisense strand;
[0258] 2) Among the four nucleotides located at positions 10-13 (starting from the 5' end) of the antisense strand on the sense strand, at least two are fluorinated modified nucleotides;
[0259] 3) positions 2, 6, 14, and 16 (starting from the 5'-end) of the antisense strand are all fluorinated modified nucleotides, and the nucleotides at other positions are all non-fluorinated modified nucleotides;
[0260] 4) at least one of positions 10 and 15 of the antisense strand is an X nucleotide; and / or the antisense strand contains only one X nucleotide located at position 15 (starting from the 5'-end);
[0261] 5) Optionally, the duplex region comprises 19-23 base pairs.
[0262] In one embodiment, in the double-stranded oligonucleotide molecule of the present disclosure, in the direction from the 5' end to the 3' end, the 15th nucleotide of the antisense strand in the duplex region is an X nucleotide, and the nucleotides located at positions 2 and 8 (starting from the 5' end) of the antisense strand on the sense strand are also X nucleotides.
[0263] In one embodiment, the double-stranded oligonucleotide molecule described in the present disclosure further has a thiophosphate linkage modification, illustratively: one or two thiophosphate linkage modifications in the nucleotides at positions 1-5 (starting from the 5'-end) of the sense chain, and / or one or two thiophosphate linkage modifications in the nucleotides at positions 18-23 (counting from the 5'-end of the antisense chain) of the antisense chain.
[0264] In some embodiments, the double-stranded oligonucleotide of the present disclosure is as shown in formula (II), wherein each nucleotide in the duplex region is a modified nucleotide.
[0265] In other embodiments, the double-stranded oligonucleotide of the present disclosure is as shown in formula (IIa), wherein each nucleotide in the duplex region is a modified nucleotide, and the overhang is located at the 3' end of the antisense strand, and the length of the overhang nucleotide sequence is 1 to 3 nucleotides. Exemplarily, the ratio of the length of the sense strand and the antisense strand of the double-stranded oligonucleotide provided by the present disclosure can be 19 / 19, 19 / 21, 19 / 22, 20 / 20, 21 / 21, 21 / 22, 21 / 23, 22 / 22, 22 / 24, 22 / 25, 23 / 25, etc. In some embodiments, the sense strand and antisense strand of the double-stranded oligonucleotide of the present disclosure each have a length of 19 / 21 nucleotides or 21 / 23 nucleotides.
[0266] In some embodiments, the overhang is 2 nucleotides. Exemplarily, the overhang is dTdT (consecutive thymidine deoxyribonucleotides) or UU.
[0267] In some embodiments, the double-stranded oligonucleotide represented by the above formula (II) of the present disclosure comprises a sense strand with a length of 19 to 21 nucleotides and an antisense strand with a length of 19-23 nucleotides, wherein the sequences of the antisense strand and the sense strand are complementary to each other to form a duplex region of 17 to 21 base pairs; and the double-stranded oligonucleotide has a nucleotide overhang at the 3′ end of the antisense strand, and optionally: the antisense strand or the sense strand independently comprises 1 to 4 phosphorothioate internucleotide bonds, for example, can be but not limited to 1, 2, 3 or 4; and / or, the sense strand of the double-stranded oligonucleotide is conjugated to a ligand.
[0268] As for the nucleotide overhang, exemplarily, the 3′ end of the antisense strand has an overhang of 2-4 nucleotides and the 5′ end of the antisense strand has a blunt end.
[0269] In some embodiments, the double-stranded oligonucleotide represented by the above formula (II) of the present disclosure has the following characteristics, from the 5' end to the 3' end: 1) at least one of the 8th, 9th, 10th, or 15th nucleotides of the antisense strand is an X nucleotide; and positions 2, 6, 14, and 16 (calculated from the 5' end) of the antisense strand are all fluorinated nucleotides; 2) there are one or two X nucleotides on the sense strand, and at least one X nucleotide on the sense strand is located opposite to any one of positions 2, 8, 12, or 15 (calculated from the 5' end) of the antisense strand; and, among the four nucleotides on the sense strand located opposite to positions 10-13 (calculated from the 5' end) of the antisense strand, at least two fluorinated nucleotides are present.
[0270] In some embodiments, at least one of the phosphate groups in the phosphate-sugar backbone of the sense and antisense strands of the double-stranded oligonucleotides provided herein is a thio-modified phosphate group (i.e., a phosphorothioate group). The phosphorothioate group described herein is a phosphorothioate group formed by replacing at least one oxygen atom in the phosphodiester bond of a phosphate group with a sulfur atom; in some embodiments, the phosphate group having a modified group is a phosphorothioate group formed by replacing one oxygen atom in the phosphodiester bond with a sulfur atom.
[0271] In some embodiments, in the double-stranded oligonucleotides disclosed herein, the phosphorothioate group is present at the terminal region of the sense strand and / or the terminal region of the antisense strand, wherein the terminal region includes three, four, or five consecutive nucleotides at the 5' and 3' ends. In other embodiments, based on the first nucleotide being the terminal nucleotide of the single strand, the phosphorothioate group is present between any two consecutive nucleotides in the first to third nucleotide sequences.
[0272] Illustratively, based on the single-stranded terminal nucleotide being the first nucleotide, the phosphorothioate group may be present at one or more of the following positions in the terminal region of the sense strand and / or antisense strand: between the 1st and 2nd nucleotides at the 5' end, between the 2nd and 3rd nucleotides at the 5' end, between the 1st and 2nd nucleotides at the 3' end, and between the 2nd and 3rd nucleotides at the 3' end.
[0273] In some embodiments, the 5'-terminal nucleotide of the antisense strand is a 5'-phosphate nucleotide or a 5'-phosphate analog modified nucleotide. In one embodiment, the 5'-phosphate analog modified nucleotide is a vinyl phosphate modified nucleotide (e.g., 5'-VP) or a phosphorothioate modified nucleotide. Alternatively, the 5'-VP can be 5'-E-VP, 5'-Z-VP, or a combination thereof.
[0274] The double-stranded oligonucleotides disclosed herein can be various double-stranded oligonucleotides that regulate gene expression. In some embodiments, they can be double-stranded oligonucleotides that inhibit or downregulate gene expression, such as siRNA; in some embodiments, they can be double-stranded oligonucleotides that activate or upregulate gene expression, such as saRNA.
[0275] In one embodiment, in the double-stranded oligonucleotide of the present disclosure:
[0276] 1) The antisense strand, measured from the 5'-3' direction, comprises at least one of the 10th or 15th nucleotides selected from the following modified nucleotides: 2'-O-MOE, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2-CH3, and 2'-O-CH2-O-CH2-CF3; and positions 2, 6, 14, and 16 of the antisense strand are all fluorinated modified nucleotides; the remaining positions of the antisense strand are methoxy-modified nucleotides;
[0277] 2) On the sense strand, the position opposite to any one of positions 2, 8, or 15 (starting from the 5' end) of the antisense strand is a modified nucleotide selected from the following: 2'-O-MOE, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2-CH3, 2'-O-CH2-O-CH2-CF3; and, among the four nucleotides on the sense strand opposite to positions 10-13 (starting from the 5' end of the antisense strand), at least two are fluorinated modified nucleotides; the remaining positions on the sense strand are methoxy-modified nucleotides;
[0278] 3) Both the sense and antisense strands contain at least one phosphorothioate group, and the phosphorothioate group is located at the terminal region of each single strand, wherein the terminal region is 3-5 nucleotides in length.
[0279] In one embodiment, the double-stranded oligonucleotide further comprises a 5'-VP modified nucleotide.
[0280] In one embodiment, each sense strand and antisense strand of the double-stranded oligonucleotide of the present disclosure has 17-30 nucleotides. In an example, the sense strand has 19-21 nucleotides, and the antisense strand has 19-25 nucleotides. In an example, the sense strand has 19 or 21 nucleotides, and the antisense strand has 21 or 23 nucleotides.
[0281] In one embodiment, the nucleotide at position 1 of the 5'-end of the antisense strand in the double-stranded oligonucleotide duplex is selected from the group consisting of: A, dA, dU, U, or dT.
[0282] In one embodiment, the antisense strand of the double-stranded oligonucleotide (dsRNA) of the present invention is 100% complementary to the target RNA and can inhibit its expression by RNA interference. In another embodiment, the antisense strand of the double-stranded oligonucleotide of the present invention is complementary to the target RNA at least 95%, at least 90%, at least 85%, or at least 80% base pair ratio.
[0283] The double-stranded oligonucleotide dsRNA described in the present disclosure may be represented by formula (II), or include a duplex region represented by formula (I).
[0284] In one embodiment, a double-stranded oligonucleotide of the present disclosure comprises a sense strand and an antisense strand, wherein:
[0285] (a) The justice chain has:
[0286] (i) 19-21 nucleotides in length;
[0287] (ii) an ASGPR ligand attached to the 3′ end, wherein the ASGPR ligand is GalNAc or a derivative thereof;
[0288] (iii) a nucleotide modified with a 2'-bulky group at at least one of the para positions 2, 8, and 15 (counted from the 5' end) relative to the antisense strand;
[0289] (iv) at least two 2'-fluoro-modified nucleotides are present in the four nucleotides located opposite positions 10-13 (counted from the 5' end) of the antisense strand; and optionally, the remaining positions are independently selected from one or at least one of 2'-OMe-modified nucleotides, 2'-deoxy-modified nucleotides or 2'-bulky group-modified nucleotides; wherein the 2'-bulky group modification is selected from one or more of the following modified nucleotides: 2'-O-MOE, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2-CH3, 2'-O-CH2-O-CH2-CF3;
[0290] and
[0291] (b) the antisense strand thereof, which has:
[0292] (i) 21-23 nucleotides in length;
[0293] (ii) at least one of the 10th or 15th nucleotides of the antisense strand is a 2'-bulky group-modified nucleotide;
[0294] (iii) positions 2, 6, 14 and 16 of the antisense strand are all 2'-fluoro-modified nucleotides; and optionally, the remaining positions of the antisense strand are selected from one or at least one of 2'-OMe-modified nucleotides, 2'-deoxy-modified nucleotides or 2'-bulky group-modified nucleotides; wherein the 2'-bulky group modification is selected from one or more of the following modified nucleotides: 2'-O-MOE, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2-CH3, 2'-O-CH2-O-CH2-CF3;
[0295] (iv) having at least one phosphorothioate linkage between nucleotides in the terminal region;
[0296] (v) Optionally, there is an overhang consisting of 2-3 nucleotides at the 3'-end of the antisense strand, and a blunt end at the 5'-end of the antisense strand.
[0297] In one embodiment, the double-stranded oligonucleotide disclosed herein has phosphorothioate linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 of the antisense strand (counting from the 5' end). In one embodiment, the 3'-end of the antisense strand has an overhang consisting of two nucleotides, and the 5'-end of the antisense strand is blunt.
[0298] In one embodiment, the double-stranded oligonucleotide disclosed herein comprises: a nucleotide modified with a 2'-bulky group at position 15 of the antisense strand, counted from the 5'-end; a nucleotide modified with a 2'-bulky group at any position opposite to positions 2, 8, and 15 of the antisense strand on the sense strand; and the 2'-bulky group provides a spatial volume for the nucleotide at that position that is greater than that of the 2'-OMe modification.
[0299] In one embodiment, the antisense strand has a nucleotide modified with a 2'-bulky group at position 15; and the position opposite to position 15 on the sense strand is a nucleotide modified with a 2'-bulky group.
[0300] In one embodiment, the antisense strand has a nucleotide modified with a 2'-bulky group at position 15; and the position opposite to position 8 on the sense strand is a nucleotide modified with a 2'-bulky group.
[0301] In one embodiment, the antisense strand has a nucleotide modified with a 2'-bulky group at position 15; and the nucleotide modified with a 2'-bulky group is located opposite to position 2 on the sense strand.
[0302] In one embodiment, the antisense strand has a 2'-bulky group-modified nucleotide at position 15; and the 2'-bulky group-modified nucleotides are located opposite to positions 2 and 8 on the sense strand.
[0303] In an optional embodiment, there is a 2'-bulky group modified nucleotide on the sense strand at a position opposite to the antisense strand seed region (wherein the antisense strand seed region is at positions 1-8, calculated from the 5'-end).
[0304] Optionally, the 2'-bulky group is selected from one or more of the following: 2'-O-MOE, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2-CH3, 2'-O-CH2-O-CH2-CF3.
[0305] For example, when the length of the sense strand is 21 nucleotides, the nucleotides modified with the 2'-bulky group are at positions 7, 14, and 20 based on the 5'-end (corresponding to positions 15, 8, and 2 of the antisense strand, respectively).
[0306] For example, when the length of the sense strand is 19 nucleotides, the nucleotides modified with the 2'-bulky group are at positions 5, 12, and 18 based on the 5'-end (corresponding to positions 15, 8, and 2 of the antisense strand, respectively).
[0307] The double-stranded oligonucleotides provided herein can be used alone, or combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition, or combined with a conjugated molecule to form an oligonucleotide conjugate, or in other forms. When used, an effective amount of the double-stranded oligonucleotide, the pharmaceutical composition, or the oligonucleotide conjugate can be contacted with a cell to modulate the expression of a target gene, or the double-stranded oligonucleotide, the pharmaceutical composition, or the conjugate can be administered to a subject to modulate the expression of a target gene, thereby achieving the purpose of treating a pathological condition or disease associated with the expression level of the target gene.
[0308] In another aspect, the present disclosure provides a double-stranded oligonucleotide comprising a sense strand and an antisense strand, each strand having 17 to 35 nucleotides, wherein each nucleotide is a modified or unmodified nucleotide, and the sense strand and the antisense strand are at least partially reverse-complementary to form a double-stranded region; characterized in that the double-stranded oligonucleotide comprises at least one nucleotide modified with a 2'-disubstituent, and each substituent in the 2'-disubstituent is independently selected from methyl or fluorine;
[0309] Wherein, when the double-stranded region of the double-stranded oligonucleotide contains a 2'-disubstituted modified nucleotide, the 2'-disubstituted modified nucleotide is selected from a 2'-diF substituted nucleotide; or, when a position outside the double-stranded region of the double-stranded oligonucleotide contains a 2'-disubstituted modified nucleotide, the 2'-disubstituted modified nucleotide is selected from a 2'-F-2'-Me substituted nucleotide.
[0310] In some embodiments, the double-stranded oligonucleotide has one or more of the following characteristics:
[0311] (1) When the double-stranded oligonucleotide comprises a 2'-bis-F substituted nucleotide, the 2'-bis-F substituted nucleotide is located at least one of positions 7, 8, 9, or 10 from the 5' end of the sense strand;
[0312] (2) when the double-stranded oligonucleotide comprises a 2'-bis-F substituted nucleotide, the 2'-bis-F substituted nucleotide is located at least one of positions 2, 4, 6, 8, 9, 10, 12, 14, or 16 from the 5' end of the antisense strand;
[0313] (3) When the double-stranded oligonucleotide contains a 2'-F-2'-Me substituted nucleotide, the 2'-F-2'-Me substituted nucleotide is located outside the double-stranded region of the oligonucleotide.
[0314] (4) When the double-stranded oligonucleotide contains a 2'-F-2'-Me substituted nucleotide, the 2'-F-2'-Me substituted nucleotide is located at the overhang at the 3' end of the antisense strand.
[0315] In some embodiments, in feature (1), when the double-stranded oligonucleotide comprises 2'-bis-F substituted nucleotides, the 2'-bis-F substituted nucleotides are located at least 2 or at least 3 of positions 7, 8, 9 or 10 from the 5' end of the sense strand.
[0316] In some embodiments, in feature (2), when the double-stranded oligonucleotide comprises a 2'-bis-F substituted nucleotide, the 2'-bis-F substituted nucleotide is located at least two of positions 2, 4, 6, 8, 9, 10, 12, 14, or 16, starting from the 5' end of the antisense strand. On the other hand, the present disclosure provides a double-stranded oligonucleotide conjugate, which contains a double-stranded oligonucleotide provided by the present disclosure or a double-stranded oligonucleotide obtained according to the method of the present disclosure, and a conjugated group conjugated to the double-stranded oligonucleotide. The present disclosure can further improve the blood stability and targeting of the double-stranded oligonucleotide of the present disclosure by forming a pharmaceutical composition with a suitable carrier or forming an oligonucleotide conjugate with a suitable conjugated molecule. The conjugated molecule can be a conjugated molecule targeting tissues such as the liver, lungs, and kidneys.
[0317] In some embodiments, the conjugated group comprises a joint and a pharmaceutically acceptable targeting group, and the double-stranded oligonucleotide, the joint and the targeting group or the delivery auxiliary group are covalently or non-covalently linked in sequence, and each of the targeting groups is selected from a ligand that can bind to a cell surface receptor. In general, the targeting group is 1-6. In one embodiment, the targeting group is 2-4. The conjugation site of the double-stranded oligonucleotide and the conjugated group can be at the 3' end or 5' end of the double-stranded oligonucleotide sense strand, or at the 5' end of the antisense strand, or in the internal sequence of the double-stranded oligonucleotide. In some specific embodiments, the conjugation site of the double-stranded oligonucleotide and the conjugated group is at the 3' end of the double-stranded oligonucleotide sense strand.
[0318] The oligonucleotide conjugates can be synthesized by methods that have been described in detail in the prior art. For example, WO2015006740A2 describes in detail the preparation methods of various siRNA conjugates.
[0319] In yet another aspect, the present disclosure provides a conjugate or coupling of a double-stranded oligonucleotide, wherein the conjugate comprises the double-stranded oligonucleotide described herein and a targeting group to provide tissue-specific targeting.
[0320] In some embodiments, the conjugates of the present disclosure are specifically targeted to hepatocyte surface receptors, thereby specifically targeting liver tissue. In some embodiments, the targeting group of the present disclosure is a ligand with affinity for asialoglycoprotein receptors, thereby specifically targeting the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes. Exemplarily, the targeting group is a ligand group containing N-acetyl-galactosamine (GalNAc) or a derivative thereof.
[0321] In one embodiment, the double-stranded oligonucleotide provided by the present disclosure is linked to at least one ASGPR ligand. Exemplarily, the ASGPR ligand is GalNAc or a derivative thereof attached via a bivalent or trivalent branched linker.
[0322] In some embodiments, the ASGPR ligand is attached to the 5'-end or 3'-end of the sense or antisense strand of the double-stranded oligonucleotide via a linker to form a conjugate; illustratively, the conjugate has the following structural formula (B):
[0323] Wherein, Nu represents the double-stranded oligonucleotide or other nucleic acid drug active molecules (such as single-stranded oligonucleotide) described in the present disclosure.
[0324] In one embodiment, the ligand can be conjugated to the 3'-end or the 5'-end of the sense strand of the double-stranded oligonucleotide.
[0325] The present disclosure also provides uses of the double-stranded oligonucleotide and reagents thereof. In one embodiment, the use is for inhibiting target gene expression in a subject. The subject can be any animal, preferably a mammal, such as a mouse, rat, sheep, cattle, dog, cat, or human.
[0326] In some embodiments, the present disclosure further provides a pharmaceutical composition comprising the double-stranded oligonucleotide described herein and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can be any available carrier.
[0327] In some embodiments, there are no particular requirements for the content of the double-stranded oligonucleotide and the pharmaceutically acceptable carrier in the pharmaceutical composition. The pharmaceutical composition may further comprise other pharmaceutically acceptable excipients, which may be one or more of various preparations or compounds conventionally used in the art. For example, the other pharmaceutically acceptable excipients may include at least one of a pH buffer, a protective agent, and an osmotic pressure regulator.
[0328] In some embodiments, the present disclosure provides a method for treating and / or preventing a disease or symptom associated with the level of mRNA expressed by a target gene, the method comprising administering to a subject in need thereof an effective amount of a double-stranded oligonucleotide, pharmaceutical composition, and / or oligonucleotide conjugate provided by the present disclosure. In some embodiments, the disease or symptom associated with the level of mRNA expressed by the target gene is hepatitis, liver fibrosis, liver proliferative disease, and / or dyslipidemia. In some embodiments, the dyslipidemia is hypercholesterolemia, hypertriglyceridemia, or atherosclerosis.
[0329] In some embodiments, the present disclosure provides a use of the double-stranded oligonucleotide, the pharmaceutical composition containing the double-stranded oligonucleotide, or the oligonucleotide conjugate in the preparation of a medicament for treating and / or preventing a pathological condition or disease (e.g., gene overexpression) caused by the level of mRNA expressed by a target gene.
[0330] In some embodiments, the target gene is a gene abnormally expressed in hepatocytes. In some embodiments, the target gene is an endogenous gene expressed in the liver. Endogenous genes expressed in the liver include, but are not limited to, ApoB, ApoC, ANGPTL3, PCSK9, SCD1, TIMP-1, Col1A1, FVII, STAT3, p53, HBV, HCV, and the like.
[0331] In some embodiments, the disease is selected from chronic liver disease, hepatitis, liver fibrosis, liver proliferative disease, and dyslipidemia.
[0332] In some embodiments, the dyslipidemia is hypercholesterolemia, hypertriglyceridemia, or atherosclerosis.
[0333] In some embodiments, the present disclosure provides a method for regulating gene expression, wherein the method comprises contacting an effective amount of the aforementioned double-stranded oligonucleotide, the aforementioned pharmaceutical composition, or the aforementioned oligonucleotide conjugate with the cell expressing the gene.
[0334] In some embodiments, the present disclosure provides a method for treating a pathological condition or disease caused by abnormal gene expression, the method comprising administering to a subject an effective amount of the above-mentioned double-stranded oligonucleotide, the above-mentioned pharmaceutical composition or the above-mentioned oligonucleotide conjugate. In some embodiments, the abnormal expression is overexpression, and accordingly, the regulation is to inhibit the overexpression. In some embodiments, the regulation refers to inhibiting the expression of a target gene in hepatocytes, and the mRNA expressed by the target gene is selected from the mRNA expressed by the hepatitis B virus gene (HBV), the mRNA expressed by the angiopoietin-like protein 3 (ANGPTL3) gene, or the mRNA expressed by the apolipoprotein C3 (ApoC3) gene.
[0335] In some embodiments, the double-stranded oligonucleotide, pharmaceutical composition or oligonucleotide conjugate disclosed herein can also be used to treat other liver diseases, including cancer, hepatocellular carcinoma (HCC), liver metastasis or hepatoblastoma.
[0336] In some embodiments, the drug can be administered to a subject by any suitable route known in the art, including but not limited to oral or parenteral routes, such as intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, airway administration (aerosol), pulmonary administration, nasal administration, rectal administration, and topical administration (including buccal administration and sublingual administration). The frequency of administration can be once a week, once a month, or once a year.
[0337] In some embodiments, the present disclosure further provides a method for delivering the aforementioned double-stranded oligonucleotide, the aforementioned pharmaceutical composition, or the aforementioned oligonucleotide conjugate to a specific target in a subject by subcutaneous or intravenous administration.
[0338] The present disclosure provides a kit comprising the double-stranded oligonucleotide as described above, the pharmaceutical composition as described above, and / or the oligonucleotide conjugate as described above.
[0339] In some embodiments, the kits described herein may provide the double-stranded oligonucleotide in one container. In some embodiments, the kits described herein may include a container for providing a pharmaceutically acceptable excipient. In some embodiments, the kits described herein may also include other ingredients such as stabilizers or preservatives. In some embodiments, the kits described herein may include at least one other therapeutic agent in a container other than the container providing the double-stranded oligonucleotide described herein.
[0340] In the kit of the present disclosure, the double-stranded oligonucleotide and the pharmaceutically acceptable carrier and / or excipient and the double-stranded oligonucleotide composition and / or conjugate, and / or the pharmaceutically acceptable excipient can be provided in any form, such as liquid form, dry form or lyophilized form. In some embodiments, the double-stranded oligonucleotide and the pharmaceutically acceptable carrier and / or excipient and the double-stranded oligonucleotide composition and / or conjugate and the optional pharmaceutically acceptable excipient are substantially pure and / or sterile. In some embodiments, sterile water can be provided in the kit of the present disclosure.
[0341] Unless otherwise specified, the base composition and modification meanings described in the embodiments of the present disclosure are as follows: capital letters A, U, G, C, and T represent the base composition of the nucleotide; the lowercase letter m indicates that the nucleotide represented by the previous letter is a 2'-methoxy modified nucleotide; the lowercase letter f indicates that the nucleotide represented by the previous letter is a 2'-fluoro modified nucleotide; the lowercase letter d indicates that the nucleotide represented by the previous letter is a 2'-deoxyribonucleotide; the capital letters TBDMS in brackets, i.e., (TBDMS), indicate that the nucleotide represented by the previous letter is a 2'-O-tert-butyldimethylsilyl modified nucleotide; the capital letters TOM in brackets, i.e., (TOM), indicate that the nucleotide represented by the previous letter is a 2'-O-triisopropylmethoxysilane modified nucleotide; the capital letters MOE in brackets, i.e., (MOE), indicate that the nucleotide represented by the previous letter is a 2'-O-methoxyethyl modified nucleotide; the lowercase letter s indicates that the nucleotides represented by the two letters before and after it are connected by a phosphorothioate bond.
[0342] In the present disclosure, the structural formula of compound L96-PS is shown in formula (C):
[0343] Wherein, PS represents a polystyrene resin solid phase support, and the compound L96-PS was purchased from Ailiying Pharmaceutical Group (Tianjin) Co., Ltd. with a loading capacity of 120±12 μmol / g (detection method: UV / HPLC).
[0344] Unless otherwise stated, the reagents and consumables (Table 1) and instruments and equipment (Table 2) used in this disclosure were all commercially available products from the following manufacturers.
[0345] Table 1
[0346] Table 2
[0347] Unless otherwise specified, the dsRNA (referred to as siRNA in the examples) sequences used in this disclosure were synthesized by Suzhou Beixin Biotechnology Co., Ltd.; the PCR primer synthesis was completed by Beijing Qingke Biotechnology Co., Ltd.; the experimental animals C57BL / 6J mice and ICR mice were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd.; and the blood biochemical index detection was completed by Beijing Sinoin Biotechnology Co., Ltd.
[0348] Unless otherwise stated, the real-time PCR detection data of the in vivo / in vitro siRNA activity experiments in each embodiment of the present disclosure were all calculated using the ΔΔCt method to perform relative quantitative calculation of the target gene mRNA in each test group. The calculation method is summarized as follows:
[0349] ΔCt(test group) = Ct(test group target gene) - Ct(test group reference gene)
[0350] ΔCt(control group) = Ct(control group target gene) - Ct(control group internal reference gene)
[0351] ΔΔCt(test group)=ΔCt(test group)-ΔCt(control group average)
[0352] ΔΔCt(control group) = ΔCt(control group) - ΔCt(control group average)
[0353] The mRNA expression level of the target gene in the test group was normalized with the control group as the benchmark, and the remaining expression level of the target gene mRNA in the control group was defined as 100%.
[0354] Relative residual expression level of target gene mRNA in the test group = 2 -ΔΔCt (Test group) × 100%
[0355] Test group target gene mRNA inhibition rate = 100% - test group target gene mRNA relative expression level
[0356] In vivo / in vitro activity test data are based on The experimental data were plotted and analyzed using GraphPad Prism 8.0 software. The ±SD and ±STDEV values represent standard deviations.
[0357] Unless otherwise stated, the ratios of reagents described in the examples of the present disclosure are calculated on a volume basis (v / v).
[0358] The scheme of the present disclosure will be explained below in conjunction with the examples. Those skilled in the art will understand that the following examples are only used to illustrate the present disclosure and should not be considered to limit the scope of the present disclosure. Where specific techniques or conditions are not specified in the examples, they are carried out according to the techniques or conditions described in the literature in this area or according to the product instructions. Where the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be obtained commercially.
[0359] Preparation of Nucleoside Monomer Analogs Modified with Large Steric Volume
[0360] The reagents and their sources used in the preparation examples of this disclosure are shown in Table 3:
[0361] Table 3
[0362] Preparation Example 1: Synthesis of Compound NM062
[0363] The synthetic route of compound NM062 is as follows:
[0364] (1-1) Synthesis of Compound 2
[0365] Compound 1 (10 g, 40.97 mmol, uridine) was dissolved in 100 ml of pyridine, and 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (14.22 g, 45.07 mmol) was added. The mixture was stirred at 25°C for 16 hours. After completion of the reaction, the reaction solution was concentrated to remove the solvent, diluted with 300 ml of dichloromethane, and washed twice with 100 ml of saturated aqueous ammonium chloride (2 x 100 ml) and then twice with 100 ml of saturated aqueous sodium chloride (2 x 100 ml). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by normal phase column chromatography (elution gradient: petroleum ether / ethyl acetate = 3 / 1, v / v) to obtain compound 2 (11.5 g, 57.7% yield). MS ESI (m / z) = 487.27 [M+H] + .
[0366] (1-2) Synthesis of Compound 3
[0367] Compound 2 (11 g, 22.62 mmol) was dissolved in 77 ml of dimethyl sulfoxide at 25°C, and 77 ml of acetic acid and 38 ml of acetic anhydride were added. The mixture was stirred at 25°C for 16 hours. After completion of the reaction, 500 ml of ethyl acetate was added for dilution, and the mixture was washed twice with 100 ml of saturated sodium bicarbonate solution (2 × 100 ml) and twice with 100 ml of saturated sodium chloride solution (2 × 100 ml). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by normal phase column chromatography (elution gradient: petroleum ether / ethyl acetate = 3 / 1, v / v) to obtain compound 3 (11.22 g, yield 90.81%). MS ESI (m / z) = 546.23 [M+H] + .
[0368] (1-3) Synthesis of Compound 4
[0369] Compound 3 (5 g, 9.15 mmol) was dissolved in 50 ml of tetrahydrofuran at 25 °C, and ethanol (4.21 g, 91.5 mmol) was added. The atmosphere was replaced with nitrogen three times, and the reaction system was cooled to -40 °C with a dry ice acetonitrile bath. A solution of N-iodosuccinimide (2.47 g, 10.98 mmol) in tetrahydrofuran (5 ml) and a solution of trifluoromethanesulfonic acid (2.75 g, 18.3 mmol) in tetrahydrofuran (5 ml) were added dropwise at -40 °C. Under a nitrogen atmosphere, the reaction solution was stirred at -40 °C for 1 hour. After completion of the reaction, 8 ml of triethylamine was added to quench the reaction, and a 10% by mass aqueous solution of sodium thiosulfate was added. The mixture was extracted four times with 150 ml of dichloromethane (4 × 150 ml). The organic phases were combined and washed twice with 80 ml of saturated aqueous sodium bicarbonate (2 × 80 ml) and once with 100 ml of saturated brine (1 × 100 ml). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by normal phase column chromatography (elution gradient: petroleum ether / ethyl acetate = 4 / 1, v / v) to obtain compound 4 (4.78 g, yield 95.96%). MS ESI (m / z) = 544.26 [M+H] + .
[0370] (1-4) Synthesis of Compound 5
[0371] Compound 4 (4 g, 7.35 mmol) was dissolved in 32 ml of methanol at 25°C, and ammonium fluoride (1.36 g, 36.75 mmol) was added. The mixture was stirred at 60°C for 16 hours. After the reaction was completed, the solvent was removed by spin drying and the mixture was purified by normal phase column chromatography (elution gradient: dichloromethane / methanol = 20 / 1, v / v) to obtain compound 5 (2.05 g, yield 92.34%). MS ESI (m / z) = 303.2 [M+H] + .
[0372] (1-5) Synthesis of Compound 6
[0373] Compound 5 (2 g, 6.62 mmol) was dissolved in 20 ml of pyridine under an ice bath. The ice bath was cooled to 0°C, and 4,4'-bismethoxytrityl chloride (2.77 g, 7.94 mmol) was added portionwise. The reaction solution was stirred at 0°C for 1 hour. After completion of the reaction, 2 ml of methanol was added to quench the reaction. The solvent was removed by spin drying, and 50 ml of saturated aqueous ammonium chloride was added. The mixture was extracted three times with 50 ml of ethyl acetate (3 × 50 ml). The organic phases were combined, washed once with 100 ml of saturated brine (1 × 100 ml), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by normal phase column chromatography (elution gradient: petroleum ether / ethyl acetate = 1 / 1, v / v) to obtain compound 6 (2.28 g, yield 55.67%). MS ESI (m / z) = 604.3 [M+H] + .
[0374] (1-6) Synthesis of Compound NM062
[0375] Compound 6 (1.5 g, 2.48 mmol) was repeatedly dried three times with 10 ml of acetonitrile (3×10 ml), then dissolved in 15 ml of dichloromethane. A solution of 3-{[bis(diisopropylamino)phosphoryl]oxy}propionitrile (899.6 mg, 2.98 mmol, repeatedly dried three times with 10 ml of acetonitrile (3×10 ml)) in dichloromethane (15 ml) was added first, followed by addition of 1H-imidazole-4,5-dicarbonitrile (374.8 mg, 1.984 mmol). The mixture was replaced with nitrogen three times and stirred at 25°C in a nitrogen atmosphere for 1 hour. After completion of the reaction, the reaction solution was diluted with 30 ml of saturated aqueous sodium bicarbonate solution and extracted three times with 20 ml of dichloromethane (3×20 ml). The organic phases were combined and washed twice with 30 ml of saturated brine (2×30 ml), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by reverse phase column chromatography (elution gradient: water / acetonitrile = 1 / 9, v / v) to obtain compound NM062 (1.7 g, yield 85.14%). MS ESI (m / z) = 604.3 [M+H] + .
[0376] 1H NMR (400MHz, DMSO-d6) δ = 11.41 (s, 1H), 7.75 (dd, J = 8.2, 10.6Hz, 1H), 7.43-7.35 (m, 2 H),7.35-7.29(m,2H),7.29-7.21(m,5H),6.90(dd,J=6.1,7.8Hz,4H),5.88(dd,J=2. 3,4.2Hz,1H),5.35(dd,J=8.5,9.6Hz,1H),4.81-4.68(m,2H),4.48-4.33(m,2H),4.1 9-4.04(m,1H),3.74(d,J=2.0Hz,7H),3.58-3.44(m,4H),3.39-3.31(m,2H),3.30(br s,1H),2.78(t,J=5.9Hz,1H),2.63(t,J=5.9Hz,1H),1.16-1.03(m,12H),0.98(d,J=6.7Hz,3H).
[0377] Preparation Example 2: Synthesis of Compound NM063
[0378] The synthetic route of compound NM063 is as follows:
[0379] (2-1) Synthesis of Compound 7
[0380] At 25°C, compound 3 (5 g, 9.15 mmol) was dissolved in 50 ml of tetrahydrofuran, and trifluoroethanol (9.15 g, 91.5 mmol) was added. The atmosphere was replaced with nitrogen three times, and the temperature of the dry ice acetonitrile bath was lowered to -40°C. A solution of N-iodosuccinimide (2.47 g, 10.98 mmol) in tetrahydrofuran (5 ml) and a solution of trifluoromethanesulfonic acid (2.75 g, 18.3 mmol) in tetrahydrofuran (5 ml) were added dropwise at -40°C, and the mixture was stirred at -40°C for 1 hour under a nitrogen atmosphere. After completion of the reaction, 80 ml of triethylamine was added to the reaction solution to quench it. A 10% by mass aqueous solution of sodium thiosulfate was added, and the mixture was extracted four times with 150 ml of dichloromethane (4 × 150 ml). The organic phases were combined and washed twice with 80 ml of saturated aqueous sodium bicarbonate solution (2 × 80 ml) and once with 100 ml of saturated brine (1 × 100 ml). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by normal phase column chromatography (elution gradient: petroleum ether / ethyl acetate = 4 / 1, v / v) to obtain compound 7 (3.04 g, yield 55.51%). MS ESI (m / z) = 599.23 [M+H] + .
[0381] (2-2) Synthesis of Compound 8
[0382] Compound 7 (3 g, 5.01 mmol) was dissolved in methanol (32 mL) at 25°C, and ammonium fluoride (926.85 mg, 25.05 mmol) was added. The reaction solution was stirred at 60°C for 16 hours. After completion of the reaction, the solvent was removed by spin drying and the product was purified by normal phase column chromatography (elution gradient: dichloromethane / methanol = 20 / 1, v / v) to obtain compound 8 (1.51 g, yield 83.43%). MS ESI (m / z) = 356.26 [M+H] + .
[0383] (2-3) Synthesis of Compound 9
[0384] Compound 8 (1.51 g, 4.24 mmol) was dissolved in pyridine (15 mL) under an ice bath. The ice bath was cooled to 0°C, and 4,4'-bismethoxytrityl chloride (1.73 g, 5.09 mmol) was added portionwise. The reaction solution was stirred at 0°C for 1 hour. After completion of the reaction, methanol (2 mL) was added to quench the reaction. The solvent was removed by spin drying, and saturated aqueous ammonium chloride (50 mL) was added. The mixture was extracted with ethyl acetate (3 × 50 mL). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by normal phase column chromatography (elution gradient, petroleum ether / ethyl acetate = 1 / 1, v / v) to obtain compound 9 (2.08 g, yield 74.53%). MS ESI (m / z) = 681.32 [M+Na] + .
[0385] (2-4) Synthesis of Compound NM063
[0386] Compound 9 (1.9 g, 2.89 mmol) was repeatedly dried with acetonitrile (3×10 mL) and dissolved in dichloromethane (15 mL). A solution of 3-{[bis(diisopropylamino)phosphoryl]oxy}propionitrile (1.307 g, 3.46 mmol) in dichloromethane (15 mL) dried with acetonitrile (3×10 mL) was added, and 1H-imidazole-4,5-dicarbonitrile (272.5 mg, 2.312 mmol) was added. The atmosphere was replaced with nitrogen three times. Under a nitrogen atmosphere, the reaction solution was stirred at 25°C for 1 hour. After the reaction was completed, saturated aqueous sodium bicarbonate solution (30 mL) was added for dilution, and the mixture was extracted with dichloromethane (3×20 mL). The organic phases were combined, washed with saturated brine (2×30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by reverse phase column chromatography (C18 column, elution gradient: water / acetonitrile = 1 / 9, v / v) to obtain compound NM063 (2.07 g, yield 83.55%). MS ESI (m / z) = 859.43 [M+H] + .
[0387] 1H NMR (400MHz, DMSO-d6) δ = 11.41 (s, 1H), 7.77 (dd, J = 6.0, 7.9Hz, 1H), 7.43-7.35 (m, 2H), 7.35- 7.18(m,7H),6.95-6.85(m,4H),5.90-5.83(m,1H),5.28(d,J=8.1Hz,1H),4.99-4.86(m,2H),4 .53-4.40(m,2H),4.26-4.02(m,3H),3.85-3.59(m,8H),3.52(qd,J=6.7,10.4Hz,2H),3.43-3. 32(m,2H),2.81-2.75(m,1H),2.63(t,J=5.9Hz,1H),1.16-1.04(m,9H),0.97(d,J=6.7Hz,3H).
[0388] Preparation Example 3: Synthesis of Compound NM096
[0389] In this preparation example, the synthetic route of compound NM096 is as follows:
[0390] (3-1) Synthesis of Compound 10
[0391] Compound 3 (3 g, 5.49 mmol, 1 eq) was dissolved in tetrahydrofuran (30 mL) at 25°C, and n-butanol (4.06 g, 54.92 mmol, 10 eq, CAS No. 71-36-3) was added. The atmosphere was replaced with nitrogen three times, and the reaction system was cooled to -40°C with dry ice. A solution of N-iodosuccinimide (1.48 g, 6.59 mmol, 1.2 eq, abbreviated as NIS, CAS No. 516-12-1) in tetrahydrofuran (5 mL) and a solution of trifluoromethanesulfonic acid (1.64 g, 10.98 mmol, 2 eq, abbreviated as TfOH, CAS No. 1493-13-6) in tetrahydrofuran (5 mL) were added dropwise. The reaction system was stirred at -40°C for 1 hour and quenched by the addition of triethylamine (6 mL). After the reaction, the reaction solution was concentrated and extracted with dichloromethane (2×50 mL). The mixture was washed with saturated aqueous sodium bicarbonate solution (2×50 mL) and saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1, volume ratio v / v) to obtain compound 10 (3.05 g, yield 96.95%) as a white solid. MS ESI (m / z) = 573.3 [M+H] + .
[0392] (3-2) Synthesis of Compound 11
[0393] Compound 10 (3.05 g, 5.33 mmol, 1 eq) was dissolved in tetrahydrofuran (30 mL) at 25°C. A solution of tetrabutylammonium fluoride (CAS No. 429-41-4) in tetrahydrofuran (10.66 mL, 1 M, 10.66 mmol, 2 eq) was added, and the reaction mixture was stirred at 25°C for 3 hours. After completion of the reaction, the reaction mixture was concentrated and purified by column chromatography (eluent: dichloromethane / methanol = 10 / 1, v / v) to obtain compound 11 (1.7 g, yield 98.27%) as a white solid. MS ESI (m / z) = 353.4 [M+Na] + .
[0394] (3-3) Synthesis of Compound 12
[0395] Compound 11 (1.7 g, 5.15 mmol, 1 eq) was dissolved in pyridine (17 mL) at 25°C and cooled to 0°C in an ice bath. 4,4'-bis(methoxytrityl) chloride (2.27 g, 6.69 mmol, 1.3 eq, abbreviated as DMTrCl, CAS No. 40615-36-9) was added portionwise. The reaction mixture was stirred at 25°C for 1 hour and quenched by methanol. After completion of the reaction, the reaction mixture was concentrated and diluted with ethyl acetate (50 mL). The mixture was washed with saturated aqueous ammonium chloride (2 × 30 mL) and saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1, v / v) to afford Compound 12 (2.44 g, 74.89% yield) as a yellow solid. MS ESI (m / z) = 633.3 [M+H] + .
[0396] (3-3) Synthesis of Compound NM096
[0397] Compound 12 (2.44 g, 3.85 mmol, 1 eq) was repeatedly dried with acetonitrile (3×30 mL) and dissolved in dichloromethane (25 mL). A solution of bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.63 g, 5.78 mmol, 1.5 eq, CAS No. 102691-36-1) in dichloromethane (25 mL) dried with acetonitrile (3×10 mL) was added, and 1H-imidazole-4,5-dicarbonitrile (364.2 mg, 3.08 mmol, 0.8 eq, CAS No. 1122-28-7) was added. The atmosphere was replaced with nitrogen three times, and the reaction system was stirred at 25°C under a nitrogen atmosphere for 1 hour. After the reaction was completed, saturated aqueous sodium bicarbonate (50 mL) was added to the reaction solution for dilution, and the mixture was extracted with dichloromethane (3×30 mL). The organic phases were combined, washed with saturated aqueous sodium chloride (2×30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1, v / v) to obtain compound NM096 (2.7 g, yield 84.11%) as a white solid. MS ESI (m / z) = 833.4 [M+H] + .
[0398] 1 H NMR (400MHz, DMSO-d6) δ11.36(s,1H),7.72(dd,J=11.8,8.1Hz,1H),7.42-7.29(m,4H),7.29-7.20(m,5H),6.89(dd,J=8.6,5.8Hz,4H),5. 89(dd,J=5.3,3.1Hz,1H),5.37(t,J=7.7Hz,1H),4.79-4.66(m,2H),4.40(dp,J=19.0,4.8Hz,2H),4.12(dq,J=20.3,3.8Hz,1H),3.74(d,J =2.1Hz,7H),3.71-3.58(m,1H),3.53(dq,J=9.8,6.9Hz,2H),3.49-3.40(m,2H),3.39-3.32(m,1H),2.78(t,J=6.1Hz,1H),2.63(t,J=5.9H z,1H),1.42(dq,J=10.1,6.8Hz,2H),1.26(dq,J=14.3,7.3Hz,2H),1.20-1.06(m,10H),0.99(d,J=6.7Hz,3H),0.83(td,J=7.4,3.5Hz,3H).
[0399] Preparation Example 4: Synthesis of Compound NM097
[0400] In this preparation example, the synthetic route of compound NM097 is as follows:
[0401] (4-1) Synthesis of Compound 13
[0402] Compound 3 (3 g, 5.49 mmol, 1 eq) was dissolved in tetrahydrofuran (30 mL) at 25°C, and cyclopropanol (3.18 g, 54.92 mmol, 10 eq) was added. The atmosphere was replaced with nitrogen three times, and the reaction system was cooled to -40°C with dry ice. A solution of NIS (1.48 g, 6.59 mmol, 1.2 eq) in tetrahydrofuran (5 mL) and a solution of TfOH (1.64 g, 10.98 mmol, 2 eq) in tetrahydrofuran (5 mL) were added dropwise. The reaction system was stirred at -40°C for 1 hour and quenched by the addition of triethylamine (6 mL). After completion of the reaction, the reaction solution was concentrated and extracted with dichloromethane (2×50 mL). The organic phases were combined and washed with saturated aqueous sodium bicarbonate solution (2×50 mL) and saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1, v / v) to obtain compound 13 (2.59 g, yield 84.78%) as a white solid. MS ESI (m / z) = 557.3 [M+H] + .
[0403] (4-2) Synthesis of Compound 14
[0404] Compound 13 (2.59 g, 4.66 mmol, 1 eq) was dissolved in tetrahydrofuran (30 mL) at 25°C, and a solution of tetrabutylammonium fluoride in tetrahydrofuran (9.32 mL, 1 M, 9.32 mmol, 2 eq) was added. The reaction mixture was stirred at 25°C for 3 hours. After completion of the reaction, the reaction mixture was concentrated and purified by column chromatography (eluent: dichloromethane / methanol = 20 / 1, v / v) to obtain compound 14 (1.45 g, yield 99.3%) as a white solid. MS ESI (m / z) = 337.1 [M+Na] + .
[0405] (4-3) Synthesis of Compound 15
[0406] Compound 14 (1.45 g, 4.62 mmol, 1 eq) was dissolved in pyridine (15 mL) at 25°C and cooled to 0°C in an ice bath. DMTrCl (2.05 g, 6.00 mmol, 1.3 eq) was added portionwise. The reaction mixture was stirred at 25°C for 1 hour and quenched with methanol. After completion of the reaction, the reaction mixture was concentrated and diluted with ethyl acetate (50 mL). The mixture was washed with saturated aqueous ammonium chloride (2 × 30 mL) and saturated aqueous sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1, v / v) to afford compound 15 (1.69 g, 59.5% yield) as a yellow solid. MS ESI (m / z) = 617.2 [M+H] + .
[0407] (4-4) Synthesis of Compound NM097
[0408] Compound 15 (1.69 g, 2.74 mmol, 1 eq) was repeatedly dried with acetonitrile (3 × 10 mL) and dissolved in dichloromethane (20 mL). A solution of bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.24 g, 4.11 mmol, 1.5 eq) in dichloromethane (25 mL) dried with acetonitrile (3 × 10 mL) was added, and 1H-imidazole-4,5-dicarbonitrile (258.9 mg, 2.19 mmol, 0.8 eq) was added. The atmosphere was replaced with nitrogen three times, and the reaction system was stirred at 25 ° C under a nitrogen atmosphere for 1 hour. After the reaction was completed, saturated aqueous sodium bicarbonate (50 mL) was added to the reaction solution for dilution, and the mixture was extracted with dichloromethane (3×30 mL). The organic phases were combined, washed with saturated aqueous sodium chloride (2×30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1, v / v) to obtain compound NM097 (1.7 g, yield 75.96%) as a white solid. MS ESI (m / z) = 817.2 [M+H] + .
[0409] 1H NMR(400MHz, DMSO-d6)δ11.40(s,1H),7.76(dd,J=10.9,8.1Hz,1H),7.42-7.29(m,4H),7.29-7.21(m,5H),6.89 (td,J=6.6,3.2Hz,4H),5.90(dt,J=7.1,3.6Hz,1H),5.40-5.24(m,1H),4.94-4.68(m,2H),4.56-4.37(m,2H),4 .13(dt,J=22.0,4.1Hz,1H),3.74(d,J=2.1Hz,7H),3.71-3.44(m,4H),3.35(t,J=3.6Hz,1H),3.30(d,J=4.8Hz, 1H),2.78(t,J=5.9Hz,1H),2.63(t,J=5.9Hz,1H),1.15-1.08(m,9H),0.98(d,J=6.8Hz,3H),0.56-0.36(m,4H).
[0410] Preparation Example 5: Preparation of Compound NM098
[0411] In this preparation example, the synthetic route of compound NM098 is as follows:
[0412] (5-1) Synthesis of Compound 16
[0413] Compound 3 (3 g, 5.49 mmol, 1 eq) was dissolved in tetrahydrofuran (30 mL) at 25°C, and neopentyl alcohol (4.83 g, 54.92 mmol, 10 eq, CAS No. 75-84-3) was added. The atmosphere was replaced with nitrogen three times, and the reaction system was cooled to -40°C with dry ice. A solution of NIS (1.48 g, 6.59 mmol, 1.2 eq) in tetrahydrofuran (5 mL) and a solution of TfOH (1.64 g, 10.98 mmol, 2 eq) in tetrahydrofuran (5 mL) were added dropwise. The reaction solution was stirred at -40°C for 1 hour and quenched by the addition of triethylamine (6 mL). After completion of the reaction, the reaction solution was concentrated and extracted with dichloromethane (2×50 mL). The organic phases were combined, washed with saturated aqueous sodium bicarbonate solution (2×50 mL) and saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1, v / v) to obtain compound 16 (3.06 g, yield 95.03%) as a white solid. MS ESI (m / z) = 587.3 [M+H] + .
[0414] (5-2) Synthesis of Compound 17
[0415] Compound 16 (3.06 g, 5.22 mmol, 1 eq) was dissolved in tetrahydrofuran (30 mL) at 25°C, and a solution of tetrabutylammonium fluoride in tetrahydrofuran (10.44 mL, 1 M, 10.44 mmol, 2 eq) was added. The reaction mixture was stirred at 25°C for 3 hours. After completion of the reaction, the reaction mixture was concentrated and purified by column chromatography (eluent: dichloromethane / methanol = 10 / 1, v / v) to obtain compound 17 (1.78 g, yield 99.1%) as a white solid. MS ESI (m / z) = 367.1 [M+Na] + .
[0416] (5-3) Synthesis of Compound 18
[0417] Compound 17 (1.78 g, 5.17 mmol, 1 eq) was dissolved in pyridine (15 mL) at 25°C and cooled to 0°C in an ice bath. DMTrCl (2.28 g, 6.72 mmol, 1.3 eq) was added portionwise. The reaction mixture was stirred at 25°C for 1 hour and quenched with methanol. After completion of the reaction, the reaction mixture was concentrated and diluted with ethyl acetate (50 mL). The mixture was washed with saturated aqueous ammonium chloride (2 × 30 mL) and saturated aqueous sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1, v / v) to afford compound 18 (2.50 g, yield 74.85%) as a yellow solid. MS ESI (m / z) = 647.3 [M+H] + .
[0418] (5-4) Synthesis of Compound NM098
[0419] Compound 18 (2.50 g, 3.87 mmol, 1 eq) was repeatedly dried with acetonitrile (3 × 10 mL) and dissolved in dichloromethane (30 mL). A solution of bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.75 g, 5.80 mmol, 1.5 eq) in dichloromethane (25 mL) dried with acetonitrile (3 × 10 mL) was added, and 1H-imidazole-4,5-dicarbonitrile (364.9 mg, 3.10 mmol, 0.8 eq) was added. The atmosphere was replaced with nitrogen three times, and the reaction system was stirred at 25 ° C under a nitrogen atmosphere for 1 hour. After the reaction was completed, saturated aqueous sodium bicarbonate (50 mL) was added to the reaction solution for dilution, and the mixture was extracted with dichloromethane (3×30 mL). The organic phases were combined, washed with saturated aqueous sodium chloride (2×30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1, v / v) to obtain compound NM098 (2.84 g, yield 86.87%) as a white solid. MS ESI (m / z) = 847.4 [M+H] + .
[0420] 1 H NMR (400MHz, DMSO-d6) δ11.41(s,1H),7.72(dd,J=9.6,8.1Hz,1H),7.43-7.30(m,4H),7.30-7.20(m,5H),6.89(td,J=6.8, 3.3Hz,4H),5.89(dd,J=4.6,2.4Hz,1H),5.38(d,J=8.0Hz,1H),4.85-4.66(m,2H),4.38(dp,J=15.0,4.9,4.4Hz,2H),4.12 (dd,J=20.1,3.7Hz,1H),3.74(d,J=2.2Hz,7H),3.70-3.46(m,3H),3.42-3.32(m,1H),3.28(t,J=5.4Hz,1H),3.19-3.08(m ,2H),2.78(td,J=5.9,2.1Hz,1H),2.62(t,J=5.9Hz,1H),1.15-1.08(m,9H),0.98(d,J=6.7Hz,3H),0.82(d,J=5.9Hz,9H).
[0421] Preparation Example 6: Preparation of Compound NM099
[0422] In this preparation example, the synthetic route of compound NM099 is as follows:
[0423] (6-1) Synthesis of Compound 19
[0424] Compound 3 (3 g, 5.49 mmol, 1 eq) was dissolved in tetrahydrofuran (30 mL) at 25 °C, and cyclopentanol (4.74 g, 54.92 mmol, 10 eq) was added. The atmosphere was replaced with nitrogen three times, and the reaction system was cooled to -40 °C with dry ice. A solution of NIS (1.48 g, 6.59 mmol, 1.2 eq) in tetrahydrofuran (5 mL) and a solution of TfOH (1.64 g, 10.98 mmol, 2 eq) in tetrahydrofuran (5 mL) were added dropwise. The reaction system was stirred at -40 °C for 1 hour and quenched by the addition of triethylamine (6 mL). After completion of the reaction, the reaction solution was concentrated and extracted with dichloromethane (2×50 mL). The mixture was washed with saturated aqueous sodium bicarbonate solution (2×50 mL) and saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1, v / v) to obtain compound 19 as a white solid (3.20 g, yield 99.6%). MS ESI (m / z) = 585.3 [M+H] + .
[0425] (6-2) Synthesis of Compound 20
[0426] Compound 19 (3.20 g, 5.48 mmol, 1 eq) was dissolved in tetrahydrofuran (30 mL) at 25°C, and a solution of tetrabutylammonium fluoride in tetrahydrofuran (10.95 mL, 1 M, 10.95 mmol, 2 eq) was added. The reaction mixture was stirred at 25°C for 3 hours. After completion of the reaction, the reaction mixture was concentrated and purified by column chromatography (eluent: dichloromethane / methanol = 20 / 1, v / v) to obtain compound 20 (1.87 g, yield 99.3%) as a white solid. MS ESI (m / z) = 365.1 [M+Na] + .
[0427] (6-3) Synthesis of Compound 21
[0428] Compound 20 (1.87 g, 5.47 mmol, 1 eq) was dissolved in pyridine (20 mL) at 25°C, and the ice bath was cooled to 0°C. DMTrCl (2.41 g, 7.11 mmol, 1.3 eq) was added portionwise. The reaction mixture was stirred at 25°C for 1 hour and quenched with methanol. After completion of the reaction, the reaction mixture was concentrated and diluted with ethyl acetate (50 mL). The mixture was washed with saturated aqueous ammonium chloride (2 × 30 mL) and saturated aqueous sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to afford compound 21 (2.18 g, yield 61.93%) as a yellow solid. MS ESI (m / z) = 645.3 [M+H] + .
[0429] (6-4) Synthesis of Compound NM099
[0430] Compound 21 (2.18 g, 3.38 mmol, 1 eq) was dried with acetonitrile three times (10 ml each time) and then dissolved in dichloromethane (20 mL). A solution of bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.53 g, 5.08 mmol, 1.5 eq) in dichloromethane (25 mL) dried with acetonitrile (3×10 mL) was added, and 1H-imidazole-4,5-dicarbonitrile (319.7 mg, 2.71 mmol, 0.8 eq) was added. The atmosphere was replaced with nitrogen three times, and the reaction system was stirred at 25°C under a nitrogen atmosphere for 1 hour. After the reaction was completed, saturated aqueous sodium bicarbonate (50 mL) was added to the reaction solution for dilution, and the mixture was extracted with dichloromethane (3×30 mL). The organic phases were combined and washed with saturated aqueous sodium chloride (2×30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain compound NM099 (2.28 g, yield 79.80%) as a white solid. MS ESI (m / z) = 845.3 [M+H] + .
[0431] 1 H NMR (400MHz, DMSO-d6) δ11.40(s,1H),7.72(dd,J=12.3,8.1Hz,1H),7.35(dt,J=21.9,6.3Hz,4H),7.26(t,J=8.9Hz, 5H),6.89(dd,J=8.6,5.7Hz,4H),5.90(d,J=5.6Hz,1H),5.47-5.34(m,1H),4.72(dq,J=14.7,7.1Hz,2H),4.49-4.31( m,2H),4.18-4.07(m,2H),3.74(d,J=2.0Hz,7H),3.70-3.46(m,3H),3.35(q,J=7.5,4.9Hz,1H),3.29(d,J=3.2Hz,1H) ,2.78(t,J=6.0Hz,1H),2.63(t,J=5.9Hz,1H),1.72-1.35(m,8H),1.12(td,J=6.7,4.4Hz,9H),0.99(d,J=6.7Hz,3H).
[0432] Preparation Example 7: Preparation of Compound NM054
[0433] In this preparation example, the synthetic route of compound NM054 is as follows:
[0434] (7-1) Synthesis of Compound NM054-2
[0435] Compound NM054-1 (3 g, 11.54 mmol, 1.0 eq, (2'R)-2'-deoxy-2'-fluoro-2'-methyluridine, CAS No. 863329-66-2) and pyridine (30 ml) were added to a 500 ml reactor. The temperature was lowered to 0°C, and 4,4'-bismethoxytrityl chloride (4.29 g, 12.7 mmol, 1.1 eq) was added portionwise. The atmosphere was purged with nitrogen three times. The reaction system was stirred at 25°C under a nitrogen atmosphere for 3 hours. HPLC indicated the absence of starting material. After completion of the reaction, the reaction solution was concentrated and extracted with purified water (50 ml) and ethyl acetate (50 ml). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to yield compound NM054-2 (2.7 g, 41.7% yield). MS ESI (m / z) = 563.0 [M+H] + .
[0436] (7-2) Synthesis of Compound NM054
[0437] Compound NM054-2 (2.7 g, 4.8 mmol, 1.0 eq) was added to a 100 ml reactor. Bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.74 g, 5.76 mmol, 1.2 eq) was added portionwise. 4,5-Dicyanoimidazole (0.45 g, 3.8 mmol, 0.8 eq, CAS No. 1122-28-7) and dichloromethane (27 ml) were then added. The atmosphere was purged with nitrogen three times. The reaction system was stirred at 25°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, aqueous sodium bicarbonate solution (20 ml) was added to the reaction mixture. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by reverse phase column chromatography (eluent: acetonitrile / water = 90 / 10, v / v) to afford compound NM054 (3.0 g). MS ESI (m / z) = 763 [M+H] + .
[0438] Preparation Example 8: Preparation of Compound CR01008 and Compound CR01008Z
[0439] (8-1) Synthesis of Compound CR01008
[0440] In this preparation example, the synthetic route of compound CR01008 is as follows:
[0441] (8-1-1) Synthesis of Compound CR01008-2
[0442] Compound CR01008-1 (10.0 g, 1.0 eq, trans-4-(Boc-amino)cyclohexylcarboxaldehyde, CAS No. 181308-57-6) and formaldehyde solution (8.9 g, 37 mass %, 2.4 eq) were dissolved in 33 ml of methanol, and 13 ml of a 45.3 mass % KOH aqueous solution was added dropwise. After the addition was complete, the mixture was stirred at 25°C for 30 minutes, then heated to 60°C and refluxed at 60°C for 2 hours. After the reaction was completed, the reaction solution was cooled to room temperature and evaporated to dryness under reduced pressure to obtain a crude white solid. A small amount of water was added to the crude product to slurry it, and the mixture was filtered to obtain compound CR01008-2 (9 g, yield 78.9%) as a white solid. MS-ESI (m / z) = 260 [M+H] + .
[0443] (8-1-2) Synthesis of Compound CR01008-3
[0444] Compound CR01008-2 (9 g, 1 eq) was dissolved in 70 ml of 1,4-dioxane. A 45 ml solution of hydrogen chloride in 1,4-dioxane (4 M) was added, and the mixture was stirred at 25°C for 1 hour. After completion of the reaction, the reaction solution was evaporated to dryness under reduced pressure to obtain compound CR01008-3 (6.8 g, 100% yield) as a white solid.
[0445] (8-1-3) Synthesis of Compound CR01008-5
[0446] Compound CR01008-3 (1.8 g, 2.0 eq), compound CR01008-4 (2.1 g, 1.0 eq, 5-[[(2R,3R,4R,5R,6R)-3-acetylamino-4,5-diacetoxy-6-(acetoxymethyl)-2-tetrahydropyranyl]oxy]pentanoic acid) and N,N-diisopropylethylamine (3.5 g, 6.0 eq, abbreviated as DIEA) were dissolved in 15 ml of DMF, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.9 g, 1.1 eq, abbreviated as HBTU, CAS No. 94790-37-1) was added, and the reaction was stirred at 25°C in a nitrogen atmosphere for 3 hours. After the reaction was completed, the reaction solution was evaporated to dryness under reduced pressure and purified by reverse phase purification (eluent: 22% acetonitrile aqueous solution) to obtain compound CR01008-5 (1.78 g, yield 64.4%) as a white solid. MS-ESI (m / z) = 589 [M+H] + .
[0447] (8-1-4) Synthesis of Compound CR01008-6
[0448] Compound CR01008-5 (1.54 g, 1.0 eq) was dissolved in 15 ml of pyridine. The reaction system was cooled to 0°C using an ice-water bath and 4,4'-dimethoxytriphenylmethane (1.32 g, 1.5 eq, DMTrCl, CAS No. 40615-36-9) was added at 0°C. The reaction was allowed to react at 25°C for 3 hours. 15 ml of methanol was added to the reaction solution to quench the reaction. After completion of the reaction, the reaction solution was evaporated to dryness under reduced pressure and purified by reverse phase purification (eluent: 60% acetonitrile in water by volume) to obtain compound CR01008-6 (1 g, 42.7% yield) as a yellow solid. MS-ESI (m / z) = 891 [M+H] + .
[0449] (8-1-5) Synthesis of Compound CR01008
[0450] Compound CR01008-6 (1.08 g, 1.0 eq) was dissolved in 20 ml of anhydrous dichloromethane. 4,5-Dicyanoimidazole (115 mg, 0.8 eq, DCI, CAS No. 1122-28-7) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (732 mg, 2.1 eq, CAS No. 102691-36-1) were added, respectively. The atmosphere was purged with nitrogen three times, and the mixture was stirred at 25°C for 2 hours. After completion of the reaction, 20 ml of saturated aqueous sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted three times with 20 ml of dichloromethane (3 x 20 ml). The organic phases were combined and evaporated to dryness under reduced pressure. The organic phases were then purified by reverse phase chromatography (eluent: 72 vol% aqueous acetonitrile solution) and dried under vacuum for 12 hours to obtain compound CR01008 (1 g, 76.0% yield) as a white powder. MS-ESI (m / z) = 1091 [M+Na] + .
[0451] 1H NMR(400MHz, DMSO-d6)δ1.05(d,J=6.7Hz,6H).1.14(d,J=6.7Hz,6H),1.37–1.17(m,5H),1.60–1.40(m,6H),1.68–1.62(m,1H),1.80(s,3H), 1.80(s,3H),1.92(s,3H),2.02(s,5H),2.13(s,3H),2.71(t,J=5.9Hz,2H),2.79(d,J=8.4Hz,1H),2.87(d,J=8.4Hz,1H),3.36(s,1H),3.58– 3.39(m,3H),3.69–3.60(m,2H),3.75(s,7H),3.90(dt,J=11.2,8.8Hz,1H),4.05(s,3H),4.51(d,J=8.4Hz,1H),4.99(dd,J=11.3,3.4Hz,1H) ,5.24(d,J=3.4Hz,1H),5.78(s,1H),6.93–6.87(m,4H),7.35–7.21(m,7H),7.44–7.37(m,2H),7.66(d,J=7.8Hz,1H),7.84(d,J=9.2Hz,1H).
[0452] (8-2) Synthesis of Compound CR01008Z
[0453] In this preparation example, the synthetic route of compound CR01008Z is as follows:
[0454] (8-2-1) Synthesis of Compound CR01008-7
[0455] Compound CR01008-6 (500 mg) was dissolved in 10 ml of dichloromethane, and compound 8 (succinic anhydride, 112 mg), 4-dimethylaminopyridine (6.8 mg, DMAP, CAS No. 1122-58-3), and triethylamine (226.2 mg) were added. The atmosphere was purged with nitrogen three times, and the mixture was stirred at 25°C for 16 hours. Flash purification was performed to obtain compound CR01008-7 (300 mg, yield 53.6%). MS-ESI (m / z) = 1013 [M+Na] + .
[0456] (1.2.2) Synthesis of compound CR01008Z
[0457] Compound CR01008-7 (50 mg, aminoCPG (1.25 g, 80 μmol / g, 0.1 mmol), HBTU (27 mg), and DIEA (12 mg) were added to a 20 ml sample vial and shaken for 16 hours. After the reaction, the reaction solution was filtered to obtain a filter cake, which was washed once with 10 ml of acetonitrile (1×10 ml) and then dried in vacuo. The dried filter cake, DMAP (3 mg), Cap1 (10 ml), and Cap2 (1 ml) were added to a 20 ml sample vial and shaken for 6 hours. After the reaction, the reaction solution was filtered to obtain a filter cake, which was washed once with 10 ml of acetonitrile (1×10 ml) and then dried in vacuo to obtain compound CR01008Z (1.03 g, loading 20-30 μmol / g).
[0458] Cap1 and Cap2 are capping reagents, Cap1 is a 20% by volume N-methylimidazole mixed solution in pyridine / acetonitrile, with a volume ratio of pyridine to acetonitrile of 3:5; Cap2 is a 20% by volume acetic anhydride solution in acetonitrile.
[0459] Example 1 Synthesis of siRNA
[0460] siRNA synthesis is no different from the conventional phosphoramidite solid-phase synthesis method. When synthesizing the forward and antisense chains containing large spatial bulk group structures such as TBDMS, TOM, MOE, and when it is necessary to introduce nucleotides modified with large spatial bulk groups, the above-mentioned phosphoramidite monomers replace the nucleotide monomers at the corresponding sites of the original parent sequence.
[0461] The siRNA sequence (single-stranded siRNA) to be synthesized was introduced into the ABI394 synthesizer, and Universal CPG / PS or compound CR01008Z was used as a carrier. Synthesis was performed according to the set synthesis program. During the synthesis process, compound CR01008 was regarded as a nucleoside monomer.
[0462] The introduction of each base requires four steps of DMTr removal, coupling, oxidation, and capping. 2'-OMe, 2'-F, 2'-TOM, 2'-TBDMS, and 2'-MOE modified nucleoside phosphoramidite monomers were purchased from Shanghai Zhaowei Technology Development Co., Ltd. Compound NM062 was synthesized by the method shown in Preparation Example 1, and compound NM063 was synthesized by the method shown in Preparation Example 2. 5-Ethylmercapto-1H-tetrazole (ETT) was used as an activator (0.6M acetonitrile solution), 0.2M hydrogenated xanthan gum dissolved in a 1:1 volume ratio of acetonitrile and pyridine (Suzhou Kelema) solution was used as a thiolation reagent, and 0.05M iodine dissolved in a 9:1 volume ratio of pyridine and water solution (Suzhou Kelema) was used as an oxidant.
[0463] After the synthesis is complete, the carrier is removed and air-dried. Deprotection is performed using concentrated ammonia (50°C, 16 hours). After the reaction is completed, the supernatant is placed in a -20°C refrigerator and cooled for 10 minutes. After centrifugation, the supernatant is transferred to another centrifuge tube, concentrated to dryness, and purified using RP-HPLC with mobile phase A consisting of 0.1M TEAA and mobile phase B consisting of acetonitrile. The purified fractions are analyzed by HPLC, MS, and UV. Qualified fractions are collected and lyophilized to obtain single-stranded siRNA. The resulting single-stranded siRNA is annealed to obtain double-stranded siRNA.
[0464] The structural formula of the siRNA conjugate using (CR01008)(CR01008)(CR01008Z) (also known as (CR01008×3)) as the delivery vector is shown below:
[0465] in, Represents siRNA. (CR01008×3) is conjugated to the 3' end of the sense strand of the siRNA via a phosphodiester bond.
[0466] The structural formula of the siRNA conjugate using L96 as the delivery vector is shown below:
[0467] in, L96 is conjugated to the 3' end of the sense strand of the siRNA via a phosphodiester bond.
[0468] The siRNA compound sequences and modification information involved in each embodiment described in this disclosure are shown in Table 4.
[0469] Table 4
[0470] (Gemcitabine) represents a nucleotide in siRNA, and its structural formula is
[0471] (NM054) represents a nucleotide in siRNA, and its structural formula is
[0472] (NM096) represents a nucleotide in siRNA, and its structural formula is
[0473] (NM097) represents a nucleotide in siRNA, and its structural formula is
[0474] (NM098) represents a nucleotide in siRNA, and its structural formula is
[0475] (NM099) represents a nucleotide, and its structural formula is
[0476] Example 2 In vitro inhibitory activity of siRNA modified with TBDMS at different sites on complement component 3 (CC3) mRNA
[0477] In this example, an in vitro cell screening method was used to evaluate the inhibitory activity of the TBDMS-modified compounds RX502002-RX502041 at different sites on the sense and antisense strands and the reference compound RX502001 without TBDMS modification against the target gene CC3 in HepG2 cells.
[0478] 1. Preparation of test samples
[0479] After centrifugation, each siRNA sample was dissolved in an appropriate amount of 1×PBS according to the specifications of each tube to prepare a 20 μM stock solution, which was then further diluted with 1×PBS to a 5 μM working solution.
[0480] 2. Cell Culture and Plating
[0481] HepG2 cells were cultured and proliferated in DMEM medium containing 10% FBS at 37°C in a 5% CO2 incubator. Before plating, the medium was discarded and the cells were rinsed with 0.25% trypsin. After trypsinization, the cells were digested with the culture medium to terminate the digestion. The cells were resuspended, centrifuged at 800 rpm for 5 minutes, and resuspended in fresh DMEM medium containing 10% FBS. The cells were counted and diluted to a density of 1×10 5 cells / mL, and after thorough mixing, plate the cells in a 24-well plate at 500 μL / well. After culturing for 24 h, transfection was performed.
[0482] 3. Cell Transfection
[0483] 1) Prepare Solution 1 - siRNA Mixture:
[0484] Mix 49.4 μL of Opti-MEM medium and 0.6 μL of siRNA test substance working solution (5 μM) per well. Prepare three replicate wells for each siRNA test substance.
[0485] 2) Prepare Solution 2 - Lipofectamine 3000 mixture:
[0486] Gently invert to mix the transfection reagent, dilute 2 μL of Lipo3000 reagent with 48 μL of Opti-MEM medium per cell well, pipette gently 3 to 5 times to mix, and let stand for 5 minutes; prepare 3 replicate wells for each siRNA test product.
[0487] 3) Prepare solution 3 - a mixture of solution 1 and solution 2:
[0488] One portion (50 μL) of solution 1 was gently mixed with one portion (50 μL) of solution 2 to prepare solution 3 (100 μL) transfection complex, and incubated at room temperature for 20 min.
[0489] Remove the cell culture plate to be transfected, discard the original culture medium, and add 500 μL of Opti-MEM medium. Add 100 μL of the incubated solution 3 dropwise to the cell culture wells to achieve a siRNA test concentration of approximately 5 nM in each cell transfection well. Incubate the cell culture plate in a 37°C, 5% CO2 incubator for another 4 hours. Add 1 mL of DMEM medium containing 20% FBS to each well. Continue incubating at 37°C, 5% CO2 for 24 hours.
[0490] The Blank control group consisted of HepG2 cells cultured normally without any transfection operation; the Mock control group consisted of a control group in which no siRNA was added to the transfection complex and only Lipofectamine 3000 transfection reagent was added.
[0491] 4. Detection
[0492] RNA extraction: Total RNA was extracted from cells in each well using the fully automatic nucleic acid extraction instrument and nucleic acid extraction kit produced by Zhejiang Hanwei Technology Co., Ltd. according to the instructions.
[0493] Reverse transcription reaction: 1 μg of total RNA extracted from each well was taken and reverse transcription was performed using the Promega Reverse Transcription System (A3500) and Oligo(dT) 15 Prepare 20 μL of reverse transcription system according to the kit instructions and complete the reverse transcription reaction. After the reaction is complete, add 80 μL of RNase-free water to the reverse transcription system to obtain the cDNA solution for real-time PCR detection.
[0494] Real-time PCR detection: using ABI SYBR TMSelect Master Mix (Catalog number: 4472908) reagent, prepare 20 μL Real-time PCR reaction system per PCR detection well according to the method described in the kit instructions, each detection system contains 5 μL cDNA template obtained by the above reverse transcription reaction, 10 μL SYBR TM Select Master Mix, 0.5 μL of 10 μM upstream primer, 0.5 μL of 10 μM downstream primer (primer information see Table 5), and 4 μL of RNase-Free H2O. The prepared reaction system was placed on an ABI StepOnePlus PCR instrument and amplified using a three-step real-time PCR protocol: pre-denaturation at 95°C for 10 minutes, followed by denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 30 seconds. This denaturation, annealing, and extension process was repeated for 40 cycles. After completion, gene expression differences were calculated using the aforementioned ΔΔCt method.
[0495] Table 5
[0496] The relative expression levels of target gene CC3 mRNA (Figure 1) and the residual activity of target gene CC3 mRNA (Table 6) were calculated after HepG2 cells were transfected with siRNA modified with TBDMS at different sites on the sense chain. The results showed that compared with the reference sequence (RX502001) without TBDMS modification, the in vitro activity of siRNA sequences modified with TBDMS at positions 5 (RX502027), 6 (RX502028), 12 (RX502034), 13 (RX502035), and 18 (RX502040) of the sense chain was improved; TBDMS modification at positions 7 (RX502029), 8 (RX502030), 9 (RX502031), and 10 (RX502032) of the sense chain significantly weakened the in vitro activity of the siRNA sequences.
[0497] Table 6
[0498] After HepG2 cells were transfected with siRNA modified with TBDMS at different sites on the antisense chain, the relative expression levels of the target gene CC3 mRNA (Figure 2) and the residual activity of the target gene CC3 mRNA (Table 7) were calculated. Compared with the reference sequence without TBDMS modification (RX502001), TBDMS modification at positions 8 (RX502009) and 15 (RX502016) of the antisense chain further enhanced the in vitro activity of the siRNA sequence.
[0499] Table 7
[0500] The above results indicate that the effect of TBDMS modification on siRNA sequence activity is related to the modification site. Modification of specific sites with large TBDMS groups does not affect siRNA activity and may even further enhance the activity.
[0501] Example 3. Inhibitory activity of siRNA conjugates modified with TBDMS at different sites on mouse serum CC3 protein
[0502] This example evaluated the inhibitory activity of TBDMS-modified compounds RZM02004, RZM02005, and RZM02006 at different sites of the antisense strand and the reference compound RZM02001 without TBDMS modification on serum CC3 protein levels in mice based on the Elisa detection method and principle.
[0503] 1. Animal Grouping, Dosing, and Blood Collection
[0504] 6-8 week old C57BL / 6j mice were randomly divided into 5 groups according to body weight, with 5 mice in each group. Each group of mice was given the above-mentioned siRNA conjugate by subcutaneous administration in the abdomen, with a dose of 3 mg / kg per mouse and a dosing volume of 5 mL / kg. The PBS control group was given the same volume of PBS solution without siRNA conjugate. Blood was drawn before administration as pre-dose, and the day was recorded as the first day (D0). After administration, blood was collected from the fundus venous plexus of each mouse using a coagulant tube (purchased from Kangshifei, 220518) on D14, D28, D42, D56, D70 and D91, with a blood volume of approximately 0.1 mL / mouse / time. Blood was collected using a coagulant tube (purchased from Kangshifei, 220518), the blood sample was kept at 4°C overnight, centrifuged at 1800g at 4°C for 10 minutes, and the serum was separated and stored at -80°C.
[0505] 2. Serum CC3 protein detection
[0506] Serum samples were diluted 1:10,000 using a 10-fold serial dilution method. CC3 protein levels in the serum of each mouse were measured using a mouse Complement C3 ELISA kit (abcam, ab157711). Standard working solutions and subsequent sample loading procedures were prepared according to the kit's instructions. The ELISA plate was placed in a multi-function microplate reader (Biotek Synergy H1) and absorbance was measured at 450 nm. Graphpad Prism 8.0 was used to perform a four-parameter fit (formula: Y = Bottom + (X^Hillslope) * (Top-Bottom) / (X^Hillslope + EC50^Hillslope)) to plot the calibration curve and calculate R-squared. Protein concentrations in each sample were calculated by substituting OD450 values into the calibration curve and multiplying by the corresponding dilution factor. The values were then normalized to the pre-dose values.
[0507] 3. Results Analysis
[0508] The expression levels of serum CC3 protein in mice after administration (Figure 3) and the residual activity of the target gene CC3 mRNA (Table 8) were statistically analyzed. The results showed that siRNAs with TBDMS at position 18 of the sense chain (RZM02004), position 15 of the antisense chain (RZM02005), and position 21 of the antisense chain (RXM02006) had comparable activities to the reference sequence without TBDMS modification (RZM02001), and all were able to produce a highly effective and sustained inhibitory effect on the serum CC3 protein level. By D91, the inhibitory effects of TBDMS-modified RZM02004 (remaining level 61.69%), RZM02005 (remaining level 45.29%), and RXM02006 (remaining level 56.75%) on serum CC3 protein levels were significantly higher than those of the reference sequence RZM02001 (remaining level 72.75%), suggesting that TBDMS large group modification at specific siRNA sites does not affect sequence activity and may even further enhance sequence activity.
[0509] Table 8
[0510] Example 4. In vitro inhibitory activity of siRNA conjugates modified with TBDMS at different sites on angiopoietin-like protein 3 (ANGPTL3) mRNA in mouse primary hepatocytes
[0511] In this example, an in vitro primary mouse hepatocyte screening method was used to evaluate the inhibitory activity of RZ597065 and other compounds with TBDMS modifications at different sites on the sense chain, and RZ597084 and other compounds with TBDMS modifications at different sites on the antisense chain, in comparison with the reference compound RZ597024 without TBDMS modification and the negative control compound RZ000002 without any known gene targeting, against the target gene ANGPTL3 in primary mouse hepatocytes.
[0512] 1. Preparation of test samples
[0513] After centrifugation, each of the above siRNA conjugate test samples was dissolved in an appropriate amount of 1×PBS according to the specifications of each tube to prepare a 20 μM stock solution, which was then further diluted with 1×PBS to a 5 μM working solution.
[0514] 2. Isolation of Primary Mouse Hepatocytes
[0515] (1) Anesthesia: C57BL / 6j mice were intraperitoneally injected with 0.04 mL / 10 g of 10% chloral hydrate solution.
[0516] (2) Perfusion: Immobilize the animal and disinfect its abdomen and chest with 75% ethanol. Open the abdominal cavity and locate the portal vein and inferior vena cava. Insert the indwelling needle into the inferior vena cava and begin perfusing HBSS at a rate of 120 drops / min. Cut the portal vein, confirm that the perfusion fluid flows out of the cut portal vein, secure the infusion set, and continue perfusion for 4 minutes.
[0517] (3) Digestion of hepatocytes: Replace the HBSS with 0.08% type IV collagenase (Collagenase from Clostridium histolyticum, Sigma) and continue perfusion at a rate of 120 drops / min for 8 minutes.
[0518] (4) Isolation of primary hepatocytes: Remove the perfused liver from the animal and place it in a sterile culture dish containing 10 mL of DMEM, then shred it. Remove undigested liver tissue and connective tissue by filtering through a 75 μm cell sieve. Centrifuge and resuspend the cells in DMEM and wash them twice. Add 10 mL of DMEM medium containing 10% FBS, resuspend, count, and proceed to the drug uptake experiment.
[0519] 3. Free uptake of siRNA conjugates:
[0520] Freshly isolated mouse primary hepatocytes were plated into type I collagen-coated 12-well cell culture plates (Corning), with 5×10 5 For living cells, 2 mL of DMEM medium containing 10% FBS.
[0521] Add 2 μL of the 5 μM siRNA conjugate working solution to each well and mix gently. This results in a final concentration of 5 nM siRNA conjugate in each well. A blank control group consists of untreated primary mouse hepatocytes that have not been exposed to the siRNA conjugate. Incubate the treated primary mouse hepatocytes in a 37°C, 5% CO2 incubator for 24 hours.
[0522] 4. Detection
[0523] RNA extraction: Total RNA was extracted from cells in each well using the fully automatic nucleic acid extraction instrument and nucleic acid extraction kit produced by Zhejiang Hanwei Technology Co., Ltd. according to the instructions.
[0524] Reverse transcription reaction: 1 μg of total RNA extracted from each well was taken and the oligo(dT) was selected using the Promega reverse transcription kit (Reverse Transcription System, A3500). 15 Prepare 20 μL of reverse transcription system according to the kit instructions and complete the reverse transcription reaction. After the reaction is complete, add 80 μL of RNase-free water to the reverse transcription system to obtain the cDNA solution for real-time PCR detection.
[0525] Real-time PCR detection: using ABI SYBR TM Select Master Mix (Catalog number: 4472908) was prepared according to the method described in the kit instructions to prepare 20 μL of real-time PCR reaction system per PCR detection well. Each detection system contained 5 μL of cDNA template obtained by the above reverse transcription reaction, 10 μL of SYBR TM Select Master Mix, 0.5 μL of 10 μM upstream primer, 0.5 μL of 10 μM downstream primer (primer information see Table 9), and 4 μL of RNase-Free H2O. The prepared reaction system was placed on an ABI StepOnePlus PCR instrument and amplified using a three-step real-time PCR protocol: 95°C pre-denaturation for 10 minutes, followed by 95°C denaturation for 30 seconds, 60°C annealing for 30 seconds, and 72°C extension for 30 seconds. This denaturation, annealing, and extension process was repeated for 40 cycles. After completion, gene expression differences were calculated using the ΔΔCt method described above.
[0526] Table 9
[0527] 5. Results Analysis
[0528] The relative expression levels of the target gene ANGPTL3 mRNA (Figure 4) and the residual activity (Table 10) were calculated after mouse primary hepatocytes freely took up TBDMS-modified siRNAs at different sites on the sense chain. The results showed that compared with the reference sequence (RZ597024) without TBDMS modification, TBDMS modifications at positions 5 (RZ597069), 6 (RZ597070), 12 (RZ597076), 13 (RZ597077), and 18 (RZ597082) of the sense chain helped to enhance the in vitro activity of the siRNA sequence; whereas TBDMS modifications at positions 2 (RZ597066), 3 (RZ597067), 7 (RZ597071), 8 (RZ597072), 9 (RZ597073), and 10 (RZ597074) of the sense chain significantly weakened the in vitro activity of the siRNA sequence.
[0529] Table 10
[0530] The relative expression levels of the target gene ANGPTL3 mRNA (Figure 5) and the residual activity (Table 11) were calculated after mouse primary hepatocytes freely took up siRNA modified with TBDMS at different sites on the antisense chain. The results showed that compared with the reference sequence without TBDMS modification (RZ597024), the antisense chain positions 8 (RZ597030), 9 (RZ597031), 10 (RZ597086), 15 (RZ597091), 20 (RZ597096), and 21 (RZ597097) contributed to the improvement of the in vitro activity of the siRNA sequence.
[0531] Table 11
[0532] The experimental conclusions suggested by the experimental results of Example 4 are highly similar to those of Example 2, both indicating that the effect of TBDMS modification on the activity of siRNA sequences is related to the modification site, and that TBDMS macro-group modification at a specific site does not affect siRNA activity and may even further enhance activity.
[0533] Example 5. Inhibitory activity of siRNA conjugates modified with TBDMS at different sites against ANGPTL3 mRNA in mice
[0534] This example uses the mouse in vivo target gene inhibition activity evaluation method to evaluate the inhibitory activity of siRNA conjugates RZ597026 and RZ597030 with TBDMS modification at different sites of the antisense strand, and the reference conjugate RZ597024 without TBDMS modification on the target gene ANGPTL3 in mice.
[0535] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, with 25 mice in each group. Each group of mice was given the above-mentioned siRNA conjugate by subcutaneous administration in the abdomen, with a dose of 3 mg / kg per mouse and a dosing volume of 5 mL / kg. The PBS control group was given the same volume of PBS solution without siRNA conjugate. The day of administration was recorded as the first day (D0), and 5 mice were killed in each group on D7, D14, D28 and D56 after administration. The animals were grossly dissected, liver tissue was collected, and cut into several 2 mm 3 Small pieces were preserved in RNAlater. An appropriate amount of liver tissue sample was removed from the RNAlater and homogenized in a Tissuelyser II automated tissue homogenizer for 60 seconds. RNA extraction, reverse transcription, and real-time PCR were performed according to the detection methods described in Example 4. Relative quantification of target gene mRNA in each test group was performed using the aforementioned ΔΔCt method.
[0536] The expression levels of ANGPTL3 mRNA in mice after administration ( Figure 6 ) and the residual activity of ANGPTL3 mRNA ( Table 12 ) were statistically analyzed. Similar to the conclusions of the in vitro primary hepatocyte experiment in Example 4, the antisense chain position 8 (RZ597030) tolerated TBDMS modification well. The in vivo activity and duration of efficacy of RZ597030 were superior to those of the reference sequence without TBDMS modification (RZ597024). However, TBDMS modification at position 4 (RZ597026) of the antisense chain had a relatively large effect on the in vivo activity of the sequence.
[0537] Table 12
[0538] The in vivo experimental results of Example 5 once again verified that the effect of TBDMS modification on the activity of siRNA sequences is related to the modification site. Modification of specific sites with large TBDMS groups does not affect the activity of siRNA and may even further improve the activity.
[0539] Example 6. In vitro inhibitory activity of siRNA conjugates modified with TOM at different sites on factor XI (FXI) mRNA in primary mouse hepatocytes
[0540] Using the same experimental methods as in Example 4, the inhibitory activity of siRNA conjugates with TOM modifications at different sites on the antisense strand was evaluated against the target gene FXI in primary mouse hepatocytes. The differences were that this example replaced the siRNA conjugates used in Example 4 with siRNA conjugates with TOM modifications at different sites on the antisense strand; and that this example replaced the target gene FXI detection primers used in Example 4 with the primers shown in Table 13. Relative quantification of target gene mRNA in each test group was performed using the aforementioned ΔΔCt method.
[0541] Table 13
[0542] The relative expression levels of target gene FXI mRNA (Figure 7) and FXI expression were calculated after mouse primary hepatocytes freely took up siRNA modified with TOM at different sites on the positive chain. The residual activity of mRNA was measured (Table 14). The results showed that compared with the reference sequence without TOM modification (RZ594001), TOM modification at positions 5 (RZ594011), 6 (RZ594012), 12 (RZ594018), 13 (RZ594019), 18 (RZ594024), and 19 (RZ594025) of the sense chain helped to improve the in vitro activity of the siRNA sequence; TBDMS modification at positions 2 (RZ594008), 3 (RZ594009), 7 (RZ594013), 8 (RZ594014), 9 (RZ594015), and 10 (RZ594016) of the sense chain had a more obvious weakening effect on the in vitro activity of the siRNA sequence.
[0543] Table 14
[0544] After the free uptake of siRNA with TOM modification at different sites on the antisense chain by mouse primary hepatocytes, the relative expression level of the target gene FXI mRNA (Figure 8) and the residual activity of FXI mRNA (Table 15) were calculated. Compared with the reference sequence without TOM modification (RZ594001), the antisense chain positions 7 (RZ594004), 8 (RZ594005), 9 (RZ594006), 10 (RZ594030), 15 (RZ594035), 20 (RZ594040), and 21 (RZ594041) contributed to the improvement of the in vitro activity of the siRNA sequence.
[0545] Table 15
[0546] The results of Example 6 show that the effect of TOM modification on siRNA sequence activity is related to the modification site. Modification of the TOM macrogroup at a specific site does not affect siRNA activity and may even further enhance activity. Its effect pattern is highly similar to that of TOM modification.
[0547] Example 7. Inhibitory activity of siRNA conjugates modified with TOM at different sites against CC3 mRNA in mice
[0548] In this example, the target gene inhibition activity evaluation method in mice was used to evaluate the inhibitory activity of the sense chain 19-position TOM-modified conjugate RZ502013, the antisense chain 10-position TOM-modified conjugate RZ502016, and the reference conjugate without TOM modification RZ002001 on the target gene CC3 in mice.
[0549] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, with 5 mice in each group. Each group of mice was given the above siRNA conjugate by subcutaneous administration in the abdomen, with a dose of 3 mg / kg per mouse and a dosing volume of 5 mL / kg. The PBS control group was given the same volume of PBS solution without siRNA conjugate. The day of administration was recorded as the first day (D0), and the mice were killed on D7 after administration. The animals were grossly dissected, liver tissue was collected, and cut into several 2 mm 3 Small pieces were preserved in RNAlater. An appropriate amount of liver tissue sample was removed from the RNAlater and disrupted in a Tissuelyser II automated tissue homogenizer for 60 seconds. RNA extraction, reverse transcription, and real-time PCR were performed according to the detection methods described in Example 2. Relative quantification of target gene mRNA in each test group was performed using the aforementioned ΔΔCt method. The difference was that this example used a TOM-modified siRNA conjugate instead of the siRNA conjugate used in Example 4; relative quantification of target gene mRNA in each test group was performed using the aforementioned ΔΔCt method.
[0550] The expression level of CC3 mRNA in mice after administration ( Figure 9 ) and the residual activity of CC3 mRNA ( Table 16 ) were statistically analyzed. The results showed that the in vivo activity (D7) of the siRNA conjugate RZ502013 with TOM modification at position 19 of the siRNA sense chain was higher than that of the reference conjugate RZ002001, and the in vivo activity of the siRNA conjugate RZ502016 with TOM modification at position 10 of the antisense chain was comparable to that of the reference conjugate RZ002001.
[0551] Table 16
[0552] The in vivo results of Example 7 indicate that modification of the TOM macrogol group at a specific site does not affect siRNA activity and may even further enhance the activity.
[0553] Example 8. Inhibitory activity of siRNA conjugates modified with MOE at different sites on CC3 mRNA in HepG2 cells
[0554] Using the same experimental methods as in Example 2, we evaluated the in vitro activity of siRNA compounds modified with MOE at different sites on the sense strand, such as RX502165, and at different sites on the antisense strand, such as RX502172, as well as the non-MOE-modified reference compound RX502001, on HepG2 cells. This example replaced the siRNA compound used in Example 2 with siRNA compounds modified with MOE at different sites on the sense and antisense strands. Relative quantification of target gene mRNA in each test group was performed using the aforementioned ΔΔCt method.
[0555] The results of Example 8 show that the effect of MOE modification on siRNA sequence activity is related to the modification site. MOE group modification at a specific site does not affect siRNA activity and can even further improve activity. Its effect pattern is highly similar to that of TBDMS modification and TOM modification.
[0556] The relative expression levels of the target gene CC3 mRNA (Figure 10) and the residual activity of CC3 mRNA (Table 17) were calculated after HepG2 cells were transfected with siRNA modified with MOE at different sites on the sense chain. The results showed that compared with the reference sequence without MOE modification (RX502001), MOE modifications at positions 5 (RZ594011), 12 (RX502115), 18 (RX502116), and 19 (RX502117) of the sense chain helped to improve the in vitro activity of the siRNA sequence; MOE modifications at positions 7 (RX502166), 8 (RX502167), 9 (RX502168), and 10 (RX502169) of the sense chain had a more obvious weakening effect on the in vitro activity of the siRNA sequence.
[0557] Table 17
[0558] The relative expression levels of the target gene CC3 mRNA ( Figure 11 ) and the residual activity of CC3 mRNA ( Table 18 ) were calculated after HepG2 cells were transfected with siRNA modified with MOE at different sites on the antisense chain. The results showed that compared with the reference sequence without MOE modification (RX502001), positions 8 (RX502118), 10 (RX502119), and 15 (RX502120) of the antisense chain contributed to the improvement of the in vitro activity of the siRNA sequence.
[0559] Table 18
[0560] The results of Example 8 show that the effect of MOE modification on siRNA sequence activity is related to the modification site. MOE group modification at a specific site does not affect siRNA activity and can even further improve activity. Its effect pattern is highly similar to that of TBDMS modification and TOM modification.
[0561] Example 9. Inhibitory activity of multi-site MOE-modified conjugates on CC3 mRNA in HepG2 cells
[0562] Using the same experimental methods as in Example 2, we evaluated the in vitro activity of siRNA compounds with multiple MOE modifications on the sense strand (RX502123), siRNA compounds with multiple MOE modifications on the antisense strand (RX502130), and compounds with MOE modifications on both the sense and antisense strands (RX502146), as well as a non-MOE-modified reference compound (RX502001) and a negative control compound (RZ000002) that does not target any known targets, on HepG2 cells. This example differed from the siRNA compounds used in Example 2 by replacing them with the aforementioned sense and / or antisense MOE-modified siRNA compounds. Relative quantification of target gene mRNA in each test group was performed using the aforementioned ΔΔCt method.
[0563] After HepG2 cells were transfected with siRNA modified with multiple sites of MOE at the positive chain, the relative expression level of the target gene CC3 mRNA (Figure 12) and the residual activity of CC3 mRNA (Table 19) were calculated. The results showed that the in vitro activity of the siRNA reference sequence (RX502001) with multiple sites of MOE modification at positions 6, 12, 18, and 19 of the positive chain was comparable to that of the siRNA reference sequence without MOE modification (RX502001). Among them, the compound RX502126 with simultaneous MOE modification at positions 12 and 18 of the positive chain had an in vitro activity slightly higher than that of the reference sequence RX502001.
[0564] Table 19
[0565] The relative expression level of the target gene CC3 mRNA (Figure 13) and the residual activity of CC3 mRNA (Table 20) were calculated after HepG2 cells were transfected with siRNA modified with multi-site MOE on the antisense chain. The in vitro activities of the antisense chain modified with multi-site MOE at positions 8, 10, 15, 20, and 21 were comparable to those of the siRNA reference sequence without MOE modification (RX502001). Among them, the in vitro activities of multiple modified sequences, such as the compound RX502130 modified with MOE at positions 8 and 15 of the sense chain, were even slightly higher than those of the reference sequence RX502001.
[0566] Table 20
[0567] The relative expression levels of target gene CC3 mRNA ( FIG. 14 ) and the residual activity of CC3 mRNA ( Table 21 ) were calculated after HepG2 cells were transfected with siRNAs modified with multiple sites of MOE on the sense chain and antisense chain, respectively. The results showed that the compounds modified with MOE at positions 6, 12, and 18 of the sense chain and positions 8, 10, 15, 20, and 21 of the antisense chain had comparable in vitro activities to the siRNA reference sequence (RX502001) without MOE modification, among which the compounds modified with MOE at positions 18, 12, and 18 of the sense chain and positions 8, 10, 15, 20, and 21 of the antisense chain had comparable in vitro activities to the siRNA reference sequence (RX502001) without MOE modification. Multiple modified sequences, including compound RX502151, with MOE modification at position 15 of the antisense strand; compound RX502154, with MOE modification at positions 6 and 12 of the sense strand and positions 8 and 15 of the antisense strand; compound RX502156, with MOE modification at positions 6, 18 of the sense strand and positions 8 and 15 of the antisense strand; and compound RX502158, with MOE modification at positions 12, 18 of the sense strand and positions 8 and 15 of the antisense strand, all showed slightly higher in vitro activity than the reference sequence RX502001. Even RX502164, with MOE modification at positions 6, 12, and 18 of the sense strand and positions 8, 10, 15, 20, and 21 of the antisense strand, still maintained good in vitro activity.
[0568] Table 21
[0569] The results of Example 9 show that the effect of MOE modification on the activity of siRNA sequences is related to the modification site. Single or multiple MOE modifications at specific sites on the sense and / or antisense chains can be well tolerated and can still well maintain or even further enhance the activity of the siRNA sequence.
[0570] Example 10. Inhibitory activity of siRNA conjugates with MOE modification at different sites on the sense and / or antisense strands against CC3 mRNA in mice
[0571] Using the same experimental methods as Example 7, siRNA conjugates with MOE modifications at different sites on the sense and / or antisense strands, as well as the unmodified reference conjugate RZ502031, were evaluated for their inhibitory activity against the target gene CC3 in mice. This example used the aforementioned sense and / or antisense strand MOE-modified siRNA compounds instead of the siRNA compound used in Example 7. The target gene mRNA in each test group was relative quantified using the aforementioned ΔΔCt method. RNA extraction, reverse transcription, and real-time PCR were performed according to the detection methods described in Example 2, and the target gene mRNA in each test group was relative quantified using the aforementioned ΔΔCt method. The target gene mRNA in each test group was relative quantified using the aforementioned ΔΔCt method.
[0572] After administration of the siRNA conjugates described in this example, CC3 mRNA expression levels in mice (Figures 15 and 16) and residual CC3 mRNA activity (Tables 22 and 23) were statistically analyzed. The results showed that multi-site MOE modification at specific sites on the sense and / or antisense strands can still maintain or even further enhance the in vivo activity of siRNA sequences. The siRNA conjugate RZ502039, with MOE modification at positions 6 and 18 of the sense strand and positions 8 and 15 of the antisense strand, and the siRNA conjugate RZ502036, with MOE modification at positions 12 and 18 of the sense strand and position 15 of the antisense strand, showed higher in vivo activity (day 21) than the reference conjugate RZ502031. However, MOE modification at position 14 of the antisense strand (RZ502087) significantly affected the in vivo activity of the siRNA.
[0573] Table 22
[0574] Table 23
[0575] The results of Example 10 show that the effect of MOE modification on the activity of siRNA sequences is related to the modification site. Single or multiple MOE modifications at specific sites on the sense and / or antisense chains can be well tolerated and can still well maintain or even further enhance the activity of the siRNA sequence. However, at other sites, even single-site MOE modification can significantly affect the activity of the siRNA sequence.
[0576] Example 11. Inhibitory activity of siRNA conjugates with MOE modification at different sites on the sense and / or antisense strands against SOD1 mRNA in mice
[0577] Using the same experimental methods as in Example 7, siRNA conjugates with MOE modifications at different sites on the sense and / or antisense strands, as well as the unmodified reference conjugate RZ599001, were evaluated for their inhibitory activity against the target gene SOD1 in mice. This example used the aforementioned MOE-modified siRNA compounds instead of the siRNA compounds used in Example 7. The target gene mRNA in each test group was relative quantified using the aforementioned ΔΔCt method. RNA extraction, reverse transcription, and real-time PCR were performed according to the detection methods described in Example 2, and the target gene mRNA in each test group was relative quantified using the aforementioned ΔΔCt method.
[0578] The expression levels of SOD1 mRNA in mice (Figure 17) and residual activity (Table 24) were statistically analyzed on days 7 and 21 after administration. The results showed that the effect of MOE modification on siRNA sequence activity was related to the modification site. Single or multiple MOE modifications at specific sites on the sense and / or antisense strands were well tolerated and could still maintain or even further enhance siRNA sequence activity.
[0579] Table 24
[0580] Example 12. In vitro activity evaluation of siRNA conjugates with different modification schemes against target gene C3 in HepG2 cells
[0581] In this example, the human liver cancer cell line HepG2 was used to comparatively evaluate the inhibitory activity of various siRNA conjugates formed by converting different modification schemes of RZ002003, RZ002006, RZ002011 and RZ002031 on the target gene C3 mRNA in cells.
[0582] Test sample preparation:
[0583] After centrifugation, dissolve each siRNA sample in PBS according to the specifications of each tube to prepare a 20 μM stock solution. This stock solution was then serially diluted with PBS to produce 0.5 μM and 0.05 μM working solutions. Dosage testing was performed at final duplex concentrations of 5 nM and 0.5 nM.
[0584] 96-well transfection and detection:
[0585] HepG2 cells grown to near confluence were digested with trypsin, and the cells were washed to prepare a cell suspension. 100 μL of cell suspension was added to each well of a 96-well plate, with 12,000 cells per well. The cells were cultured in a 37°C, 5% CO2 incubator. After the cells adhered for 24 hours, the DMEM medium in the 96-well plate was aspirated and 80 μL of Opti-MEM was added to each well. TM Culture medium was added, and the 96-well plate was then placed in an incubator for further incubation. 1 μL of the 0.1 μM and 0.01 μM working solutions were dispersed in 9 μL of Opti-MEM to form the siRNA mixture. 0.3 μL of RNAiMAX was dispersed in 9.7 μL of Opti-MEM and mixed with each siRNA mixture to form a transfection complex. The transfection complex was incubated at room temperature for 10 minutes, and then the transfection complex was added to the 96-well plate at a rate of 20 μL / well. After 4 hours of incubation, 100 μL of DMEM medium containing 20% FBS was added to each well, and the 96-well plate was placed in an incubator for a further 24 hours. For the mock control group, 0.3 μL of RNAiMAX was dispersed in 9.7 μL of Opti-MEM, followed by 10 μL of Opti-MEM. The mixture was incubated at room temperature for 10 minutes; then, 20 μL of the complex was added to the 96-well plate at a rate of 20 μL / well. After culturing for 4 hours, 100 μL of DMEM medium containing 20% FBS was added to each well, and the 96-well plate was placed in an incubator and cultured for a further 24 hours.
[0586] The 96-well plate was removed and total RNA was extracted using a fully automatic nucleic acid extractor (purchased from Zhejiang Hanwei Technology Co., Ltd.) and a nucleic acid extraction kit (purchased from Zhejiang Hanwei Technology Co., Ltd., GO-MNTR-100) according to the standard operating procedures for total RNA extraction.
[0587] Use reverse transcription kit (Thermo Fisher Scientific company, RevertAid First Strand cDNA Synthesis Kit, K1622) and select Oligo (dT) 18 reverse transcription primer, configure 20 μ L reverse transcription system according to the method for reverse transcription kit specification sheet record and complete reverse transcription reaction.Then use real-time fluorescence quantitative PCR kit (Thermo Fisher Scientific company, TaqMan Fast Advanced Master Mix, 4444557) to detect the expression of target gene mRNA in HepG2 cells on fluorescence quantitative PCR instrument (Bio-Rad company, CFX Opus 384).In this real-time fluorescence quantitative PCR method, using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene as internal reference gene, use the primer for target gene and the primer for GAPDH internal reference gene to detect target gene and GAPDH internal reference gene respectively.The sequence of detection primer is referring to Table 25.
[0588] Table 25
[0589] According to the instructions of the real-time fluorescence quantitative PCR kit, 10 μL of real-time PCR reaction system was prepared for each PCR detection well. Each reaction system contained 4 μL of the cDNA solution obtained by the reverse transcription reaction, 5 μL of TaqMan TM Fast Advanced Master Mix (2×), 0.15 μL of 10 μM upstream primer, 0.15 μL of 10 μM downstream primer, 0.15 μL of 10 μM probe primer, and 0.55 μL of RNase-Free H2O. The prepared reaction system was placed in a real-time fluorescence quantitative PCR instrument (Bio-Rad, CFX Opus 384) for real-time PCR amplification using a two-step protocol: 50°C for 2 minutes, followed by pre-denaturation at 95°C for 20 seconds, denaturation at 95°C for 3 seconds, annealing and extension at 60°C for 30 seconds, and 40 cycles of denaturation, annealing, and extension. In this real-time fluorescence quantitative PCR method, the expression level and inhibition rate of the target gene C3 mRNA in each test group were relative quantified using the aforementioned ΔΔCt method.
[0590] The results of Example 12 showed that at doses of 5 nM and 0.5 nM, siRNAs converted with different modification schemes of RZ002003, RZ002006, RZ002011 and RZ002031 could significantly inhibit the expression of C3 gene mRNA in HepG2 cells and had higher in vitro activity than the original sequences RZ002003, RZ002006, RZ002011 and RZ002031 ( Figures 18a, 18b, 18c, 18d; Tables 26a, 26b, 26c, 26d).
[0591] Table 26a
[0592] Table 26b
[0593] Table 26c
[0594] Table 26d
[0595] Example 13. In vitro evaluation of the activity of siRNA conjugates with different modification schemes against the target gene angiotensinogen (AGT) in Huh7 cells
[0596] In this example, the human liver cancer cell line Huh7 was used to compare and evaluate the inhibitory activity of various siRNA conjugates formed by converting RZ003017 and RZ003020 with different modification schemes on the target gene AGT mRNA in cells.
[0597] Test sample preparation:
[0598] After centrifugation, dissolve each siRNA sample in PBS according to the specifications of each tube to prepare a 20 μM stock solution. This stock solution was then serially diluted with PBS to produce 0.1 μM and 0.01 μM working solutions. Dosage testing was performed at final duplex concentrations of 1 nM and 0.1 nM.
[0599] 96-well transfection and detection:
[0600] Huh7 cells grown to near confluence were digested with trypsin, and the cells were washed to prepare a cell suspension. 100 μL of cell suspension was added to each well of a 96-well plate, with 12,000 cells per well. The cells were cultured in a 37°C, 5% CO2 incubator. After the cells adhered for 24 hours, the DMEM medium in the 96-well plate was aspirated and 80 μL of Opti-MEM was added to each well. TMThe 96-well plates were then placed in an incubator and incubated for an additional 24 hours. A mock control group consisted of 0.3 μL of 0.1 μM and 0.01 μM working solutions diluted in 9 μL of Opti-MEM to form a siRNA mixture. 0.3 μL of RNAiMAX diluted in 9.7 μL of Opti-MEM was then mixed with each siRNA mixture to form a transfection complex. The transfection complex was incubated at room temperature for 10 minutes, and then 20 μL of the complex was added to each 96-well plate. After 4 hours of incubation, 100 μL of DMEM medium supplemented with 20% FBS was added to each well, and the 96-well plate was placed in an incubator and incubated for an additional 24 hours. For the mock control group, 0.3 μL of RNAiMAX was diluted in 9.7 μL of Opti-MEM, followed by 10 μL of Opti-MEM. The mixture was incubated at room temperature for 10 minutes, and then 20 μL of the complex was added to each 96-well plate. After 4 hours of incubation, each well was supplemented with 100 μL of DMEM medium supplemented with 20% FBS, and the 96-well plate was placed in an incubator for an additional 24 hours. RNA extraction, reverse transcription, and real-time fluorescence quantitative PCR were performed as described in Example 12. In this real-time fluorescence quantitative PCR, relative quantification of target gene mRNA expression levels and inhibition rates in each test group was performed using the aforementioned ΔΔCt method. Detection primer sequences are shown in Table 27.
[0601] Table 27
[0602] The results of Example 13 showed that at doses of 1 nM and 0.1 nM, siRNAs converted with different modification schemes of RZ003017 and RZ003020 could significantly inhibit the expression of AGT gene mRNA in HepG2 cells and had comparable or higher in vitro activity than the original sequences RZ003017 and RZ003020 ( Figure 19 ; Table 28 ).
[0603] Table 28
[0604] Example 14. Evaluation of the protein-lowering effect of siRNA conjugates with different modification schemes in hREN×hAGT hypertensive mice
[0605] In this example, enzyme-linked immunosorbent assay (ELISA) was used to determine the effects of reference siRNA conjugates RZ003021, RZ003065, and RZ003066 on the expression of AGT protein in the serum of hREN×hAGT hypertensive mice at different time points after single administration.
[0606] Animal grouping, drug administration and tissue sample collection:
[0607] 9-11 week old hREN×hAGT hypertensive mice (purchased from Saiye (Suzhou) Biotechnology Co., Ltd.) were grouped according to systolic blood pressure levels (all male). Each test group was given a predetermined dose of drug conjugate and a PBS control group was added. The drug dose for all mice was calculated based on body weight and administered as a single dose by subcutaneous injection in the abdomen. Each drug conjugate was administered in the form of a 0.3 mg / mL (calculated as siRNA) PBS solution at a dosing volume of 10 mL / kg mouse body weight, i.e., the dose of each drug conjugate was 3 mg / kg mouse body weight (calculated as siRNA). The PBS control group was given the same volume of PBS solution (without drug conjugate). Before administration (denoted as pre-dose, pre-drug value), the day of administration was recorded as day 0 (denoted as D0), and on the 7th day (denoted as D7), 14th day (denoted as D14), 21st day (denoted as D21), 28th day (denoted as D28), and 56th day (denoted as D56) after administration, sera were collected from all groups of mice, and AGT protein expression was determined using a human angiotensinogen kit (IBL, 27412).
[0608] The results of Example 14 showed that at a single dose of 3 mg / kg, RZ003021, RZ003065, and RZ003066 were all able to effectively reduce AGT protein levels in hREN×hAGT hypertensive mice, among which RZ003066 had better activity and duration of efficacy than RZ003021 and RZ003065 ( Figure 20 , Table 29 ).
[0609] Table 29
[0610] Example 15. Effect of siRNA conjugates on lipoprotein (A) (LPA) mRNA activity in vivo in a HDI mouse model
[0611] This example uses a BALB / c mouse hydrodynamic injection model to compare and evaluate the in vivo activity of LPA-targeted siRNAs using different modification schemes and GalNAc conjugated structures.
[0612] Plasmid construction:
[0613] Sangon Biotech (Shanghai) Co., Ltd. was commissioned to construct the LPA gene sequence (NM_005577.4) into the pcDNA-CMV vector plasmid to form the pcDNA-CMV-RG001 expression plasmid.
[0614] Mouse model construction:
[0615] The BALB / c mouse hydrodynamic injection model is established by rapidly injecting a pcDNA-CMV-RG001 plasmid solution through the tail vein at high pressure. On day 3 of the experiment, mice were injected with 10 μg of pcDNA-CMV-RG001 via the tail vein hydrodynamic injection over 5 seconds, at an injection volume of 8% of their body weight. The plasmid DNA for injection was diluted with physiological saline, prepared immediately prior to injection, and stored at 4°C.
[0616] Animal grouping, drug administration and tissue sample collection:
[0617] 6-8 week old BALB / c mice (all female) were randomly divided into groups according to body weight, with 5 mice in each group. Each test group was given a predetermined dose of drug conjugate and a PBS control group was added. All mice were dosed according to body weight, and a single dose was administered by subcutaneous injection in the abdomen. Each drug conjugate was administered in the form of a 0.1 mg / mL (calculated as siRNA) PBS solution, and the administration volume was 10 mL / kg mouse body weight. That is, the dosage of each drug conjugate was 1 mg / kg mouse body weight (calculated as siRNA). The PBS control group was given the same volume of PBS solution (not containing drug conjugate). The day of administration was recorded as day 0 (recorded as D0), and plasmid injection was performed on the 3rd day after administration (recorded as D3). On the 4th day (recorded as D4), 5 mice of all groups were killed. The mice were subjected to gross dissection and the liver tissue of each mouse was collected. The liver tissue was cut into about 2 mm 3 Small pieces were stored with RNA later.
[0618] For each mouse, an appropriate amount of liver tissue sample was taken from RNA later, and the liver tissue sample was broken in a Tissuelyser II type fully automatic tissue homogenizer for 60s. Then, a fully automatic nucleic acid extractor (purchased from Zhejiang Hanwei Technology Co., Ltd.) and a nucleic acid extraction kit (purchased from Zhejiang Hanwei Technology Co., Ltd., GO-MNTR-100) were used to extract total RNA according to the standard operating procedures for total RNA extraction. Reverse transcription reaction and fluorescence quantitative PCR were as described in Example 12. In this real-time fluorescence quantitative PCR method, the Nero gene on the plasmid backbone was used as an internal reference gene, and primers for the target gene and the Nero internal reference gene were used to detect the target gene and the Nero internal reference gene, respectively. The sequences of the detection primers are shown in Table 30.
[0619] Table 30
[0620] According to the instructions of the real-time fluorescence quantitative PCR kit, 10 μL of real-time PCR reaction system was prepared for each PCR detection well. Each reaction system contained 4 μL of the cDNA solution obtained by the reverse transcription reaction, 5 μL of TaqMan TM Fast Advanced Master Mix (2×), 0.15 μL 10 μM upstream primer, 0.15 μL 10 μM downstream primer (primer information see Table 11), 0.15 μL 10 μM probe primer, 0.55 μL RNase-Free H2O. The configured reaction system was placed on a real-time fluorescence quantitative PCR instrument (Bio-Rad, CFX Opus 384), and Real-time PCR amplification was performed using a two-step method. The amplification program was 50°C for 2 min, followed by pre-denaturation at 95°C for 20 s, denaturation at 95°C for 3 s, annealing and extension at 60°C for 30 s, and the denaturation, annealing and extension process was repeated for 40 cycles. In this real-time fluorescence quantitative PCR method, the expression level and inhibition rate of the target gene mRNA in each test group were relatively quantitatively calculated using the ΔΔCt method according to the technical method described in the embodiment.
[0621] The results of Example 15 showed that at a dose of 1 mg / kg, RZ001032 was more active than RZ001003, RZ001034 was more active than RZ001005, RZ001037 was more active than RZ001008, RZ001039 was more active than RZ001012, and RZ001044 was more active than RZ001026 ( Figure 21 , Table 31).
[0622] Table 31
[0623] Example 16 Evaluation of the inhibitory activity of siRNA conjugates on the target gene LPA in hApo(a) transgenic mice
[0624] hApo(a) transgenic mice were developed by Saiye (Suzhou) Biotechnology Co., Ltd. based on its unique The platform constructs conditional knock-in human Apo(a) transgenic mice. The construction process includes:
[0625] (1) Targeting vector design and construction: The human LPA gene was constructed into a vector to form a CAG promoter-loxP-PGK-Neo-6*SV40 pA-loxP-Kozak-Human LPA CDS-rBG pA targeting vector. This vector can insert the human LPA gene (NM_005577.4) into the intergenic region between the Eif4enif1 and Drg1 genes at the Hipp11 locus on mouse chromosome 11 in vivo. The targeting vector was verified by enzyme digestion, PCR, and sequencing. After the targeting vector was verified, plasmid extraction and linearization were performed.
[0626] (2) Electroporation of the targeting vector into embryonic stem cells and screening for positive clones: The targeting vector was electroporated into mouse embryonic stem (ES) cells, and positive selection was performed using Neo and negative selection was performed using DTA. Drug-resistant clones were selected, and ES cells were verified using PCR, karyotype analysis, and Southern blot.
[0627] (3) Mouse production: Positive ES cells are microinjected, and the injected blastocysts are transferred into pseudopregnant female mice. After birth, the mice are identified and tested to obtain TurboKnockout mice with reproductive succession.
[0628] (4) Obtaining hApo(a) transgenic mice: Liver-specific Cre-expressing mice were hybridized with TurboKnockout mice, the resistance gene in the middle of the loxP site was removed, and the expression of the human LPA gene was activated to obtain hApo(a) transgenic mice.
[0629] EXAMPLES In this example, enzyme-linked immunosorbent assay (ELISA) was used to determine the Apo(a) protein expression levels in the serum of hApo(a) transgenic mice at different time points after a single administration of siRNA conjugates RZ001032 and RZ001034.
[0630] Animal grouping, drug administration and tissue sample collection:
[0631] Apo (a) transgenic mice (commissioned to be constructed by Saiye (Suzhou) Biotechnology Co., Ltd.) were grouped according to the level of Apo (a) in serum. Each test group was given a predetermined dose of drug conjugate and a PBS control group was added. The drug dose of all mice was calculated according to body weight, and a single dose was administered by subcutaneous injection in the abdomen. Each drug conjugate was administered in the form of a 0.1 mg / mL (calculated as siRNA) PBS solution, and the administration volume was 10 mL / kg mouse body weight, that is, the dosage of each drug conjugate was 1 mg / kg mouse body weight (calculated as siRNA). The PBS control group was given the same volume of PB11), and serum from all groups of mice was collected on the 28th day (denoted as D28), the 35th day (denoted as D35), the 42nd day (denoted as D42), the 49th day (denoted as D49), and the 56th day (denoted as D56), and Apo (a) protein expression was determined using a human Lipoprotein A ELISA kit (Abcam, ab212165).
[0632] The results of Example 16 showed that both RZ001032 and RZ001034 could significantly reduce the Apo(a) protein level in Apo(a) transgenic mice at a single dose of 1 mg / kg ( FIG. 22 , Table 32 ).
[0633] Table 32
[0634] Example 17. Inhibitory activity of siRNA conjugates modified with NM062 and NM063 at different sites of the antisense strand against SOD1 mRNA in mice
[0635] This example uses the in vivo mouse evaluation method described in Example 7 to evaluate the inhibitory activity of siRNA conjugates modified with NM062 and NM063 at different sites on the antisense strand, and reference conjugates RZ599001 and RZ599015 without NM062 and NM063 modifications, against the target gene SOD1 in mice.
[0636] 6-8 week old C57BL / 6j mice were randomly divided into 6 groups according to body weight, with 15 mice in each group. Each group of mice was given the above siRNA conjugate by subcutaneous administration in the abdomen. The dose of each mouse in the PBS control group was 5 mL / kg, and the dose of each mouse in the siRNA conjugate experimental group was 3 mg / kg (calculated as siRNA) in a volume of 5 mL / kg. The day of administration was recorded as day 0 (D0). After administration, 5 mice in each group were killed on the 7th day (D7), the 28th day (D28), and the 56th day (D56). The animals were grossly dissected, and the liver tissue was collected and cut into several 2 mm 3Small pieces were stored in RNAlater. RNA extraction, reverse transcription, and quantitative PCR were performed as described above. Gene expression differences were calculated using the ΔΔCt method. Primers are shown in Table 33.
[0637] Table 33
[0638] The expression levels of SOD1 mRNA in mice (Figure 23) and residual activity (Table 34) were statistically analyzed on D7, D28, and D56 after administration. The results showed that modification with NM062 and NM063 at specific sites in the siRNA antisense strand was well tolerated, and modification with NM062 and NM063 at positions 8 and 15 of the antisense strand could further enhance the activity of the siRNA sequence.
[0639] Table 34
[0640] Example 18. Inhibitory activity of antisense strand NM096, NM098 and NM099 modified siRNA conjugates on SOD1 mRNA in mouse primary liver cells
[0641] The above experimental method for evaluating the inhibitory activity of target genes in primary mouse liver cells was used to evaluate the inhibitory activity of siRNA conjugates RZ599136, RZ599138, RZ599139 and RZ599062 modified with NM096 at position 15 of the antisense chain, and the control RZ599062 against the target gene SOD1 in primary mouse liver cells.
[0642] The isolation and cell culture procedures of primary mouse hepatocytes were as described above. Primary mouse hepatocytes were obtained from fresh liver tissue of C56BL / 6j mice, with a cell count of 2×10 5 The cells / well were inoculated in a 12-well culture plate, and each group of double-stranded siRNA conjugates was gradiently diluted with PBS to a working solution of 10 μM (in terms of siRNA). 1 μL / well of the siRNA conjugate working solution of each concentration was added to the above-mentioned 12-well culture plate, which was equivalent to a final transfection concentration of 10 nM (in terms of siRNA) for the siRNA conjugate. Two culture wells were set up for each concentration of siRNA. 1 μL / well of PBS was added to the other two culture wells as blank control wells (BLANK). Shake the culture plate to mix evenly. Continue to culture in a 37°C, 5% CO2 cell culture incubator for 24 hours. The relative quantification of the target gene mRNA in each test group was performed according to the aforementioned ΔΔCt method. The primers used in this example are shown in Table 33. The relative quantification of the target gene mRNA in each test group was performed according to the aforementioned ΔΔCt method.
[0643] The results of Example 18 showed that the antisense strand 15-position modified siRNA conjugates NM096, NM098, and NM099 had comparable inhibitory activity compared to the control RZ599062 on mouse primary liver cells ( FIG. 24 , Table 35 ).
[0644] Table 35
[0645] Example 19. Evaluation of the inhibitory activity of the 2'-position double F-substituted siRNA conjugate on the target gene SOD1 in mouse primary liver cells
[0646] Example 19 used the aforementioned experimental method for evaluating target gene inhibitory activity in primary mouse liver cells to evaluate the inhibitory activity of the siRNA conjugate RZ599051, with a double F modification at the 2' position of the 8th nucleotide of the sense strand, and the reference siRNA conjugate RZ599001, with F modification at the 8th position, against the target gene SOD1 in primary mouse hepatocytes. The isolation and cell culture procedures for primary mouse hepatocytes were as described above. Primary mouse hepatocytes were extracted from fresh liver tissue of C56BL / 6j mice and cultured at a cell count of 2×10 5 Cells / well were seeded in a 12-well culture plate, and each group of double-stranded siRNA conjugates was gradiently diluted with PBS to a working solution of 5 μM (in terms of siRNA). 1 μL / well of the siRNA conjugate working solution of each concentration was added to the above-mentioned 12-well culture plate, which was equivalent to a final transfection concentration of 5 nM (in terms of siRNA) for the siRNA conjugate. Two culture wells were set up for each concentration of siRNA. 1 μL / well of PBS was added to the other two culture wells as blank control wells (BLANK). Shake the culture plate to mix evenly. Continue to culture in a 37°C, 5% CO2 cell culture incubator for 24 hours. The relative quantification of the target gene mRNA in each test group was calculated according to the aforementioned ΔΔCt method. The primers used in this example are shown in Table 34.
[0647] The results of Example 19 show that the siRNA conjugate RZ599051 with a double F modification at the 2' position of the 8th nucleotide of the sense strand has comparable inhibitory activity to the reference conjugate RZ599001. (Figure 25, Table 36)
[0648] Table 36
[0649] Example 20. Evaluation of the inhibitory activity of the siRNA conjugate with double F substitution at the 2' position of the sense strand against the target gene SOD1 in mouse primary liver cells
[0650] In Example 20, using the aforementioned experimental method for evaluating target gene inhibitory activity in primary mouse liver cells, the inhibitory activity of siRNA conjugates RZ599055 (with a double F modification at the 2' position of nucleotide 8 on the sense strand), siRNA conjugate RZ599056 (with a double F modification at the 2' position of nucleotide 9 on the sense strand), and reference conjugate RZ599001 against the target gene SOD1 was evaluated in primary mouse hepatocytes. RZ599055 differs from RZ599051 in Example 19 in that the nucleotide modifications at positions 10 on the sense strand and 12 on the antisense strand are replaced by F modifications instead of methoxy.
[0651] Mouse primary hepatocytes were cultured at a cell count of 2×10 5 Cells were seeded / well in a 12-well culture plate. Each set of double-stranded siRNA conjugates was diluted with PBS to a 5 μM working solution (based on siRNA). 1 μL / well of each siRNA conjugate working solution was added to each 12-well plate, equivalent to a final transfection concentration of 5 nM (based on siRNA). Two wells were set up for each siRNA concentration. 1 μL / well of PBS was added to two additional wells as blank controls. The primers for this example are shown in Table 34.
[0652] The results of Example 20 showed that the siRNA conjugates RZ599055, which had a double F modification at the 2' position of nucleotide 8 of the sense strand, and RZ599056, which had a double F modification at the 2' position of nucleotide 9 of the sense strand, had inhibitory activity comparable to or superior to that of the reference conjugate RZ599001 ( Figure 26 , Table 37 ).
[0653] Table 37
[0654] Example 21. Evaluation of the inhibitory activity of the siRNA conjugate with double F substitution at the 2' position of the sense strand against the target gene ANGPTL3 in primary mouse liver cells
[0655] Example 21 used the aforementioned experimental method for evaluating target gene inhibitory activity in primary mouse liver cells to evaluate the inhibitory activity of siRNA conjugate RZ597101, which has a double F modification at the 2' position of nucleotide 8 on the sense strand, and reference conjugate RZ597002 against the target gene ANGPTL3 in primary mouse hepatocytes. RZ597101 differs from reference conjugate RZ597002 in that the nucleotide modifications at positions 10 and 12 of the sense strand are replaced by F modifications instead of methoxy, and the nucleotide modification at position 15 of the antisense strand is replaced by a moe modification instead of a methoxy modification at the 2' position.
[0656] Mouse primary hepatocytes were cultured at a cell count of 2×10 5Cells were seeded / well in a 12-well culture plate. Each set of double-stranded siRNA conjugates was diluted in PBS to a 10 μM working solution (based on siRNA). 1 μL / well of each siRNA conjugate working solution was added to each 12-well plate, equivalent to a final transfection concentration of 10 nM (based on siRNA). Two wells were set up for each siRNA concentration. 1 μL / well of PBS was added to two additional wells as blank controls. The primers for this example are shown in Table 9.
[0657] The results of Example 21 show that the siRNA conjugate RZ597101 has superior inhibitory activity to the reference conjugate RZ597002. (Figure 27, Table 38)
[0658] Table 38
[0659] Example 22. Evaluation of the inhibitory activity of the siRNA conjugate with double F substitution at the 2' position of the sense strand against the target gene complement factor B (CFB) in primary mouse liver cells
[0660] Example 22 used the aforementioned experimental method for evaluating target gene inhibitory activity in primary mouse liver cells to evaluate the inhibitory activity of siRNA conjugates RZM11508, RZM11509, and RZM11510 against the target gene CFB in primary mouse hepatocytes. The differences between the conjugates RZM11015 and the reference conjugate RZM11015 were that the nucleotide modifications at positions 10 of the sense strand and 12 of the antisense strand in RZM11508 were replaced with F-modifications instead of methoxy. RZM11509, based on the modification pattern of RZM11508, replaced the 2'-position methoxy with moe modification at position 15 of the antisense strand. RZM11510 differed from RZM11509 in that the nucleotide at position 7 of the sense strand was replaced with a double F-modified nucleotide at the 2'-position.
[0661] Mouse primary hepatocytes were cultured at a cell count of 2×10 5 Cells were seeded / well in a 12-well plate. Each set of double-stranded siRNA conjugates was serially diluted with PBS to a 10 μM working solution (based on siRNA). 1 μL / well of each siRNA conjugate working solution was added to the 12-well plate, equivalent to a final transfection concentration of 10 nM (based on siRNA). Two wells were set up for each siRNA concentration. 1 μL / well of PBS was added to two additional wells as blank controls.
[0662] Table 39
[0663] The results of Example 22 showed that the siRNA conjugates RZM11508, RZM11509, and RZM11510 had superior inhibitory activity compared to the reference conjugate RZ011015. ( Figure 28 , Table 40)
[0664] Table 40
[0665] Example 23. Evaluation of the inhibitory activity of the siRNA conjugate with double F substitution at the 2' position of the sense strand against the target gene CFB in mice
[0666] This example uses a target gene inhibitory activity assessment method in mice to evaluate the inhibitory activity of siRNA conjugates RZM11509 and RZM11510 and a reference conjugate RZM11015 on the target gene CFB in mice.
[0667] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, with 10 mice in each group. Each group of mice was given the above-mentioned siRNA conjugate by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA) in a volume of 5 ml / kg. The day of administration was recorded as D0, and 5 mice in each group were killed on the 7th day (D7) and the 28th day (D28) after administration. The animals were grossly dissected, and the liver tissue was collected and cut into several 2 mm 3 Small pieces were stored in RNAlater. RNA extraction, reverse transcription, and real-time PCR were performed as described above. Relative quantification of target gene mRNA in each test group was performed using the ΔΔCt method described above. Primers are listed in Table 39.
[0668] The results of Example 23 show that the siRNA conjugates RZM11509 and RZM11510 showed comparable inhibitory activity against the target gene at D7 compared to the reference conjugate RZM11015; however, D28 showed superior inhibitory activity compared to the reference conjugate ( Figure 29 , Table 41 ).
[0669] Table 41
[0670] Example 24. Evaluation of the inhibitory activity of the antisense strand specific site 2' double F substituted siRNA conjugate against the target gene ANGPTL3 in mouse primary liver cells
[0671] Example 24 The above-mentioned mouse liver primary cell inhibitory activity evaluation experimental method was used to evaluate the inhibitory activity of the siRNA conjugate RZ597060 with double F modification at the 2' position of the antisense strand 6 nucleotide and the reference conjugate RZ597002 against the target gene ANGPTL3 in mouse primary hepatocytes. Mouse primary hepatocytes were cultured at a cell count of 2×10 5 Cells were seeded / well in a 12-well culture plate. Each set of double-stranded siRNA conjugates was gradiently diluted with PBS to a 10 μM working solution (based on siRNA). 1 μL / well of each siRNA conjugate working solution was added to the 12-well plate, equivalent to a final transfection concentration of 10 nM (based on siRNA). Two wells were set up for each siRNA concentration. 1 μL / well of PBS was added to two additional wells as blank controls. RNA extraction, reverse transcription, and real-time PCR were performed as described above. Relative quantification of target gene mRNA in each test group was performed using the ΔΔCt method described above. Primers are shown in Table 9.
[0672] The results of Example 24 showed that the siRNA conjugate RZ597060, which has a double F modification at the 2' position of the 6th nucleotide of the antisense strand, has comparable inhibitory activity to the reference conjugate RZ597002. (Figure 30, Table 42)
[0673] Table 42
[0674] Example 25. Evaluation of the inhibitory activity of the antisense strand specific site 2' double F substituted siRNA conjugate on the target gene CFB in mouse primary liver cells
[0675] Example 25 The above-mentioned mouse liver primary cell target gene inhibitory activity evaluation experimental method was used to evaluate the inhibitory activity of the siRNA conjugates RZM11504 with a double F modification at the 2' position of the antisense strand 14 nucleotide, RZM11505 with a double F modification at the 2' position of the antisense strand 16 nucleotide, and the reference conjugate RZM11001 against the target gene CFB in mouse primary hepatocytes. Mouse primary hepatocytes were cultured at a cell count of 2×10 5Cells were seeded / well in a 12-well culture plate, and each set of double-stranded siRNA conjugates was gradiently diluted with PBS to a 10 μM working solution (based on siRNA). 1 μL / well of each siRNA conjugate working solution was added to the 12-well culture plate, equivalent to a final transfection concentration of 10 nM (based on siRNA). Two culture wells were set up for each siRNA concentration. 1 μL / well of PBS was added to two additional culture wells as blank controls. RNA extraction, reverse transcription, and real-time PCR detection were performed as described above, and relative quantification of target gene mRNA in each test group was calculated using the aforementioned ΔΔCt method. Primers are shown in Table 39.
[0676] The results of Example 25 showed that the siRNA conjugates RZM11504, which has a double F modification at the 2' position of nucleotide 14 of the antisense strand, and RZM11505, which has a double F modification at the 2' position of nucleotide 16 of the antisense strand, had superior inhibitory activity compared to the reference conjugate RZM11001 ( Figure 31 , Table 43 ).
[0677] Table 43
[0678] Example 26. Evaluation of the inhibitory activity of the antisense strand specific site 2' double F substituted siRNA conjugate on the target gene CFB in mouse primary liver cells
[0679] Example 26 employed the aforementioned experimental method for evaluating target gene inhibitory activity in primary mouse liver cells to evaluate the inhibitory activity of the siRNA conjugate RZM11507, which has a double F modification at the 2' position of nucleotide 14 of the antisense strand, and the reference conjugate RZM11502 against the target gene CFB in primary mouse hepatocytes. The difference from Example 25 was that the 2'-position methoxy modification at nucleotide 15 of the antisense strand was replaced by a moe modification.
[0680] Mouse primary hepatocytes were cultured at a cell count of 2×10 5 Cells were seeded / well in a 12-well culture plate, and each set of double-stranded siRNA conjugates was gradiently diluted with PBS to a 10 μM working solution (based on siRNA). 1 μL / well of each siRNA conjugate working solution was added to the 12-well culture plate, equivalent to a final transfection concentration of 10 nM (based on siRNA). Two culture wells were set up for each siRNA concentration. 1 μL / well of PBS was added to two additional culture wells as blank controls. RNA extraction, reverse transcription, and real-time PCR detection were performed as described above, and relative quantification of target gene mRNA in each test group was calculated using the aforementioned ΔΔCt method. Primers are shown in Table 39.
[0681] The results of Example 26 show that the siRNA conjugate RZM11507, which has a double F modification at the 2' position of nucleotide 14 of the antisense strand, has superior inhibitory activity compared to the reference conjugate RZM11502. ( Figure 32 , Table 44)
[0682] Table 44
[0683] Example 27. Evaluation of the inhibitory activity of the antisense strand specific site 2' double F substituted siRNA conjugate on the target gene CFB in mice
[0684] This example used an in vivo mouse target gene inhibition activity assessment method to evaluate the inhibitory activity of siRNA conjugates RZM11502 and RZM11507 against the target gene CFB in mice. The differences between RZM11502 and the reference conjugate RZM11001 are that the nucleotide modifications at positions 10 of the sense strand and 12 of the antisense strand of RZM11502 are replaced by F-modifications instead of methoxy, and the nucleotide modification at position 15 of the antisense strand is replaced by a moe modification instead of a 2'-position methoxy. RZM11507 differs from RZM11502 in that the nucleotide at position 14 of the antisense strand has a double F-modification at the 2' position.
[0685] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, with 15 mice in each group. Each group of mice was given the above siRNA conjugate by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA) in a volume of 5 ml / kg. The day of administration was recorded as D0, and 5 mice in each group were sacrificed on D7, D28, and D56 after administration. The animals were grossly dissected, and liver tissue was collected and cut into several 2 mm 3 Small pieces were stored in RNAlater. RNA extraction, reverse transcription, and real-time PCR were performed as described above. Relative quantification of target gene mRNA in each test group was performed using the ΔΔCt method described above. Primers are listed in Table 39.
[0686] The results of Example 27 demonstrate that the inhibitory activity of the siRNA conjugate RZM11502 was superior to that of the reference conjugate RZM11001 at D7 and D28. The siRNA conjugate RZM11507 exhibited higher inhibitory efficacy and a longer duration of action than the reference conjugate RZM11001 at D7, D28, and D56 ( Figure 33 , Table 45 ).
[0687] Table 45
[0688] Example 28. Evaluation of the inhibitory activity of the antisense strand specific site 2' double F substituted siRNA conjugate against the target gene complement component C4B (C4B) in mice
[0689] This example uses a method for evaluating target gene inhibition activity in mice to evaluate the inhibitory activity of the siRNA conjugate RZM12503 with double F modification at the 2' position of the 9th position of the antisense chain of the C4B target site and the reference conjugate RZM12501 on the target gene C4B in mice. 6-8 week old C57BL / 6j mice were randomly divided into 3 groups according to body weight, with 10 mice in each group. Each group of mice was administered the above-mentioned siRNA conjugate subcutaneously in the abdomen, wherein each mouse in the PBS control group was administered a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was administered a dose of 3 mg / kg (in terms of siRNA) with a dose volume of 5 ml / kg. The day of administration was recorded as D0, and 5 mice in each group were killed on D7 and D28 after administration, and the animals were grossly dissected, liver tissue was collected, and cut into several 2 mm 3 The small pieces were preserved in RNAlater. RNA extraction, reverse transcription reaction, and real-time PCR detection methods were as described above, and the relative quantification of target gene mRNA in each test group was calculated according to the aforementioned ΔΔCt method.
[0690] Table 46
[0691] The results of Example 28 show that the siRNA conjugate RZM12503, with a double F modification at the 2' position of the antisense strand 9, has comparable inhibitory efficacy and duration of action as the reference conjugate RZM12501 ( Figure 34 , Table 47 ).
[0692] Table 47
[0693] Example 29. Evaluation of the inhibitory activity of siRNA conjugates containing the NM054 group on the target gene SOD1 in mice
[0694] In this example, the in vivo target gene inhibitory activity assessment method for mice was used to evaluate the inhibitory activity of conjugates RZ599060 containing the NM054 group at position 20, conjugate RZ599061 containing NM054 at positions 20 and 21, and conjugate RZ599001 without this group on the SOD1 target siRNA antisense strand against the target gene SOD1 in mice.
[0695] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, with 15 mice in each group. Each group of mice was given the above siRNA conjugate by subcutaneous administration in the abdomen. The dose of each mouse in the PBS control group was 5 mL / kg, and the dose of each mouse in the siRNA conjugate experimental group was 3 mg / kg (calculated as siRNA) in a volume of 5 mL / kg. The day of administration was recorded as day 0 (D0). After administration, 5 mice in each group were killed on the 7th day (D7), the 28th day (D28), and the 49th day (D49). The animals were dissected, and the liver tissue was collected and cut into several 2 mm 3 Small pieces were stored in RNAlater. RNA extraction, reverse transcription, and quantitative PCR were performed as described above. Gene expression differences were calculated using the ΔΔCt method. Primers are shown in Table 34.
[0696] The results of Example 29 showed that compared to the control conjugate RZ599001, which did not contain the NM054 group, the conjugates RZ599060 and RZ599061, which contained the NM054 group, exhibited significantly higher inhibitory activity at D7, D28, and D49. At D49, the inhibitory activity of both RZ599060 and RZ599061 was approximately 15% higher than that of the control conjugate RZ599001 ( Figure 35 , Table 48 ).
[0697] Table 48
[0698] Example 30. Evaluation of the inhibitory activity of siRNA conjugates containing the NM054 group on the target gene ANGPTL3 in mice
[0699] In this example, the in vivo target gene inhibitory activity assessment method for mice was used to evaluate the inhibitory activity of conjugates RZ597115 containing the NM054 group at position 20 and conjugate RZ597116 containing NM054 at positions 20 and 21 on the ANGPTL3 target siRNA antisense strand, as well as the conjugate RZ597114 without this group, against the target gene ANGPTL3 in mice.
[0700] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups of 15 mice each according to body weight. Each group of mice was administered the above siRNA conjugate subcutaneously in the abdomen. The PBS control group received a dose of 5 mL / kg per mouse, and the siRNA conjugate experimental group received a dose of 3 mg / kg (as siRNA) per mouse in a 5 mL / kg dose. The day of administration was designated as D0. Five mice in each group were sacrificed on D7, D28, and D56 after administration. The animals were dissected, and liver tissue was collected and cut into several 2 mm 3Small pieces were stored in RNAlater. RNA extraction, reverse transcription, and real-time PCR were performed as described above. Gene expression differences were calculated using the ΔΔCt method. Primers are shown in Table 9.
[0701] The results of Example 30 show that conjugates RZ597115 and RZ597116 containing the NM054 group exhibited higher inhibitory activity at D7, D28, and D56 compared to the control conjugate RZ597114, which did not contain the NM054 group. At D56, the inhibitory activity of conjugate RZ597115, which contained the NM054 group at position 20 of the antisense strand, was approximately 25% higher than that of the control conjugate RZ597114; and the inhibitory activity of conjugate RZ597116, which contained NM054 at positions 20 and 21 of the antisense strand, was approximately 35% higher than that of the control conjugate RZ597114. ( Figure 36 , Table 49 )
[0702] Table 49
[0703] Example 31. Evaluation of the effect of siRNA conjugates on reducing C3 protein in cynomolgus monkeys
[0704] In this example, the ELISA method was used to determine the expression of C3 protein in the serum of cynomolgus monkeys at different time points after a single administration of (CR01008)×3 carrier conjugates RZ002099, RZ002101, RZ002106 and RZ002113.
[0705] Animal grouping, drug administration and tissue sample collection:
[0706] Healthy cynomolgus monkeys weighing 3-5 kg were divided into groups based on serum C3 protein levels, with 4 animals per group, half male and half female. Each test group was given a predetermined dose of the drug conjugate and a PBS control group was added. All animals were dosed according to body weight and administered a single subcutaneous injection in the abdomen. Each drug conjugate was administered as a 9 mg / mL PBS solution at a dosing volume of 1 mL / kg (cynomolgus monkey body weight), i.e., the dose of each drug conjugate was 9 mg (calculated as siRNA) / kg (cynomolgus monkey body weight). The PBS control group was given 1 mL / kg (mouse body weight) of PBS solution without siRNA conjugate. Serum was collected from cynomolgus monkeys before administration (recorded as pre-dose value, pre-dose), on the day of administration as day 0 (recorded as D0), on the 7th day (recorded as D7), the 14th day (recorded as D14), the 21st day (recorded as D21), the 28th day (recorded as D28), the 35th day (recorded as D35), the 42nd day (recorded as D42), the 49th day (recorded as D49), and the 56th day (recorded as D56) after administration, and C3 protein expression was determined using a human complement C3 ELISA kit (Hycult Biotech, HK366-01).
[0707] The results of Example 31 showed that at a single dose of 9 mg / kg, RZ002099, RZ002101, RZ002106, and RZ002113 all significantly reduced C3 protein levels in cynomolgus monkey serum, with RZ002106 achieving a C3 protein reduction effect of over 90% ( FIG. 37 , Table 50 ).
[0708] Table 50
[0709] Example 32. Evaluation of the AGT-lowering Effect of siRNA Conjugates in Cynomolgus Monkeys
[0710] In this example, the ELISA method was used to determine the expression of AGT protein in the serum of cynomolgus monkeys at different time points after a single administration of the (CR01008)×3 vector conjugate RZ003069.
[0711] Animal grouping, drug administration and tissue sample collection:
[0712] Healthy cynomolgus monkeys weighing 3-5 kg were grouped according to serum AGT protein levels, with 4 animals per group, half male and half female. Each test group was given a predetermined dose of drug conjugate and a PBS control group was added. All animals were dosed according to body weight and administered as a single dose using subcutaneous injection in the abdomen. Each drug conjugate was administered in the form of a 3 mg / mL PBS solution, and the administration volume was 1 mL / kg (cynomolgus monkey body weight), i.e., the dosage of each drug conjugate was 3 mg / kg (cynomolgus monkey body weight). The PBS control group was given 1 mL / kg of PBS solution without siRNA conjugate. Cynomolgus monkey serum was collected on the day of administration, recorded as day 0 (recorded as D0), and on the 7th day after administration (recorded as D7), the 14th day (recorded as D14), and the 21st day (recorded as D21), and AGT protein expression was determined using a human angiotensinogen ELISA detection kit (Immuno-Biological, 27412).
[0713] The results of Example 32 showed that RZ003069 could significantly reduce the AGT protein level in the serum of cynomolgus monkeys at a single dose of 3 mg / kg ( FIG. 38 , Table 51 ).
[0714] Table 51
[0715] After repeated research and experiments, the inventors discovered that specific modifications at single or multiple sites on the sense and / or antisense strands of oligonucleotides can make the modified oligonucleotides well-tolerated and even further enhance the activity of the oligonucleotide molecules, which has great application prospects in the development of RNA interference (RNAi) drugs.
[0716] (1) This disclosure shows that the effect of TBDMS modification on the activity of siRNA sequences is related to the modification site. Modification of a specific site with a large TBDMS group does not affect the activity of the siRNA and may even further enhance the activity.
[0717] (2) The experimental results disclosed in this paper verify that the effect of MOE modification on the activity of siRNA sequences is related to the modification site. MOE group modification at a specific site does not affect siRNA activity, and its effect pattern is highly similar to that of TBDMS modification and TOM modification.
[0718] Taking a 19-nucleotide (nt) double-stranded oligonucleotide as an example, compared to a reference sequence without MOE modification, MOE modification at one or more positions 5, 12, 18, or 19 of the sense strand helped improve the in vitro activity of the siRNA sequence. Compared to a reference sequence without MOE modification, MOE modification at one or more positions 8, 10, or 15 of the antisense strand helped improve the in vitro activity of the siRNA sequence.
[0719] (3) The present disclosure shows that the effect of MOE modification on the activity of siRNA sequences is related to the modification site. Single or multiple MOE modifications at specific sites on the sense and / or antisense strands can be well tolerated and can still well maintain or even further enhance the activity of the siRNA sequence.
[0720] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", "some implementation plans" or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present disclosure. In this specification, the schematic expressions of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.
[0721] Although the embodiments of the present disclosure have been shown and described above, it is understood that the above embodiments are illustrative and are not to be construed as limitations on the present disclosure. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present disclosure. Industrial Applicability
[0722] The present disclosure provides a modified double-stranded oligonucleotide and oligonucleotide conjugate. The double-stranded oligonucleotide and / or oligonucleotide conjugate disclosed herein has good tolerance for specific modification of single or multiple sites on the sense chain and / or antisense chain, can well maintain the pharmaceutical activity of the oligonucleotide, and has high target gene expression regulation activity.
Claims
1. A double-stranded oligonucleotide, characterized in that Comprising a sense strand and an antisense strand, each strand having 17 to 35 nucleotides, wherein each nucleotide is a modified or unmodified nucleotide; the sense strand and the antisense strand are at least partially reverse-complemented to form a double-stranded region, and the double-stranded region comprises a nucleotide modified with a large steric volume and / or a nucleotide modified with a disubstituted group; Wherein, the double-stranded region is shown in the following formula (I): SS:5'-(N)a'-(X)p'-(N)b'-(X)q'-(N)c'-(X)r'-(N)d'-3' AS:3'-(N)a-(X)p-(N)b-(X)q-(N)c-5'(I), Among them, SS represents the sense strand and AS represents the antisense strand; Each of the Xs independently represents a nucleotide in which the 2'-hydroxyl group in the ribose is substituted by a bulky group, or a nucleotide in which the 2'-hydroxyl group is substituted by a disubstituted group; The nucleotides in which the 2'-hydroxyl group in the ribose is replaced by a large steric bulky group are independently selected from the following 2'-modified nucleotides: 2'-(O) m1 (CH2) n (O) m2 R1; wherein m1 or m2 are each independently 0 or 1, and n is an integer selected from 0 to 6; wherein R1 is selected from substituted or unsubstituted C1-C6 alkyl or -Si(R2)3; wherein R2 is independently selected from substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy; wherein the substitution comprises one or more selected from the following substituents: halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, amino, cycloalkyl with no more than 6 carbon atoms, aryl with no more than 12 carbon atoms, or heteroaryl with no more than 12 carbon atoms; wherein each substituent in the disubstituent is independently selected from C1-C6 alkyl or halogen; Each of the Ns independently represents a modified or unmodified nucleotide; wherein when N represents a modified nucleotide, the 2' position of its ribose is modified and is not X, and each of the Ns independently represents one or more of the following modifications: 2'-O-alkyl, 2'-alkyl, 2'-substituted alkyl, 2'-halo, 2'-deoxy, or quasi-nucleotide, wherein the number of carbon atoms of the alkyl is 1-6; the quasi-nucleotide is selected from one or more of ENA, BNA, LNA, GNA or UNA; Said a, a', p, p', b, b', q, q', c, c', r', d' each independently represents the number of nucleotides, wherein: a' is selected from an integer of 3-8; p' is selected from an integer of 0-3; b' is selected from an integer of 4-13; q' is selected from an integer of 0-4; c' is selected from an integer of 3-9; r' is selected from an integer of 0-3; d' is selected from an integer of 0-9; a is selected from an integer of 4-7; p is selected from an integer of 0-1; b is selected from an integer of 4-8; q is selected from an integer of 0-4; c is selected from an integer of 6-10; Furthermore, p', q', r', p, and q are not all 0 at the same time, and 0≤q'+r'≤4.
2. The double-stranded oligonucleotide according to claim 1, characterized in that The X's are each independently selected from the following modified nucleotides: 2'-O(CH2) n OR1 or 2'-R3-2'-R4; wherein n is 1 or 2, and R1 is selected from substituted or unsubstituted C1-C6 alkyl, or -Si(R2)3; Wherein, R3 and R4 are each independently selected from C1-C6 alkyl or halogen.
3. The double-stranded oligonucleotide according to claim 1 or 2, characterized in that Each N is independently selected from: a 2'-OMe modified, a 2'-F modified, a 2'-H modified nucleotide, or an unmodified nucleotide; Optionally, each X is independently selected from the following modified nucleotides: 2'-O-methoxyethyl, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-R5; Wherein, R5 is an unsubstituted or substituent-substituted C1-C3 alkyl group; optionally, the substituent group is independently selected from one or more of the following substituent groups: halogen, C1-C3 alkyl, C1-C3 alkoxy, amino; Optionally, the halogen is fluorine.
4. The double-stranded oligonucleotide according to any one of claims 1 to 3, characterized in that In the direction from the 5' end to the 3' end, at least one of the 8th, 9th, 10th or 15th nucleotides of the antisense strand in the formula (I) is a modified nucleotide X, and / or the sense strand has or does not have a modified nucleotide X; Optionally, when a modified nucleotide X is present in the sense strand, at least one nucleotide X is located at a relative position corresponding to any of positions 2, 8 or 15 of the antisense strand; Optionally, the modified nucleotide X is located at least one of the 10th or 15th nucleotides of the antisense strand; Optionally, each X is independently selected from the following modified nucleotides: 2'-O-methoxyethyl, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2-CH3, 2'-O-CH2-O-CH2-CF3.
5. The double-stranded oligonucleotide according to any one of claims 1 to 4, characterized in that: q'+c'+r'+d'=9, and 0≤q'+r'≤4; Optionally, when p=0, a=5-7; Optionally, when p=1, X is located at position 15 of the antisense strand in the direction from the 5' end to the 3' end; Optionally, when q=0, b+c=14; Optionally, in the 5' to 3' end direction, at least one X in (X)p' is located at a position on the sense strand opposite to position 15 on the antisense strand; Optionally, when p'=1, X in (X)p' is located at a position opposite to position 15 of the antisense strand in the 5' to 3' end direction; Optionally, in the direction from the 5' end to the 3' end, the first 4 nucleotides of (N)b' on the sense strand contain at least 2 fluorinated modified nucleotides; Optionally, q' is 0-2; Optionally, q' is 0 or 1; Optionally, when r'=1 and q'=1, b' and c' are 5, and d' is 1; Optionally, when p'=0, a'=6; Optionally, when p'=0, a'=8; Optionally, when q' and r' are not both 0, at least one X on the sense strand is located at a position para to positions 1-8 relative to the antisense strand in the direction from the 5' end to the 3' end; Optionally, d'=1-9.
6. The double-stranded oligonucleotide according to any one of claims 1 to 5, characterized in that: a' is selected from an integer of 3-8; p' is selected from an integer of 0-2; b' is selected from an integer of 4-12; q' is selected from an integer of 0-2; c' is selected from an integer of 3-8; r' is selected from an integer of 0-2; d' is selected from an integer of 1-9; a is selected from an integer of 4-7; p is selected from 0 or 1; b is selected from an integer of 4-8; q is selected from an integer of 0-2; c is selected from an integer of 6-10; Optionally, there is at least one fluorinated modified nucleotide in each of (N)a and (N)b, and there are at least two fluorinated modified nucleotides in (N)c; Optionally, q'+c'+r'+d'=9 and 0≤q'+r'≤4; Optionally, starting from the 5'-end, the first 4 nucleotides of (N)b' contain at least 2 fluorinated modified nucleotides.
7. The double-stranded oligonucleotide according to any one of claims 1 to 6, characterized in that: a' is selected from an integer of 3-8; p' is selected from 0 or 1; b' is selected from an integer of 4-13; q' is selected from 0 or 1; c' is selected from an integer of 3-9; r' is selected from 0 or 1; d' is selected from an integer of 1-8; a is selected from an integer of 4-7; p is selected from 1; b is selected from an integer of 4-8; q is selected from 0 or 1; c is selected from an integer of 6-10; Optionally, there is at least one fluorinated modified nucleotide in (N)a, and: starting from the 5'-end, the 16th position of the antisense strand is a fluorinated modified nucleotide; Optionally, there is at least one fluorinated modified nucleotide in (N)b, and: starting from the 5'-end, the 14th position of the antisense strand is a fluorinated modified nucleotide; Optionally, there are at least two fluorinated modified nucleotides in (N)c, and: starting from the 5'-end, positions 2 and 6 of the antisense strand are both fluorinated modified nucleotides; Optionally, q'+c'+r'+d'=9, 0≤q'+r'≤2; Optionally, there is at least one X on the sense strand located in the para position relative to the antisense strand seed region, the antisense strand seed region being positions 1-8, starting from the 5'-end; Optionally, starting from the 5'-end, the first 4 nucleotides of (N)b' are located at positions opposite to positions 10-13 of the antisense strand, and at least 2 of the first 4 nucleotides are fluorinated modified nucleotides.
8. The double-stranded oligonucleotide according to any one of claims 1 to 7, characterized in that: Starting from the 5'-end, X in formula (I) is located at any position between 8 and 10 or 15 of the antisense strand; Optionally, X in the sense strand is located opposite to any of positions 2, 8 or 15 of the antisense strand; Optionally, starting from the 5'-end, X is located at the 15th position of the antisense strand, and: there is at least one fluorinated modification at the 9th or 12th position of the antisense strand, and / or the sense strand position opposite to the 10th position of the antisense strand is fluorinated.
9. The double-stranded oligonucleotide according to any one of claims 1 to 8, characterized in that: In addition to the double-stranded region, the double-stranded oligonucleotide further comprises one or more overhang regions; the overhang region has a length of 1-6 nucleotides.
10. The double-stranded oligonucleotide according to claim 9, characterized in that: The double-stranded oligonucleotide comprising the overhang region is represented by the following formula (II): SS:5'-(T)t1-(N)a'-(X)p'-(N)b'-(X)q'-(N)c'-(X)r'-(N)d'-(T)t2-3' AS:3'-(T)t1-(N)a-(X)p-(N)b-(X)q-(N)c-(T)t2-5'(II), Wherein, T represents the nucleotide at the protruding end; t1 and t2 are independently selected from integers of 0-6 and cannot be 0 at the same time; the definitions of the remaining substituents are the same as those of formula (I).
11. The double-stranded oligonucleotide according to claim 10, characterized in that: The overhanging nucleotides T are each independently selected from modified or unmodified nucleotides, and the modified nucleotides are selected from one or more of the following groups: 2'-O-alkyl, 2'-alkyl, 2'-substituted alkyl, 2'-halo, 2'-deoxy, abasic nucleotides, or inverted nucleotides.
12. The double-stranded oligonucleotide according to any one of claims 1 to 8, characterized in that: The antisense strand of the double-stranded oligonucleotide has a nucleotide overhang at the 3' end, and the overhang includes 1-3 nucleotides; the double-stranded oligonucleotide molecule is represented by the following formula (IIa): SS:5'-(N)a'-(X)p'-(N)b'-(X)q'-(N)c'-(X)r'-(N)d'-3' AS:3'-(T)t1-(N)a-(X)p-(N)b-(X)q-(N)c-5'(IIa), Wherein, t1 is an integer selected from 1-3.
13. The double-stranded oligonucleotide according to any one of claims 9 to 12, characterized in that: The overhang region also has a phosphorothioate modification.
14. The double-stranded oligonucleotide according to any one of claims 1 to 13, characterized in that: Each strand of the double-stranded oligonucleotide comprises 17-35 nucleotides; Optionally, each strand comprises 17-23 nucleotides; Optionally, each strand comprises 17-21 nucleotides; Optionally, each strand comprises 17-19 nucleotides; Optionally, each strand comprises 19-25 nucleotides; Optionally, each strand comprises 19-23 nucleotides; Optionally, each strand comprises 19-21 nucleotides; Optionally, each strand comprises 21-23 nucleotides.
15. The double-stranded oligonucleotide according to any one of claims 1 to 12, characterized in that: The double-stranded oligonucleotide has at least one of the following characteristics: Optionally, there is at least one nucleotide X on the sense strand; and starting from the 5'-end, at least one X is located opposite to any position at position 15, position 8 or position 2 of the antisense strand; Optionally, starting from the 5'-end, the four nucleotides on the sense strand corresponding to positions 10-13 of the antisense strand contain at least two fluorinated modified nucleotides; Optionally, starting from the 5'-end, positions 2, 6, 14 and 16 of the antisense strand are all fluorinated modified nucleotides; Optionally, starting from the 5'-end, at least one of the 8th, 9th, 10th and 15th positions of the antisense strand is a nucleotide X; Optionally, starting from the 5'-end, there is at least one X on the sense strand located at a position corresponding to positions 1-8 on the antisense strand; Optionally, starting from the 5'-end, position 15 on the antisense strand is nucleotide X.
16. The double-stranded oligonucleotide according to claim 15, characterized in that: The nucleotide X is independently selected from the following modified nucleotides: 2'-O-MOE, 2'-O-TBDMS, 2'-O-TOM, 2'-O-CH2-O-CH2-CH3, 2'-O-CH2-O-CH2-CF3; Optionally, both the sense strand and the antisense strand contain at least one phosphorothioate group, and the phosphorothioate group is located at the terminal region of each single strand.
17. The double-stranded oligonucleotide according to claim 12, characterized in that: The overhang (T) of the AS strand t1 Includes at least one 2'-F-2'-Me substituted nucleotide.
18. The double-stranded oligonucleotide according to claim 1 or 2, characterized in that: The double-stranded oligonucleotide further comprises at least one ligand; Optionally, the ligand comprises a liver-targeting ligand and a non-liver-targeting ligand; Optionally, the ligand is an ASGPR ligand; Optionally, the ASGPR ligand comprises GalNAc or a derivative thereof attached via a branched linker.
19. A double-stranded oligonucleotide comprising a sense strand and an antisense strand, each strand having 17 to 35 nucleotides, wherein each nucleotide is a modified or unmodified nucleotide, and the sense strand and the antisense strand are at least partially reverse-complemented to form a double-stranded region; characterized in that: The double-stranded oligonucleotide comprises at least one 2'-disubstituted modified nucleotide, and each substituent in the 2'-disubstituted group is independently selected from methyl or fluorine; Wherein, when the double-stranded region of the double-stranded oligonucleotide contains a 2'-disubstituted modified nucleotide, the 2'-disubstituted modified nucleotide is selected from a 2'-diF substituted nucleotide; or, when a position outside the double-stranded region of the double-stranded oligonucleotide contains a 2'-disubstituted modified nucleotide, the 2'-disubstituted modified nucleotide is selected from a 2'-F-2'-Me substituted nucleotide.
20. The double-stranded oligonucleotide according to any one of claims 1 to 19, characterized in that it has one or more of the following characteristics: (1) when the double-stranded oligonucleotide comprises a 2'-bis-F substituted nucleotide, the 2'-bis-F substituted nucleotide is located at least one of positions 7, 8, 9 or 10 from the 5' end of the sense strand; Optionally, the 2'-bis-F substituted nucleotides are located at least 2 or at least 3 of positions 7, 8, 9 or 10 from the 5' end of the sense strand; (2) when the double-stranded oligonucleotide comprises a 2'-bis-F substituted nucleotide, the 2'-bis-F substituted nucleotide is located at least one of positions 2, 4, 6, 8, 9, 10, 12, 14 or 16 from the 5' end of the antisense strand; Optionally, the 2'-biF substituted nucleotides are located at least 2 of positions 2, 4, 6, 8, 9, 10, 12, 14 or 16 from the 5' end of the antisense strand; (3) when the double-stranded oligonucleotide comprises a 2'-F-2'-Me substituted nucleotide, the 2'-F-2'-Me substituted nucleotide is located outside the double-stranded region of the oligonucleotide; (4) When the double-stranded oligonucleotide comprises a 2'-F-2'-Me substituted nucleotide, the 2'-F-2'-Me substituted nucleotide is located at the overhang at the 3' terminal position of the antisense strand.
21. An oligonucleotide conjugate, characterized in that The oligonucleotide conjugate contains the double-stranded oligonucleotide of any one of claims 1 to 20, and a conjugation group conjugated to the double-stranded oligonucleotide; Optionally, the conjugated group comprises a pharmaceutically acceptable targeting group and / or a delivery aid group.
22. A pharmaceutical composition, characterized in that The pharmaceutical composition contains the double-stranded oligonucleotide according to any one of claims 1 to 20 or the oligonucleotide conjugate according to claim 21.
23. Use of the double-stranded oligonucleotide according to any one of claims 1 to 20, the oligonucleotide conjugate according to claim 21, and the pharmaceutical composition according to claim 22 in the preparation of a drug for treating and / or preventing a disease or symptom associated with the mRNA level expressed by a target gene.
24. A method for treating and / or preventing a disease or symptom associated with the level of mRNA expressed by a target gene, the method comprising administering to a subject in need thereof at least one of the double-stranded oligonucleotide of any one of claims 1 to 20, the oligonucleotide conjugate of claim 21, and the pharmaceutical composition of claim 22.
25. A method for regulating the expression level of a target gene in a cell, the method comprising contacting the cell with an effective amount of at least one of the double-stranded oligonucleotide according to any one of claims 1 to 20, the oligonucleotide conjugate according to claim 21, and the pharmaceutical composition according to claim 22.
26. A kit comprising at least one of the double-stranded oligonucleotide according to any one of claims 1 to 20, the oligonucleotide conjugate according to claim 21, and the pharmaceutical composition according to claim 22.
Citation Information
Patent Citations
5′ and 2′ disubstituted nucleosides and oligomers prepared therefrom
CN102264374A
Oligonucleotide conjugates
CN104884618A
Modified double-stranded rna agents
CN107075516A
Modified oligonucleotides and methods of use
CN109952378A
Multitargeted nucleoside derivatives
CN110831605A
